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Longevity and Immune Profiles 
 
by 
 
Sam David Perez  
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Dr. Denise L. Bellinger, Chairperson 
 
 
Age-related changes in sympathetic neurotransmission in immune organs may be 
associated with immunosenescence; however no causal relationship has been established.  
From previous studies in Fischer rats (F344), we have found that during middle age, 
sympathetic nerve activity (SNA) rises in the spleen followed by a decline in 
noradrenergic (NA) innervation. Also, increased sympathetic signaling via beta-
adrenergic receptor (β-AR) and reduced proliferation of lymphocytes are evident with 
increasing age.  Although SNA progressively rises with age, effects of age on 
sympathetic factors may be different across rat strains. If causal relationships exist 
between sympathetic activity and immune function, they may be related to genotypic 
differences.   Therefore, our research consisted in two major studies.  First, in a 
longitudinal study, we characterized the age-related change in sympathetic innervation 
and sympathetic activity/tone in Brown Norway (BN) rats. The BN rat strain has a longer 
life span, a different aging pattern of NA innervation in the spleen, and a different 
immune profile compared to the F344 rat. Second, after establishing the time point during 
which sympathetic activity and NA innervation profiles in the spleens of these rats 
change, we investigated the role of increased SNA on neurotransmission in the spleen, as 
xvii 
an initial step before determining causal relationships between immune decline and 
altered sympathetic function with age.  For the longitudinal study in BN rats, we 
examined NA innervation in the spleens of animals at 8, 15, 18, 24, 27, and 32 months of 
age (8M, 15M, 18M, 24M, 27M and 32M) by histofluorescence for catecholamines and 
confirmed with morphometric analysis. We measured the concentrations of splenic 
norepinephrine (NE) and circulating catecholamines after decapitation using high-
performance liquid chromatography (HPLC).   For our second study, middle-aged BN or 
F344 rats received a 90-day treatment with rilmenidine, a centrally acting 
antihypertensive drug. 
In our first study, we observed a decline in NA nerve density in the splenic white 
pulp (45%) of BN rats at 15M.  Lower splenic NE concentrations followed at 18M, and 
were strongly correlated with nerve density.  Circulating catecholamine (CA) levels 
generally dropped with increasing age. In our second study, 15M male F344 and BN rats 
were intraperitoneally (i.p.) injected with 0, 0.5 or 1.5 µg/kg/day rilmenidine (Veh-18M, 
Rilmlo, Rilmhi, respectively).   Untreated 3M (Crtl-3M) and 18M rats (Crtl-18M) were 
used to control for effects of aging and handling/injection stress. We evaluated splenic 
NE concentration with or without synthesis blockade, NA innervation, β-AR expression, 
and β-AR-stimulated c-AMP production using HPLC, fluorescence histochemistry, β-AR 
radioligand binding, and enzyme-linked immunoassay (EIA), respectively.  We evaluated 
β-AR expression by β-AR radioligand binding assay.  Rilmenidine reduced circulating 
NE without a change in epinephrine (EPI), and reduced SNA as assessed by reduced NE 
turnover rate after synthesis blockade in both F344 and BN rats. We observed restorative 
effects of rilmenidine on splenic NA innervation in both rat strains in a dose-dependent 
xviii 
manner, supporting the hypothesis that heightened SNA contributes to nerve destruction.  
Splenocyte β-AR density was increased by the optimum dose (Rilmlo), without changing 
affinity.  β-AR-stimulated cAMP production was further augmented by either dose of 
rilmenidine in F344 rats; while in BN rats, Rilmlo partially reversed the age-related 
decline in β-AR-stimulated cAMP production.  Collectively, the results from these 
studies demonstrate an increase in splenic SNA during middle age that affects NA 
neurotransmission in the aging spleen in strain-specific manner. Chronic treatment with 
rilmenidine protected sympathetic nerves, and further enhanced β-AR-mediated signaling 
in the spleen of F344 rats.  No significant effects on sympathetic nerves or β-AR-
mediated signaling were found in the spleen of BN rats treated with rilmenidine 
compared with age-matched controls. These findings suggest that rilmenidine could 
affect host defense against age-related diseases, by modulating sympathetic signaling. 
Further, they will form the foundation for further development of shorter- and longer-
lived rodent models with differing immune phenotypes to investigate causal relationships 
between sympathetic nervous system (SNS) and immune function in aging. .  
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CHAPTER 1 
 
INTRODUCTION 
 
Epidemiological projections predict a sharp rise in the elderly population in the 
United States over the next decade (1).  The health concerns are many, particularly the 
incidence of chronic diseases, which will reduce the quality of life and increase the 
burden on the public healthcare system (2). In aging, autoimmunity, cancer and infectious 
disease rise, and efficacy for vaccination declines. These conditions are influenced by 
interactions between the immune and the central nervous systems via autonomic and 
endocrine signaling, primarily the hypothalamic-pituitary-adrenal (HPA) axis (3).    
In this project, we investigated first, the effect of age on sympathetic innervation 
activity and signaling in the BN rat, an alternative rat model from the classically used 
F344 rat model for aging.  Next, we examined whether heightened sympathetic nerve 
activity (SNA) in a lymphoid organ, such as the spleen, during aging is responsible for 
splenic NA nerve loss and altered β-AR signaling in splenocytes.  NE is the main 
neurotransmitter/neuromodulator in lymphoid organs (3, 4).  Under stimulation, NE is 
released from the extensive sympathetic nerve terminals and targets the adrenoreceptors 
expressed on the immune cells of primary and secondary lymphoid organs (4).  In young 
adults, the SNS modulates immune function, and is critical for adequate immune function 
and responses (5).  With aging, the SNS is dysregulated and immune function decline, 
but we do not know whether SNS changes in the aging spleen are consistent across 
strain/species. We also need to optimize methods to be able to manipulate the SNS to 
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study causal relationships between immune and SNS changes with advancing age. .  
There are no available models to investigate causal relationships, and we do not believe 
that there is one single strain of rat that will provide an adequate model for all scenarios 
of aging.  For these reasons, we need to develop animal models for looking at causal 
relationships between the brain and the immune system in aging, because they are 
currently not available.  To overcome this problem, we have characterized the age-related 
SNS changes in the spleen of two strains with different genetic background, longevity, 
and immune profiles.  We do not believe there will be one single strain of rat that will 
provide an adequate model for all scenarios of aging, largely because of genetics and 
environment across life span interact to mediate the aging process.   
Therefore, the research objective of this doctoral dissertation was two-fold: first, 
to longitudinally examine the effect of age on sympathetic NA innervation and 
neurotransmission in the spleen of the BN rat, a rat strain with different life span and 
immune profile than the well studied F344 rat.  Secondly, to begin investigating the 
role of the age-related alteration in sympathetic activity on neurotransmission in the 
spleen, as a first step in developing models for studying causal relationships between 
altered neurotransmission and immune function.  Experimental findings in both 
animals and humans indicate critical age-related alterations in both the SNS and the 
immune system.  In the aging SNS, there is an increased sympathetic tone that is 
accompanied by elevated levels of norepinephrine in the circulation in human older 
adults (6, 7), and in old F344 rats (8).  In rodent models for aging, changes in sympathetic 
innervation occur depending on the tissue/organ, species or strain, and concomitant 
changes occurring in the local microenvironment that regulate nerve integrity, for 
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example the available amount of NGF or other neurotrophic factors produced by the 
target cells (9).  Specifically, in the F344 rat spleen, sympathetic innervation is reduced 
(10, 11), the density of β-ARs on lymphocytes and β-AR-stimulated cAMP production 
rise with age (12).  But with respect to its aging immune system, the ability to mount a 
cellular immune response to pathogens and tumors (14, 15), as well as the capacity to 
respond to vaccines, declines (16). Also, a rise in proinflammatory cytokines and 
susceptibility to autoimmune diseases increases morbidity and mortality, as age advances 
(17).  In old F344 rats, we have observed a decline in the density of T lymphocytes and 
ED3+ macrophages population in lymphoid compartments (4). Aging rats also exhibit a 
decline in lymphoproliferation in response to concanavalin A (Con A) that is not 
associated with a change in interleukin (IL)-2 production, and weakened primary 
antibody responses to a T-dependent antigen (18).   However, other than correlative data 
from our laboratory, virtually no information exists either to support or to refute a causal 
role for sympathetic dysregulation in immunosenescence with advancing age. This 
doctoral project begins to investigate strain-specific changes in sympathetic innervation 
integrity/activity and β-ARs signaling in spleens from two well established aging rodent 
models, as an initial step toward establishing causality between aging SNS and immune 
functional changes.  Without this basic information, it will be impossible to determine in 
a meaningful way the contribution of sympathetic dysregulation on immune function 
with advancing age in laboratory rat models.  
Since, a relatively large body of literature indicates that heightened tonic 
sympathoexcitatory activity in the rostral ventral lateral medulla (RVLM) is responsible 
for increased SNS activity in hypertensive rodents, the studies described here target this 
4 
brain region pharmacologically, to chronically lower sympathetic outflow to the spleen.  
Our main hypothesis for these studies is that heightened splenic SNA during middle age 
is responsible for splenic NA nerve loss and altered β-AR signaling in splenocytes, in a 
strain-dependent manner. 
In order to test our main hypothesis, we have conducted experiments designed to 
address the following specific aims:  
Specific Aim # 1: Evaluate the role of heightened SNA as a mechanism 
contributory to altered neurotransmission in the aging spleen of the BN rat. A 
longitudinal study determined the age at which sympathetic activity, NA innervation and 
β-AR signaling changes in this strain. We considered that SNA changes in the BN rat 
may occur during middle, as in F344 rats.  A time point for experimental interventions 
aimed at investigating effects of these changes on neurotransmission was determined. 
Specific Aim #2: Evaluate the role of heightened sympathetic activity as a 
mechanism responsible for altered innervation and sympathetic signaling in immune 
cells of secondary lymphoid organs in the short-lived F344 rat.  This aim tested the 
effect of age-related increased sympathetic tone on NA nerve preservation and 
neurotransmission in the spleen by using rilmenidine, a centrally acting antihypertensive 
drug, for 90 days, to reduce global sympathetic outflow during middle age. We propose 
that chronically lowering basal sympathetic outflow to the spleen will reduce SNA and 
retard or prevent the age-related changes in nerve integrity and reverse the age-related 
rise in β-AR-mediated signaling. 
Specific Aim # 3: Evaluate the role of heightened sympathetic activity as a 
mechanism responsible for altered innervation and sympathetic signaling in immune 
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cells of secondary lymphoid organs in the long-lived BN rat.  Studies in this aim will 
provide information on the effects of a chronic reduction of SNA in the spleen of the 
aging BN rat, a strain that has a different immune profile and age-related β-AR signaling 
in the spleen than the F344 rat.  We hypothesized that diminishing sympathetic outflow 
to the spleen will prevent the age-related rise in local SNA, and reverse the age-related 
alterations in NA innervation and β-AR-mediated signaling in the spleen.  
 
Background 
Age-Related Changes in Immune Function 
Both arms of immunity innate and cell-mediated change during aging, but cell-
mediated immunity is more affected.  Proliferation, cytotoxicity, natural killer cell 
activity, IL-2 production, IL-2 receptor expression, and signal transduction are commonly 
reported to be impaired in old T cells (17).  With age there is down-regulation in the 
expression of several genes which play important roles in the T cell activation pathway 
that include c-fos, c-myc, and c-jun. There is also impairment in activation of nuclear 
transcription factors implicated in the transcriptional regulation of IL-2 mRNA (18, 19). 
Also lymphocyte proliferation is generally impaired in aging, irrespective of the 
stimulating agent, as well as a synthesis of and response to IL-2 which hamper the proper 
functioning of T lymphocytes in healthy elderly people (19).  
The role of IL-2 in impaired T cell function in aging is controversial, and the 
nature of the stimulating agent used contributes to the conflicting data.  While spleen 
cells of both young and aged rats produce high amounts of IL-2 in response to 
concanavalin A (Con A) stimulation, in allogenic mixed lymphocyte tumor cell culture, 
spleen cells from old rats produce little IL-2 compared to spleens from young rats (20). In 
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mice, the frequency of responding cells decrease in aging, but the proliferative capacity 
and immune competency of progeny cells remain intact (21). In old human subjects fewer 
responsive cells are present, and fewer cells divide with each succeeding generation, but 
the kinetics of proliferation do not change (22). Also in old mice, the proportion of cells 
competent in producing IL-2 mRNA declines, but not the amount of mRNA produced by 
those competent cells. Similarly the proportion of cells that can express high-affinity 
receptors decreases, rather than the number of high affinity receptors per positive cell or 
the affinity of the receptor for the ligand (22). Therefore, most studies indicate an age-
related decline in the proportions of T cells, which can produce IL-2, IL-2 mRNA, and 
IL-2 receptors after activation, accounting for the age-related loss of T cell proliferation. 
Regarding cytokine production, we will not cover the subject in detail because it 
is beyond the scope of the studies here. However we will mention the factors that may 
influence the lack of coherence of data regarding cytokine production. First, the particular 
species tested is important. For instance, IL-4 production is up-regulated after antigenic 
challenge in mice but not humans (23). Second, the nature of the stimulating agent used 
in in vitro culture conditions between laboratories can explain some of the controversy. 
With aging, IL-4 production was increased in short-term cultures, while in longer-term 
cultures IL-4 production by memory T cells declined under conditions that promote IL-2-
drive proliferation (24). And third, most studies have been done using unfractionated T 
lymphocytes isolated from different tissues, such peripheral mononuclear cells (PBMC), 
spleen and lymph node, all of which have different accessory cells populations. 
Therefore, careful study using defined populations of T lymphocytes and accessory cells 
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should be carried out to have a better understanding of the dysregulation of cytokine 
production due to aging. 
Aging is also associated with an increase in the CD4/CD8 ratio in human 
peripheral blood lymphocytes, and murine spleen (25, 26). But in murine lymph node and 
blood, the CD4/CD8 ratio decreases with aging (27). Also a shift towards s memory as 
compared to a naïve T cell population occurs in humans and experimental animals (26). 
Naïve CD4+ T cells are more potent in producing IL-2 compared to memory CD4+ T 
cells. This phenomenon is seen in both young as well as old mice, and indicates that the 
shift toward memory CD4+ T cells contributes to the aged-related decrease in IL-2 
production. Also an age-related increase in CD8+CD28+ T cell percentage and absolute 
number, and an increase in anti-CD3 redirected cytotoxicity by freshly isolated T cells, 
suggest immune activation within the cytotoxic arm with aging (28). Meanwhile the 
increase in CD8+CD28- T cell with aging is consistent with an age-associated decline in 
the proliferative ability of aged humans, particularly prominent in the CD8 population 
and hyporesponsiveness to co-stimulation by CD28 in T cells from aged mice (29). 
 
Aging and Basal Sympathetic Activity 
 Catecholamines, such as norepinephrine (NE) and EPI are transmitters that are 
released from active sympathetic nerves and the adrenal medulla respectively.  While 
circulating NE levels reflect the net firing activity of sympathetic nerves, EPI in the blood 
is used as a marker of adrenomedullary activity. Indices of basal sympathetic activity, 
such as elevated plasma NE, have been used as markers of normal chronological aging 
(30). NE concentrations in the urine and cerebrospinal fluid (CSF) are also higher by 
50% or more compared with young subjects (31). A rise in plasma NE levels indicates a 
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net elevation in sympathetic tone with subsequently increased NE spillover into the 
circulation (32-35). In rat models for aging (i.e.F344 rats) there are differences in the 
response to sympathetic activation; specifically in the time it takes for circulating NE 
levels to return to baseline in older rats (36, 37).  Elderly humans exhibit higher plasma 
NE levels and a delayed return to re-stimulus levels of sympathetic activity following 
many stimuli that activate the SNS, including orthostasis (38). In older adult humans, 
mild sympathetic stressors elicit an exaggerated response, indicated by elevated plasma 
NE levels compared with young adults.  Plasma EPI concentrations sampled under 
comparable conditions do not increase with age in humans (38, 39-43). This dissociation 
between age-related changes in NE and EPI is also evident in urine (34) and CSF (39).  In 
aged rats, elevated plasma NE levels also persist longer in old rats after exposure to 
stressors that activate the SNS, such as cold water immersion for 10 minutes and 
immobilization stress (40). Therefore, autonomic dysfunction in these tissues may not be 
exposed under basal conditions, but may become apparent under stressful stimuli, where 
the autonomic nervous system (ANS) responds reflexively to changes from the resting 
state.  Collectively, these findings suggest dysregulation of the SNS in aging that is 
similar in humans and the rodent models that we are using for this study.  
 
Effects of Aging on Sympathetic Neurons 
Sympathetic neurons exhibit target-specific changes with advancing age. In some 
target tissues, there are age-related changes in axonal, dendritic arborizations, and soma 
size, in response to an altered microenvironment in effector tissues (41, 42).  In aged rats, 
the density of sympathetic nerves surrounding cerebral arteries is reduced by 50% (43).  
This occurs with shrinkage of adjacent smooth muscle cells (44). In the gut, there is an 
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age-related decline in sympathetic innervation, as well as, an extensive loss of enteric 
neurons (45-47).  In the spleen of the aging male F344 rats, reports from our laboratory 
indicate that the loss of sympathetic fibers ensues concomitantly with altered splenic 
architecture and immunosenescence (48, 49). It is important to note that when 
sympathetic innervation is reduced, it usually does not result from an age-related cell 
death of sympathetic neurons (41-45). Apoptosis can be induced in mature neurons that 
are injured or lack neurotrophic support, but cell death is usually aborted (46, 47). In 
contrast to the target tissues mentioned above where a loss of sympathetic nerves has 
been reported, sympathetic neurons that supply the iris are maintained or keep growing in 
old age (50), and their dendrites do not atrophy during aging (51). Collectively, this 
literature indicates that changes in sympathetic innervation are specific to tissue type, 
species, and strain (9). Therefore microenvironment in the target tissue has an important 
influence on the integrity of sympathetic nerves that distribute to them. The latter two 
support an important role for genetic phenotype on aging changes in target tissues. 
 
Age-Related Changes in Sympathetic Innervation in Lymphoid 
Organs 
Innervation of primary and secondary lymphoid organs provides an anatomical 
substrate for the brain to communicate with the immune system (52).  Sympathetic nerves 
primarily from the superior mesenteric and celiac ganglionic plexuses (53), and sparingly 
from the sympathetic trunk (54), enter the spleen as the splenic nerve, along with the 
splenic artery.  NA nerves course in vascular and trabecular plexuses into the white pulp 
closely associated with the central arterioles and their branches (4). NA varicosities 
extend from these plexuses into the periarteriolar lymphatic sheaths (PALS) (55), ending 
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among OX19+ T lymphocytes and interdigitating cells (52, 56). There are also NA nerves 
that enter the marginal, at the periphery of the white pulp, and the parafollicular zones, 
that distribute among IgM+, B cells and ED3+ macrophages (48). Generally, NA nerves 
are not present in the follicles, where resting B cells reside, and sparse in the parenchyma 
of the red pulp, but do course along the trabeculae, vasculature, and venous sinuses in the 
red pulp (49). 
The mature pattern of NA innervation of the spleen in the rat is present by 
postnatal day 28, and adult proportions are attained by 56 days of age (57, 58).  Extensive 
studies in our laboratory have shown that in older adults F344 rats NA innervation 
declines in secondary (48, 49), but not primary (59) lymphoid organs, as indicated by 
both neurochemical measurements of NE content and the histofluorescence for 
catecholamines with morphometric analysis to measure the density of NA nerve 
terminals. In effect, neurochemical measures have shown a greater than 50% loss in NE 
concentration in spleens from 27M rats compared with young adult controls (48). NA 
nerves are lost in lymphoid compartments of the spleen, particularly in the periarteriolar 
lymphatic sheath (PALS) where T cells reside. Quantitation of fluorescent varicosities 
has revealed an age-related decrease in the density of NA nerves greater than expected 
based on splenic NE concentration. This suggests that more NE is made by fewer nerves, 
and this measure may provide a more sensitive assessment of aging changes in 
sympathetic innervation than static splenic NE concentration (9). Loss of fluorescently 
stained nerves in the spleen may be a consequence of an inability of NA nerves to 
synthesize enough NE via tyrosine hydroxylase (TH), or from actual loss of nerve fibers. 
Studies that examined alpha-methylnorepinephrine (αMNE) (100 mg/kg body weight, 
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i.p.), a compound that is taken up by high affinity carriers on NA fibers and cannot be 
metabolized by monoamine oxidase confirmed that (a) no additional sympathetic fibers 
were visualized, and (b) the surviving nerve terminals were functional in aged rats (11, 
60). Further, the uptake of [3H]-NE by lingering fibers remains functional in old animals, 
and is in fact enhanced (61).    Effects of aging on NA innervation patterns in lymphoid 
organs have been studied in various murine strains (57) and F344 rats (52, 57).  In our 
studies we extend these findings, by examining a different rat strain, the BN rat, which 
lives longer and has a different immunological and behavioral profile than F344 rats, for 
age-related changes in sympathetic neurotransmission in the spleen.      
 
Immune Effector Cell Responsiveness to Sympathetic Stimulation 
Catecholamine stimulation of β-ARs expressed on splenocytes and peripheral 
blood mononuclear cells (PBMC) from both murine and humans, increase adenylate 
cyclase activity mostly, but not exclusively via activation of β2-ARs; and suggests a 
potential for modulation of cellular activity at the level of gene expression (62).  The 
primary AR subtype expressed on T cells is the β2-AR (63-65), but cells of the immune 
system such as macrophages, thymocytes and splenocytes also express α-ARs (62, 65).  
In B cells, stimulation of β2-ARs, either prior to, or at the time of, cell activation 
increased either the number of antibody-secreting cells or the amount of antibody 
produced per cell (65).  β-AR surface expression on T cell may be influenced by cellular 
conditions.  For instance, the level of β-AR surface expression is increased 24 h after cell 
activation, without alteration of affinity, by the T cell mitogen Con A (66), although 
epigenetic mechanisms and protein kinase C (PKC) activation may down regulate surface 
expression of β-AR during Con A-induced T cell activation (67).  Contrasting results are 
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dependent on different experimental conditions (in vitro vs. in vivo), the time elapsed 
after stimulation, time of stimulation relative to mitogen stimulation, and the particular 
cell population examined and their activational states (67, 70).  Also the subtype of CD4+ 
T cell subsets, such as Th1 cells, but not Th2 cells, preferentially express the β2-AR; and 
this feature is consistent at the mRNA level (64), as well as in Th1 cells newly generated 
from naïve CD4+ T cells (65).  Different studies support the general hypothesis that β-AR 
stimulation decreases the level of mitogen- or anti-CD3 antibody-induced T cell 
proliferation (64, 61).  
Despite increased sympathetic activity in aging, many target tissues are 
hyporesponsive to NA stimulation, mainly involving changes in β-AR signaling (71-72).  
So far in rat models, longitudinal studies in F344 rats, where splenic innervation declines, 
we found that compensatory mechanisms in the SNS maintained a relative effective 
transmission with immune cells (4), through altered NE reuptake, increased stimulated 
NE release, increased β-AR expression and signaling (52). In contrast, no longitudinal 
data in lymphoid organs were available for BN rats, but observations in aged (27M) BN 
rats, showed that innervation and neurochemistry were not significantly affected (73). β-
AR interactions with G proteins may also regulate receptor activation by switching 
coupling events from Gs to Gi/Go, as reported in some cell lines and dissociated primary 
cells grown in tissue culture under certain conditions (74-76). Other postsynaptic effects 
downstream of receptor activation and the activity of adenosine cyclase, are not within 
the scope of these studies.   
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Aging and Central Autonomic Influence in the Spleen 
Two studies from the same laboratory indicate that the rostral ventrolateral 
medulla (RVLM) provides a major input to spinal preganglionic sympathetic neurons that 
project to the spleen (77, 78). Reticulospinal sympathoexcitatory neurons of the C1 area 
of this brain stem region reduce the tonic activity of these sympathoexcitatory neurons 
(79). Very little is known about the role of the ventrolateral medulla in regulating 
sympathetic outflow to other visceral organs, including lymphoid tissues.   
Sympathetic ganglia from aged humans (superior cervical and hypogastric in 
humans) (80-85), and animals (superior mesenteric-celiac and hypogastric, but not 
superior cervical ganglia in rats) (86-88) exhibit marked depletion of catecholamine 
histofluorescence. Similar findings are reported in sympathetic nerves along blood 
vessels and in other target organs (89-92). In rats (F344 rat), the effects of dysregulated 
sympathetic activity in a target organ, such as the spleen, may be reflected in the altered 
homeostatic set point for stored NE levels with advancing age (93). These findings also 
would be consistent with the regulation of NE content in sympathetic neurons by the 
local millieu of the target tissue in which their axon reside. 
 
Significance 
Strain Differences Between F344 and BN Rat Models for Aging 
In our laboratory, two rat strains, the F344 and the BN rats, which are currently 
available through the National Institute of Aging (NIA), have been used as models to 
study effects of age-related changes in SNS on sympathetic neurotransmission in the 
spleen for several reasons that are described here. The F344 rat is the best studied model 
for aging. BN and F344xBN hybrid rats are becoming more commonly used as models 
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for aging, since the NIA has established breeding colonies for these strains.  The F344 
and the BN strains are genotypically different, which confers differences in life spans, 
and distinct behavioral stress response and immunological profiles, with consequences 
for age-related pathologies that are mediated via neural-immune interactions (73, 94). 
These differences are itemized as follows: (1) F344 rats live only 75% of the life span of 
BN rats on average (94, 95); the most obvious feature to consider in our studies, as it 
reflects the life span in the general human population. (2) Age-related pathologies that 
cause morbidity and mortality differ in F344 and BN rats (96). Unlike F344 rats, there is 
low frequency of pituitary adenomas or glomerulonephritis in BN rat with increasing age 
(96, 110).  (3) Behavioral profiles in these rat strains suggest phenotypic difference in 
their limbic and stress pathways, with the F344 rat considered the hyper responsive, more 
vigilant strain under acute and chronic stress (97).  BN rats have a low baseline level of 
anxiety (111), and low learning and memory performance (112).  (4) Finally, differences 
in immune responses to mitogens, antigens and pathogens between F344 and BN rats 
indicate a Th1 and Th2 bias, respectively; it is not clear how age-related change in 
immunity affect these biases, but aging in general tends to shift an immune response 
toward a Th-type 2 response (98, 101).  Prior to this research project, extensive studies in 
our laboratory were conducted to further characterize NA innervation (99), and 
neurotransmitter levels (NE) in the aging F344 rat spleen (9). This research also 
examined correlations between the SNS activation and lymphocyte proliferation patterns 
in the splenocytes across age (100).  In chapter 2 of this dissertation, we studied the 
assessed net basal sympathetic activity, innervation and β-AR signaling in the spleen 
longitudinally across age in the BN rat. Thus, this initial investigation determined the 
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period when changes in SNA, β-AR signaling and sympathetic innervation in the spleen 
are manifested.  
 
Specific Strain Differences in Immunity 
With respect to the immune response differences, the young adult F344 rat has a 
demonstrated a bias towards a Th1 response after immunization with ovalbumin, based 
on cytokine profiles (101, 102). Compared with the Lewis rat, which has identical MHC 
class II haplotype, the F344 rat appears to be resistant to experimentally-induced 
autoimmune diseases modulated by Th1 or Th2 cytokines (103, 104, and 106). Overall 
this low susceptibility may be largely dependent on both immunological and non-
immunological factors, including the involvement of stress pathway activity (9) and local 
peptide concentration, such as neuropeptide (NPY) (105).  These features may render 
young F344 rats better able to eliminate antigens using cell-mediated immunity, so that 
the antigens are eliminated and autoimmunity is averted.  With advancing age, F344 rats 
may be more vulnerable to the allostatic load from heightened autonomic and 
neuroendocrine-mediated compensatory mechanisms, which may lead to 
immunosenescence as age progresses. Greater allostatic load from increased 
neuroendocrine outflow, particularly the HPA axis, in the face of immune senescence 
may be contributory to the high incidence of pituitary tumors in aged F344 rats (110). 
Additionally heightened SNS outflow combined with greater HPA activity may interact 
with immune senescence to increase the risk for the overt age-related pathology well 
documented in this rat strain, and contributes to the relative shorter life span of the F344 
rats (96). 
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On the other hand, with its predominant bias toward a Th2-type of immunity 
when challenged with antigen (107, 109), the BN rat provides a good model for studying 
the mechanisms that predispose the adults to increased risk for Th2-mediated 
autoimmune diseases. In comparison with Lewis rats who are predisposed to Th1-type 
autoimmune diseases, mercuric chloride (HgCl2)-induced autoimmunity can be induced 
in rat strains with a bias towards a Th2-mediated immunity. Induction of autoimmunity 
after challenge in BN rats was evident at day 7 after HgCl2 exposure characterized by the 
anomalous low frequency of erythrocytes and CD8+ with high number of B cells in the 
BN spleen, and the suppressed production of the Th1 cytokine, IFN- production (108).   
 
Specific Strain Difference in Sympathetic Activity and Innervation  
Most studies investigating the effects of sympathetic activity on NA innervation 
profiles have come from mice and the F344 rat.  Our studies are novel in that they extend 
the aging-immune literature, by examining a different rat strain that has a different SNA 
profile and may impact sympathetic neurotransmission in aging spleen cells differently 
from F344 rats.  Sympathetic nerve density, affected by increased SNA in the aged 
spleen, appears to be affected to a lesser degree by aging in BN rats (73, 96). Since, it is 
established that neurotrophic factors produced and released by target cells contribute to 
sympathetic nerve integrity (113) it seems reasonable to propose that strain differences in 
nerve integrity with normal aging may result from altered neurotrophic support in the 
splenic microenvironment.  In K14-NGF-transgenic mice, high levels of NGF expression 
are observed in spleen and peripheral lymph nodes; and the level of innervation correlates 
with the level of NGF peptide (114). Therefore neurotrophic support may play an 
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important role in sympathetic innervation in the spleen permissive to optimum 
modulatory effects of CAs on lymphocyte proliferative responses, migration and homing 
to immune sites (114, 115).  Previous reports by our laboratory have shown an age-
related reduction in the density of OX19+ T cells and ED3+ macrophages in the splenic 
white pulp, two cellular sources of neurotrophic factors (52).  Preliminary data produced 
in our laboratory confirm an age-related decline in nerve growth factor (NGF) in spleens 
from F344 rats that was not evident in BN rats (unpublished findings).   
An increase in oxidative stress as a consequence of heightened SNA may provide 
another possible mechanism to explain age-related changes in sympathetic innervation of 
the spleen. The age-related autodestruction NA splenic fibers in our rat models may be 
induced by free radicals generated by excess oxidative catecholamine metabolites 
produced by high turnover rate of NE (52).  Catecholaminergic neurons, both centrally 
and in the periphery are sensitive to oxidative stress (52, 73, 116).  Therefore, heightened 
sympathetic activity in the aged spleen would be expected to increase oxidative 
metabolites, such as 6-hydroxydopamine (6-OHDA), that are toxic to sympathetic nerve 
fibers.  Further, with age, reduced ability of target cells or neurons to absorb free radicals 
may lead to neuronal atrophy directly or by reduced ability to synthesize cellular 
components (116).  In vivo, NGF is capable to protect neurons from free radical damage 
in the CNS (116, 119), and in vitro in PC12 cells (117), by elevating the activity of 
antioxidant enzymes. Collectively, these findings support our hypothesis for oxidative 
stress mediated damage, as a mechanism involved in the destruction of sympathetic 
nerves during aging. 
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Consequences for Susceptibility to Age-Related Diseases 
The effects of sympathetic dysregulation in aging individuals can have 
detrimental effects to health, especially if these individuals have a compromised immune 
system concomitant with a heightened SNS activity. The dysregulated status of the SNS 
may profoundly affect the susceptibility of the organism to infection and/or influence 
disease course (4). The SNS activity in an individual can be reprogrammed by early 
exposure to stressful events, thereby altering the individual’s resiliency against infectious 
disease (118).  Also later in life, both clinical and animal research reports that slower 
tumor growth and better patient prognosis is positively associated with good social 
support. Although the direct mechanisms are not clear, it is well established that optimal 
interactions between the nervous system, neuroendocrine, and immune system are 
important, as positive social interactions influence these systems to inhibit tumor growth 
(120).  In disease progression, the incidence of tuberculosis increases and disease 
prognosis is worse in patients reporting stressful life event (121).  Abnormalities in 
sympathetic activity in patients during Helicobacter pylori infection can be induced by 
psychosocial stress, and a response towards a Th2 profile may promote the onset and/or 
progression of the infection (122).  Experimental observations in healthy rodents indicate 
that shifting levels of cytokine production may initially cause alterations in adequate 
immune activation following an increase in SNS activity.  In this scenario there is a 
suppression of type-1 cytokines, while enhancing type-2 cytokines production. 
Consequently, an overall shift towards a humoral immunity over cellular immunity is 
observed in these animals (3).  In the clinical setting this occurrence can be detrimental 
for the patient since cellular immunity is essential for host defense against mycobacterial 
infections.  SNS inhibition of Th1 cell-dependent immunity may lead to the development 
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of a disorder, such as peptic ulcer from chronic gastritis caused by bacterial infection 
(123, 124, and 125).  
Another example of how a deficient interface between the SNS and immune 
system occurs in a host is observed in HIV infection and sepsis.  In HIV infection, the 
pathogenesis of the disease occurs in lymphoid organs and its progression is marked by 
increased IL-10 and reduced IL-12 indicating a bias towards Th2-type immunity (126). 
The proposed mechanism for the production of Th2 cytokines involves the enhanced 
production of intracellular cAMP via β-ARs (127, 128).  During sepsis, although the 
activation of the SNS is important in modulating the activation of the immune system to 
combat infections, sustained SNS activation may have either beneficial or detrimental 
consequences for the affected individual by inducing changes in circulating levels of 
important cytokines (129, 130).  In search of therapeutic interventions during septic 
shock, pharmacological interventions that induce anti-inflammatory effects can be 
achieved by targeting subpopulations of ARs with antagonists to α2-AR and β2-AR, either 
alone or in combination (4). Recognition of bacterial lipopolysaccharide (LPS) by the 
innate immune system elicits strong pro-inflammatory responses that can eventually 
cause a fatal sepsis syndrome in humans (131). In animal models, pharmacological 
manipulation of ARs in LPS-treated mice show that plasma TNF-α levels is inhibited by 
a β-AR agonist, and by an α2-AR blockade with CH 38083 (a highly selective α2-AR 
blocker), but pretreatment by blocking β-AR increases the plasma levels of TNF-α. (132). 
Together, these data suggest a dual role for SNS activation after LPS administration that 
may include: a) reduction of TNFα through β-ARs, and b) inhibition of NE release 
through presynaptic α2-AR (133).  Therefore the use of an specific catecholamine regime 
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to treat septic shock is impossible,  For instance, the incidence of poorer survival and 
increased end-organ injury following the use of dobutamine, an β1-AR agonist, one of  
the drugs that is used to maintain adequate cardiac output under systemic septic shock.  
Although β2- instead of β1-AR appear to control monocyte/macrophage cytokine profiles, 
the use of adrenergic agents in the clinical treatment of this condition require the optimal 
balance between cardiovascular support and immunomodulation (134). Further an early 
intervention with adrenergic drugs that can suppresses IL-12 production by macrophages 
during cell-mediated immunity, increasing the risk uncontrolled bacterial growth (135). 
  In autoimmune diseases, the SNS influences the outcome of disease. If the SNS 
is hyperactive, a Th2 shift may potentiate and facilitate flares of systemic lupus 
erythematosus (SLE) (4).  But if the SNS is hypoactive a Th1 shift, as in multiple 
sclerosis (MS) or rheumatoid arthritis (RA) may be sustained. This later observation is 
also evident in pregnant women during the third trimester, as proinflammatory cytokine 
production is suppressed (136, 137). However, the role of the SNS is more complex, as it 
exerts both promotional and inhibitory mechanisms under conditions where chronic 
inflammation is a predominant hallmark of a disease. For instance the Lewis rats, a model 
for rheumatoid arthritis (RA), exhibit dysregulated stress systems, and readily develop 
experimentally-induced Th1-mediated episodes of arthritis during experimental allergic 
encephalomyelitis (EAE) (132). β-/β2-AR agonists and α1-AR blockers are reported to 
suppress chronic relapsing EAE in this rat model (138-140).  In RA, the SNS regulates 
immune events locally in the inflamed joint by inducing localized inflammatory 
responses, such as increased blood flow, vascular permeability, release of inflammatory 
mediators, and mobilization of dendritic cells.  
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In secondary lymphoid organs, the SNS regulates Th1 vs. Th2 drive through 
clonal expansion of autoreactive immune cells, as well as blood flow (4). From studies in 
our laboratory, the timing of adrenergic drug treatment relative to the adjuvant challenge 
and disease course translates into different outcomes.  Treatment of adjuvant-induced 
arthritic (AA) rats with the β2-AR agonist, terbutaline, initiated at antigen challenge, 
exacerbates disease severity. Otherwise, terbutaline treatment that is initiated at the onset 
of the disease significantly reduces the severity of the disease (141).  Altered AR 
expression and/or signaling capacity are features of impaired SNS regulation of cellular 
proliferation that may lead the pathogenesis of RA.  For instance, the reduction in the 
expression and activity of G-protein receptor-coupled kinase by PBMC, which causes 
deregulation of the β2-AR cell surface expression, influences the progression of disease in 
RA patients (142, 143).  Influences of the SNS in autoimmune disorders are complex 
(144, 145). A hypoactive SNS may sustain the Th1, whereas a hyperactive SNS may 
intensify the Th2 shift and induce flares of a disease, as seen in SLE (4). F344 rats, which 
have a hyperactive stress system, are resistant to experimental induction of Th1-mediated 
autoimmune states (e.g. arthritis, uveitis, and EAE) (146). The other rat strain in our 
studies, the BN rat may have less reactive stress pathways, and is more sensitive to Th2-
mediated autoimmune diseases such as polyarthritis, vasculitis, lupus-like syndromes 
(98)  
Collectively, the experimental observations from humans and appropriate animal 
models can provide a framework from which treatment protocols can be designed in the 
clinical realm. Treatment regimes may become possible that tailored to each individual’s 
immune response to “adjust” to a more appropriate immune response to challenge with 
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antigens or pathogens. Our studies begin to investigate the role of heightened sympathetic 
activity as a mechanism responsible for altered sympathetic innervation and 
neurotransmission across strains. Thus we begin developing rat models for exploring 
mechanisms that may help explain causal relationships between sympathetic signaling 
and immune function across different genetically and environmentally-influenced 
patterns of aging.  These two rat models of aging may be useful in understanding (1) 
racial/genetic differences that predispose individuals to certain types of age-related 
diseases; and (2) relative optimal vs. detrimental sympatho-immune interactions in aging.  
In order to understand why aging makes certain individuals vulnerable to diseases that 
increase frequency in aging, we need to understand how genetics, as well as epigenetic 
changes, interface with physiological systems like the autonomic nervous system to 
negatively affect host defense. 
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Abstract 
Aging leads to reduced cellular immunity with consequent increased rates of 
infectious disease, cancer and autoimmunity in the elderly.  The sympathetic nervous 
system (SNS) modulates innate and adaptive immunity via innervation of lymphoid 
organs. In aged Fischer 344 (F344) rats, noradrenergic (NA) nerve density in secondary 
lymphoid organs declines, which may contribute to immunosenescence with aging.  
These studies suggest there is SNS involvement in age-induced immune dysregulation.  
Objectives:  The purpose of this study was to longitudinally characterize age-related 
change in sympathetic innervation of the spleen and sympathetic activity/tone in male 
Brown Norway (BN) rats, which live longer and have a strikingly different immune 
profile than the F344 rat, the traditional animal model for aging research.  Methods:   
Splenic sympathetic neurotransmission was evaluated between 8 and 32 months of age by 
(1) NA nerve fiber density; (2) splenic norepinephrine (NE) concentration; and (3) 
circulating catecholamines levels after decapitation.   Results:  We report a decline in 
noradrenergic nerve density in splenic white pulp (45%) at 18 months of age compared 
with 8 month-old (M) rats, which is followed by a much slower rate of decline between 
18 and 32 months.  Lower splenic NE concentrations were consistent with morphometric 
findings.  Circulating catecholamines levels generally dropped with increasing age. 
Conclusion: These findings suggest there is a sympathetic-to-immune system 
dysregulation beginning at middle age.  Given the unique T-helper-2 bias in Brown 
Norway rats, altered sympathetic-immune communication may be important for 
understanding the age-related rise in asthma and autoimmunity.   
Classification Terms: Section 6. Regulatory Systems 
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Norway, BN; BN X F344 (F1), BNF1; central nervous system, CNS; delayed type 
hypersensitivity, DTH; diastolic pressure, DP; epinephrine, EPI; 
ethylenediaminetetraacetic acid, EDTA; Fischer 344, F344; glyoxylic acid condensation 
method, SPG method; high-performance liquid chromatography with electrochemical 
detection, HPLC; interleukin, IL; month-old, M; natural killer, NK; nerve growth factor, 
NGF; neurotrophin-3, NT-3; New Zealand black, white, and black and white mice, 
respectively, NZB, NZW, and NZBW; noradrenergic, NA; norepinephrine, NE; 
periarteriolar lymphatic sheath, PALS; perchloric acid, HClO4; sympathetic-adrenal 
medullary system (SAM); sympathetic nervous system, SNS; T-helper-1, Th1; T-helper-
2, Th2; Wistar-Kyoto, WK 
 
Introduction 
The central nervous system (CNS) regulates immune function, at least in part, via 
noradrenergic (NA) sympathetic nerves that innervate primary and secondary immune 
organs (reviewed in Bellinger et al., 2008b).   Norepinephrine (NE) released by 
sympathetic nerves interacts with adrenergic receptors (AR) expressed on the surface of 
cells of the immune system (reviewed in Kin and Sanders, 2006; Bellinger et al., 2008b). 
The sympathetic nervous system (SNS) modulates many aspects of immune function.  
Based on in vitro and in vivo studies in young adult rodents, the roles ascribed to the SNS 
include: (1)  limiting the magnitude of both acute and chronic inflammatory responses by 
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shifting the cytokine balance from a pro-inflammatory towards an anti-inflammatory 
cytokine profile (Vizi and Elenkov, 2002); (2) promoting T-helper-2 (Th2)-driven 
antibody responses via 2-AR signaling of B cells by up-regulating B cell accessory 
molecule expression and increasing B cell responsiveness to interleukin (IL)-4 (reviewed 
in Kin and Sanders, 2006); (3) enhancing cell-mediated responses, such as a delayed type 
hypersensitivity (DTH) reaction to a contact sensitizing agent through direct interaction 
with both T cells and antigen-presenting cells (Madden et al., 1989; Li  et al., 2004); and 
(4) influencing Th1-driven antibody responses through 2-AR stimulation of Th1 cells 
(Madden et al., 1995; Kruszewska et al., 1995; reviewed in Kin and Sanders, 2006; 
Bellinger et al., 2005).  In general, agents that activate the SNS tend to reduce T cell 
responses (Madden et al., 1989; Sanders et al., 1997; reviewed in Kin and Sanders, 2006), 
anti-viral immune reactivity (Dobbs et al., 1993), and natural killer (NK) cell activity 
(Irwin et al., 1988).  Collectively, studies performed in young adult rodents demonstrate 
that genetic background, gender, site of immunization, type of immune cells involved in 
the immune response, and timing of exposure to catecholamines during the immune 
response all contribute to the complexity of SNS interactions with the immune system 
and affect the outcome of SNS modulation of the immune response (Madden et al., 1995; 
Kin and Sanders, 2006; Bellinger et al., 2008b). Furthermore, these complexities likely 
reflect an important role of the SNS in fine-tuning an immune response with the goal of 
effectively eliminating the threat to the host and restoring immune system homeostasis.   
NA innervation of, and NE content in, secondary lymphoid organs, such as the 
spleen, can be affected by physiological changes (i.e., immune challenge or 
immunosuppression) (Yang et al., 1998; Lorton et al., 2008), immunodeficiency virus 
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infection (Kelley et al., 2003; Sloan et al., 2008), psychosocial stress (Sloan et al., 2007), 
hypertension (Purcell and Gattone, 1992), pregnancy and parturition (Bellinger et al., 
2001) and with advancing age (Bellinger et al., 1987, 2001, 2002). Age-related changes 
in sympathetic innervation of the spleen are species- and/or strain-specific.  For example, 
sympathetic NA innervation of spleens from aged C57Bl/6J and BALB/cJ mice is 
preserved (Madden et al., 1997; Bellinger et al., 2001), but declines with advancing age 
in male C3H, MRL-lpr/lpr (Breneman et al., 1993) and New Zealand mice (NZB, NZW , 
and NZBW) (Bellinger et al., 1989). In murine strains that develop autoimmune diseases 
(MRL lpr/lpr, NZB and NZBW) the onset of sympathetic nerve loss in the spleen occurs 
with, or slightly precedes the onset of the autoimmune disease (Breneman et al., 1993; 
Bellinger et al., 1989).    
In a previous study from our laboratory (Bellinger et al., 2002) we compared 
sympathetic innervation of the spleen in four strains of young (3-month-old (M)) and old 
(21M) rats. These strains of rats were chosen for study because they are commonly used 
as models for human aging and/or used to study neural-immune interactions.  We 
reported that NA innervation of spleens from male Fischer 344 (F344) and Lewis rats 
decline in normal aging, whereas NA innervation was preserved in age-matched Brown 
Norway (BN) and BN X F344 (F1; BNF1) rats.  The reason for this strain difference is 
unclear, but maybe a result of the BN and BNF1 rats having a longer life span (median 
age 32M) than F344 and Lewis rats (median age 24M) (Nadon, 2004).  Unlike F344 rats, 
the most commonly used rat model for aging, in BN rats there is low morbidity from 
pituitary adenomas or glomerulonephrosis with increasing age (Lipman et al., 1996, 
1999; Nadon, 2004).  BN and F344 rats also differ in their behavior (Rex et al., 1996; 
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Ramos et al., 1997), learning and memory (van der Staay et al., 1996), immune function 
(Sado et al., 1986; Koch 1976; Stankus and Leslie 1976; Festing, 1998; Lipman, 1996, 
1999), and stress responses (Segar et al., 2008; Duclos et al., 2005; Sarrieau et al., 1998; 
Gómez et al., 1998), which may affect NA nerve integrity in the spleen with advancing 
age.  
The purpose of the present study was to longitudinally examine the effect of age 
on sympathetic NA innervation of spleens from BN rats. Since age-related changes in 
SNS and sympatho-adrenal medullary system (SAM) reactivity may contribute to age-
induced changes in NA nerve integrity and splenic NE content via increased local 
catecholamine concentrations influencing uptake into the nerve terminals from the 
circulation, local sympathetic nerve activity, and/or affecting leukocyte migration 
(Bellinger et al., 2008b; Elenkov et al,. 2000; Madden et al., 1995), SNS and SAM 
reactivity to decapitation stress was also assessed by measuring circulating catecholamine 
levels (NE and epinephrine (EPI), respectively).  We report here an age-related decline in 
NA nerve density in the splenic white pulp, evident by morphometric analysis at 18 
months of age, and reduced splenic NE concentration between 18 and 32 months of age. 
Decapitation stress-induced plasma catecholamine levels were diminished in middle aged 
and aged rats. Given the well documented role of the SNS in immune modulation, altered 
sympathetic innervation likely affects immune competence in aging BN rats.   
 
Results 
Fluorescence Histochemistry for Catecholamines in the Spleen 
In young adult rats (8M), dense plexuses of NA fibers entered the spleen with the 
splenic artery and its branches. The greatest density of NA nerves was found in the white 
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pulp associated with the central arteriole and its branches (Fig. 1A). Fluorescent NA 
nerve fibers extend from these vascular plexuses into the periarteriolar lymphatic sheath 
(PALS) among lymphocytes and macrophages, as either linear or punctate profiles. NA 
nerve fibers also course as less dense plexuses along the venous sinuses and trabeculae in 
the red pulp, but are rarely found in splenic follicles, where B cells predominantly reside.   
At 15 months of age, declining NA nerve density was observed in all 
compartments of the spleen, mostly in the white pulp along the central arteriole (Fig. 
2.1B).  Between 18 and 32 months of age, the density of NA plexuses in the splenic white 
pulp, along the central arteriole (Fig. 2.1C-2.1F) and other regions of the spleen appeared 
comparable to that seen at 15 months of age.  Morphometric analysis of fluorescent nerve 
profiles in the splenic white pulp across age (Fig. 2.2A) confirmed our qualitative 
assessment of NA innervation (F (5,30) = 15.14, p < 0.0001).  A significant reduction in 
the mean splenic percentage of NA nerve area from 15M to 32M rats compared with 8M 
rats (p < 0.001) was found.  A scatter plot showing the percent area of NA nerve fibers in 
splenic white pulps across age is shown in Fig. 2.2B.  Linear regression analysis revealed 
a significant negative correlation (p < 0.0001) between sympathetic nerve area and 
increasing age.  
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Fig. 2.1. NA Nerves in the Splenic White Pulp across Age. 
Fluorescence histochemistry for localizing catecholamines revealed a dense plexus of 
bluish-green fluorescent noradrenergic (NA) nerves surrounding the central arteriole (ca) 
and in the adjacent white pulp (wp; indicated by arrowheads) of spleens from 8M (A). In 
15M (B) rats, NA innervation was diminished compared with 8M rats, a change that 
persisted through 32 months of age (C-F). These photographs are representative of NA 
innervation of spleens from all animals in each treatment group. 18M (C), 24M (D), 27M 
(E), and 32M (F) BN rats.  Calibration bar = 100 µm. 
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Fig. 2.2. Effect of Age on Mean Percentage of NA Nerve Area in the Splenic White 
Pulp. 
A.  The mean percent area of noradrenergic (NA) nerves in splenic white pulps was 
reduced (*, p < 0.001) between 15 and 32 months of age.  Four white pulp regions from  
6 rats per age group were used to quantify nerve area and data are expressed as mean of 
mean ± SEM.   
A 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. Relationship between Mean Percentage of NA Nerve Area in the Splenic 
White Pulp across Age. (Continued). 
B. A scatter plot demonstrates the distribution of splenic NA nerve expressed as a 
percentage of sample area in the white pulp across age. The line of best fit shows that NA 
nerve area is negatively associated (r2 = 0.344; p < 0.0001) with age. 
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NE Concentration in the Spleen 
There was a significant effect of age on splenic NE concentration (Fig. 2.3A) 
(F(5,41) = 15.39, p < 0.0001).  In 15M and 18M rats, the mean splenic NE concentration 
(Fig. 2.3A) was reduced by 25 and 45% of the 8M values, respectively (18M, p < 0.001), 
followed by a more gradual decline between 18M and 32M (8 vs.24-32M, p < 0.001).  
Additionally, posthoc analysis also revealed a significant lower mean splenic NE 
concentration at 27M and 32M than in 15M rats (27M, p < 0.001; 32M, p < 0.01), 
representing a 44% drop in splenic NE concentration.  In contrast, the mean spleen 
weight progressively increased from 15M through 32M (Fig. 2.3B) (F(5,41) = 12.67, p < 
0.0001). Spleen weights from 24M, 27M, and 32M rats were greater than 8M rats (24M, 
p < 0.01; 27-32M, p < 0.001). Similarly, spleens from 24-32M rats weighed significantly 
more than spleens from middle aged rats (15M vs. 24-32M, p < 0.001; 18M vs. 32M, p < 
0.05). Similarly, body weight progressively increased from 15M through 32M (Fig. 
2.3C). 
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Fig. 2.3. Mean Levels of Splenic NE Concentration Across Age. 
A. Mean splenic norepinephrine (NE) concentration (expressed in ng/g tissue wet weight) 
was slightly lower, but not significantly different at 15 months of age compared with 8M 
rat. Between 18 and 32 months of age, splenic NE levels significantly (*, p < 0.01) 
decreased compared with 8M levels.  Splenic NE concentrations from 27M and 32M rats 
also significantly differed (**, p < 0.001) from levels in 15M rats.  Error bars = SEM. 
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Fig. 2.3. Mean Levels of Spleen Weight Across Age (Continued). 
B.  Mean spleen weight (expressed in g) progressively rose between 8 and 32 months of 
age, with significant differences revealed by posthoc analysis in 24 through 32M rats 
compared with 8M and 15M rats (*, p < 0.01, 24M; and **, p < 0.001, 27-32M, 
respectively).  Spleen weight also was significantly higher in 32M compared with 18M 
rats (***, p < 0.05).  Error bars = SEM. 
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Fig. 2.3. Mean Levels of Body Weight across Age (Continued). 
C.  Mean body weights (expressed in g) were comparable at 8 and 15 months of age, but 
increased between 18 and 32 months of age.  *, significantly different from 8M: 18M, 24 
– 32M, p < 0.001; **, significantly different from 15M: 24 – 32M, p < 0.001; ***, 
significantly different from 18M: 24 – 27M, p < 0.001. Error bars = SEM. 
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Fig. 2.4. Relationship between Splenic NE Concentration and NA Nerve Area or 
Age in the Spleen. 
A.  The distribution of the mean percentage of NA nerve, as demonstrated by the scatter 
plot area in the white pulps that were sampled per rat across splenic NE concentration 
(ng/g) for each age group.  Linear regression analysis was used to plot the line of best fit 
and calculate r2, and reveals a positive association (p < 0.0001) between NA nerve area 
in the white pulp and splenic NE concentration. 
A 
0.0
1.0
2.0
3.0
4.0
5.0
0 20 40 60 80 100 120
Splenic NE Concentration (ng/g)
N
A
 N
er
ve
 A
re
a 
(%
)
  8
15
18
24
27
32
r2 = 0.444
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. Relationship between Age and NE Concentration in the Spleen 
(Continued). 
B.  This scatter plot represents the distribution of splenic NE concentration (ng/g) across 
age.  Linear regression analysis reveals a negative association (p < 0.0001) between 
between splenic NE concentration and increasing age (p < 0.0001).     
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Figure 4 shows the scatter plots that demonstrate the relationships between splenic 
NE concentration (Fig. 2.4A, 2.4B), percentage of NA nerve area in the splenic white 
pulps (Fig. 2.4A), and age (Fig. 2.4B). Linear regression analysis revealed a positive 
correlation (r2 = 0.444; p < 0.0001) between splenic NE concentration and NA nerve area 
in the splenic white pulp. A higher percentage of sympathetic nerves in the white pulp is 
associated with greater splenic NE concentration (Fig. 2.4A).  In contrast, increasing age 
is associated (r2 = 0.791; p < 0.0001) with reduced splenic NE concentration (Fig. 2.4B). 
 
Mean Plasma Catecholamine Concentration  
Plasma catecholamine levels in all age groups were significantly elevated over 
basal levels from previous reports (Fig. 2.5A-B). There was an effect of age on mean 
plasma catecholamine levels (Fig. 2.5A-B) (NE, F(5,34) = 5.652, p < 0.0007; EPI, 
F(5,33) = 5.143, p < 0.0014).  Mean plasma NE concentration (Fig. 2.5A) was reduced 
by 24% in 15, 24, and 27M old rats compared with young adults (15M, p < 0.05; 24M, p 
< 0.001; 27M, p < 0.01).  Similarly, plasma EPI levels (Fig. 2.5B) were highest at 8 
months of age and reduced with aging (~32-58%), with a significant decline observed at 
15, 24, and 32 months of age compared with young adult rats (15M, 24M, p < 0.01; 32M, 
p < 0.05).   
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Fig. 2.5. The Effect of Decapitation-Induced Stress on Plasma NE Concentration 
from Trunk Blood across Age. 
A.  Plasma norepinephrine (NE) concentrations (expressed in ng/ml as a mean ± SEM) 
were significantly (*, p < 0.05, p < 0.001, and p < 0.01, respectively) diminished at 15, 
24, and 27 months of age compared with 8M rats.  Dashed box represents the range of 
basal catecholamines levels reported in the literature based on assessments from awake, 
undisturbed rats from which blood was drawn via an indwelling catheter (Popper et al., 
1977; Mabry et al 1995a,b,c; Paulose and Dakshinamurti, 1987; Carruba et al., 1981; 
Kvetnansky et al., 1978). 
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Fig. 2.5. The Effect of Decapitation-Induced Stress on Plasma EPI Concentration 
from Trunk Blood across Age (Continued). 
B.  Epinephrine (EPI) concentrations in BN rats are shown across age (in months). 
Plasma EPI levels were significantly (*, p < 0.01, 15 and 24M; p < 0.05, 32M) lower at 
15, 24, and 32 months of age compared with 8M rats.  Dashed box represent the range of 
basal catecholamines levels reported in the literature based on assessments from awake, 
undisturbed rats from which blood was drawn via an indwelling catheter (Popper et al., 
1977; Mabry et al 1995a,b,c; Paulose and Dakshinamurti, 1987; Carruba et al., 1981; 
Kvetnansky et al., 1978). 
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Splenic NE Turnover Rates Across Age 
Intraperitoneal treatment with α-MPT was used to block the activity of Tyrosine 
Hydroxylase, the rate limiting step enzyme in the synthetic chain of NE.  The mean rate 
of NE loss in the spleen was measured over a 6-hour period in all age groups.  Regression 
analysis revealed that the turnover rate and turnover time of the decline of NE was 
greater (p< 0.001) diminished (p< 0.05), respectively at 15 months of age, compared with 
yound adult (8M), or older adult (18M, 27M, and 32M) rats ( table 1 ). 
 
Discussion 
In the present study, we demonstrated a dramatic age-related decline in NA 
sympathetic nerve density and NE concentration in spleens from male BN rats that was 
evident by early middle age (15M).  Splenic NE concentration positively correlated with 
sympathetic nerve area.  In contrast, both splenic NE concentration and sympathetic 
nerve area in the white pulp negatively correlated with age.  These findings are consistent 
with a loss of neurotransmitter content in the spleen as sympathetic nerves are 
concomitantly lost with advancing age. NA nerve density in the splenic white pulp, as 
well as other splenic compartments, was relatively comparable between 15 and 32 
months of age despite the progressive decline in splenic NE concentration during this 
time period. These findings suggest a dying back of sympathetic nerves in middle age 
without a change in NE metabolism.  Furthermore, these results suggest that there are 
age-related alterations in sympathetic signaling to immune cells in the aging BN rat 
spleen, because the amount of NE that is available to interact with cells of the immune 
system is reduced. 
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Table 2.1. Turnover rates and turnover times of NE in the spleen of BN male rats across 
age as determined from regression analysis of the data. Initial NE concentration was 
greater (p<0.01) in 15M BN rats compared with older rat groups (18M, 27M, 32M); and 
splenic turnover rate was significantly different (p<0.001) in 15M compared to all other 
age groups.  Initial levels of splenic NE and the rate constants are expressed as means ± 
SEM. αMPT, α-methylparatyrosine NE, norepinephrine; BN, Brown Norway rats; n, 
number of rats per age group. 
 
 
Table 2.1. 
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These findings are generally consistent with reports in male F344 rats (Bellinger et 
al., 1987, 1992a,b), the most commonly used rat model for aging. Interestly, the age at 
which NA nerve loss becomes evident is comparable in both strains of rats (18 months of 
age) despite the fact that male BN rats live 20% longer than male F344 rats (75% 
mortality by 34 and 26 months of age, respectively (Nadon, 2004)).  However, there are 
some noteworthy differences between these two strains. First, the decline in splenic nerve 
density in the white pulp is less extensive in BN compared with F344 rats (~56% vs. 75% 
at around the time of 75% mortality). This finding suggests that while the mechanisms 
that initiate the age-related decline in sympathetic innervation of the spleen may be 
similar in these two strains, the microenvironment of spleen may differ such that greater 
resilience is afforded to sympathetic nerve fibers in spleens from BN rats.  Whether this 
is a reflection of the striking differences in the immune profiles of these two strains 
awaits further study.  Similarly, how differential preservation of sympathetic innervation 
of secondary lymphoid tissues, and its consequences on immune regulation contributes to 
greater longevity, requires further investigation.   
Another difference between these two strains is that the decline in nerve density in 
old BN rats is comparable to the loss of splenic NE concentration (approximately 56-57% 
decline for both parameters at 32 months of age). In contrast, the extent of NA nerve lost 
at 27 months of age in F344 rats is much greater (75%) than the loss in splenic NE 
concentration (~50%) (Bellinger et al., 1987; 1992b).  These data, along with functional 
data in F344 rats indicating increased signaling of splenocytes via NE binding with β-AR 
(Bellinger et al., 2008a) suggest compensatory mechanisms in NE metabolism in 
response to NA nerve loss in F344 rats, which do not occur with nerve loss in BN rats.  
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NE turnover studies are needed to directly address this hypothesis; however preliminary 
findings from our laboratory (unpublished observations) showing that NE signaling of 
splenocytes via β-AR stimulation is significantly impaired in old BN rats indirectly 
supports this hypothesis. 
In a previous study from our laboratory (Bellinger et al., 2002) no significant 
differences in splenic NE concentration between 8M and 21M male BN rats were 
reported. The reason for the greater effect of aging on NA nerve integrity observed in the 
present study is not known, but may be due to differences in the vendor source. Male BN 
rats in the present study were obtained through National Institute on Aging (NIA) from 
Harlan, whereas in the earlier study animals were purchases through NIA from Charles 
River Laboratories.  These discrepancies are not unique as other studies have reported 
differences in physiological parameters depending on the vendor source (Perrotti et al., 
2001; Turnbull and Rivier, 1999; Pare and Kluczynski, 1997).  For example, 
neuroendocrine and immune responses to inflammatory stimuli differed in Sprague-
Dawley rats depending on whether they were obtained through Harlan or Charles Rivers 
Laboratories (Turnbull and Rivier, 1999).    
The loss of NA innervation of the spleen in male BN rats may be explained by (a) 
changes in neurotrophic support, neurotrophic receptor expression, and/or neurotrophic 
signal transduction in splenic sympathetic NA nerve fibers, (b) cumulative effects of 
oxidative stress on the NA nerve fibers, and/or (c) an increase in systemic inflammation 
that occurs with aging. Neurotrophic growth factors such as neurotrophin-3 (NT-3) and 
nerve growth factor (NGF) are important for maintaining and supporting NA nerve 
integrity (Levi-Montalcini, 2004).  NGF, NT-3 and brain-derived neurotrophic factor are 
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abundantly present in the spleen (Yamamoto et al., 1996).  While it is not known whether 
there is an age-related decrease in NGF activity in F344 and BN rats, there are reports of 
an age- and disease-related decline in the content of NGF in several organs.  Nishizuka 
and coworkers reported a decline in NGF in specific brain regions with age (Nishizuka et 
al., 1991; Nitta et al., 1993). There is also a decline in NGF and NT3 in the spleens of 
Lewis rats with adjuvant-induced arthritis (Bellinger et al., 2001). NGF, an essential 
neurotrophin factor for sympathetic neuron survival, is extensively distributed in the 
parenchyma of spleen. A decline in its activity may explain the age-related disappearance 
of NA nerve fibers in splenic white pulp.   
In support for a role for oxidative stress in NA nerve loss, administration of 
deprenyl, a monoamine oxidase inhibitor, reverses the 6-hydroxydopamine-induced and 
age-related loss of splenic NA innervation in young and old F344 rats respectively 
(reviewed in ThyagaRajan and Felten, 2002).  The reversal in NA neuronal loss was 
accompanied by enhanced cell-mediated immunity especially NK cell activity and IL-2 
and IFN- production (reviewed in ThyagaRajan and Felten, 2002).  These studies 
suggest growth factors and cytokines are important in maintaining sympathetic nerve 
fibers in the splenic white pulp across life span, and altered trophic support can have 
functional consequences.   
Alternatively, individual variability in aging of sympathetic innervation of the 
spleen, or survival selectivity may contribute to the differences seen; however, the 
individual variability we found in our study does not lend support to the former 
hypothesis. Other factors that may contribute include differences in animal transport to 
the study location, time of year, and housing conditions.  Collectively, these findings 
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suggest that environmental factors may affect NA nerve integrity in the aging rat spleen. 
In support of this hypothesis, Sloan et al (2008) have shown that simian 
immunodeficiency virus infection decreases sympathetic innervation of primate lymph 
nodes, possibly due to reduced neurotrophic support.  
Plasma NE and EPI levels reported here reflect a stress response to handling and 
decapitation, as they are ~5-10 and 15-80 fold greater, respectively, than measurements 
taken via indwelling catheters from awake, undisturbed rats (Popper et al., 1977; Mabry 
et al 1995a,b,c; Paulose and Dakshinamurti, 1987; Carruba et al., 1981; Kvetnansky et 
al., 1978).  Basal catecholamines were not measured in the present study, however, other 
studies in rats commonly report no effect of age on circulating NE and EPI (McCarty, 
1981, 1985; Korte et al., 1992; Mabry et al., 1995a,b,c), and some studies have found 
elevated levels (Michalikova et al., 1990).  Plasma NE and EPI concentrations from 8M 
rats in our study are comparable to levels previously reported in young BN rats (Gilad 
and Jimerson, 1981) and other rat strains under the conditions used to obtain blood in this 
study (Ben-Jonathan & Porter, 1976; Roizen et al., 1975; Popper et al., 1977).   One study 
(Gilad and Jimerman, 1981) has compared sympathetic reactivity to decapitation stress 
alone or with immobilization in young BN and Wistar-Kyoto (WK) rats, of which the 
latter strain is more reactive to stress. They found that plasma catecholamine levels 
immediately after decapitation and 0 or 10 min after immobilization stress were 
significantly higher in WK than in BN rats.  No studies that we are aware of have 
examined the effect of decapitation stress in the long-lived BN rat across age. However, 
in another study from our laboratory, no age-related change in decapitation stress-induced 
plasma NE concentrations and reduced plasma EPI levels at 24 months were found in 
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male F344 rats (Bellinger et al., 2008a), a strain with a little less than 1 year shorter 
median life span (Nadon, 2004) and greater behavioral responses to stress generally 
attributed to differences in hypothalamic-adrenocortical functioning (Marissal-Arvy et 
al., 1999; Sarrieau et al., 1998; Gómez et al., 1996, 1998; Kusnecov et al., 1995).  The 
age-related decline in decapitation-stress induced rise in plasma NE and EPI 
concentrations found in this study suggests diminished capacity of the SNS and SAM to 
effectively respond to an acute stressor in aging male BN rats. Relevant to the present 
study, Kusnecov et al. (1995) demonstrated significant differences in footshock stress 
during early diurnal and nocturnal periods of the day on T cell mitogen-induced 
lymphocyte proliferation and IL-6 response in male BN rats compared with three other 
strains of rats, including F344 rats.   
Stress studies by other investigators (Mabry et al., 1995a,b,c; Cizza et al., 1995) 
have demonstrated variable age-related differences in SNS and SAM reactivity to other 
acute and chronic stressors, depending on the type, duration, and intensity of the stressor.  
For example, in contrast to our findings in F344 rats, Mabry and colleagues (1995a) 
reported greater plasma catecholamine responses in aged F344 rats (22M) and slower 
return to baseline after termination of the stressor than those of young adult rats (3M) 
after cold (20 and 25 C) swim stress, but no aging difference when the water 
temperature was at 30 or 35 C.   In another aging study using Wistar rats (Michalíková 
et al., 1990), basal plasma catecholamines were elevated in 11 and 28M rats compared 
with young rats, and immobilization stress markedly increased plasma NE in 11M, but 
plasma NE and EPI was mildly elevated in 28M animals. Although poorly characterized 
in rats, stress-induced effects on sympathetic reactivity in humans are not attributable to 
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differences in thermoregulatory mechanisms or kinetic factors, such as neuronal uptake 
or plasma clearance rates of catecholamines (Linares and Halter, 1987; Morrow et al., 
1987; Poehlman et al., 1990; Stromberg et al., 1991).  Since visceral organs contribute 
very little to plasma NE levels (reviewed in Bellinger et al., 1998), it seems unlikely that 
reduced SNS activity in the spleen contributes to the lower plasma catecholamine levels. 
Collectively, these studies indicate an age-related impairment in the ability of animals, 
including humans, to adapt to an ever-changing environment because of defects in 
hypothalamic regulation of SNS and SAM activity in aged animals. Thus, whereas basal 
levels of circulating hormones, like NE and EPI, are often not affected by aging, defects 
in neuroendocrine and autonomic regulation become unmasked when aged animals are 
exposed to acute stressors. 
Our plasma catecholamine findings are relevant to sympathetic regulation of 
immune function in at least two ways. First, physical and psychosocial stressors can 
affect an immune function by elevating circulating stress hormones [Szelenyi and Vizi, 
2007; Starkie et al., 2005; Moncek et al., 2003; Giovambattista et al., 2000; Condé et al., 
1999; Hasko et al., 1995; Mujika et al., 2004; Brenner et al., 1998; Pederson et al., 1997; 
Pyne, 1994; Hinrichsen et al., 1992].   Second, exposure to environmental antigens is in 
and of itself a stressor, affecting the reactivity of the SNS and SAM (Sakata et al., 1994; 
Moncek et al., 2003; Giovambattista et al., 2000).  Thus, meausured plasma 
catecholamine levels reflect the effects of aging on the activation (i.e. decapitation) of 
stress pathways in normal aging laboratory BN rats. And it was important to differentiate 
the measured plasma NE levels from normal NE basal levels.  
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The functional significance of altered sympathetic reactivity to stress and 
sympathetic innervation of the aging rat spleen awaits further investigation. It is clear, at 
least in young adults, the SNS plays an important role in regulating immune function and 
that dysregulation of the SNS can affect immune-mediated diseases (reviewed in Kin and 
Sanders, 2006; Bellinger et al., 2008b; Elenkov et al., 2000). It is also well documented 
that as cell-mediated immunity declines with increasing age (reviewed in Chakravarti and 
Abraham, 1999; Shearer, 1997), there is a shift toward humoral-mediated immunity 
(Caruso et al., 1996; Castle et al., 1997). Given these data, it is tempting to speculate that 
altered NA neural signaling of the immune system may contribute to immune senescence.  
Whether this is true or not, SNS dysregulation in aging is likely to affect the host’s ability 
to optimally defend against infectious diseases, prevent autoimmunity, detect/eliminate 
cancerous cells, and influence circulating proinflammatory cytokine levels, which 
progressively rise with age.  As the immune system shifts to a Th2 response with aging, 
tolerance mechanisms have been postulated to fail leading to the production of clinically 
significant autoreactive antibodies (Stacy et al., 2002; Stephan et al., 1997).  
BN rats are unique, because they have a vigorous Th2 immune responses, 
producing cytokines IL-4, IL-6, and IL-10, along with antibody isotypes IgG1 and IgE on 
antigenic stimulation (Fournié et al., 2001). They also share many immunological and 
physical responses seen in human asthma, such as high production of IgE antibody, 
contraction of airway smooth muscle, airway hyperresponsiveness, involvement of 
leukotrienes in lung reactions, and infiltration of eosinophils and lymphocytes into the 
airway (Ohtsuka et al., 2005). BN rats are widely used to study several chemically-
induced autoimmune syndromes such as polyarthritis, vasculitis, lupus-like syndromes, 
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and other types of T helper cell dependent autoimmune diseases.  With their striking Th2 
bias, aged BN rats may provide a good model for discovering the mechanisms that 
predispose the elderly to increased risk for Th2-mediated autoimmune diseases and 
asthma. Careful analysis of species- and strain-related differences in how the SNS and 
immune system changes with advancing age and their relationship with frequencies of 
morbidity and mortality to certain types of disease may reveal risk factors and/or aging 
phenotypes that strongly predict susceptibility to certain types of diseases associated with 
aging.  
 
Experimental Procedure 
Animals 
Male, inbred, specific-pathogen-free BN/Bi (BN) rats at 8, 15, 18, 24, 27, or 32 
months of age (n of 8 per age group) were purchased under a National Institute of Aging 
(NIA) contract from Harlan Sprague-Dawley (Indianapolis, IN).  Animals were housed 
two per cage in the vivarium at Loma Linda University, an Accreditation of Laboratory 
Animal Care (ALAC)-accredited facility. The room temperature (22-25 °C) and humidity 
(30-40%) were controlled and maintained on a 12:12-h light-dark cycle.  Rats had access 
to rodent chow and water ad libitum. Animals were closely observed for changes in 
physical condition and/or presence of age-related illness. All animal experiments were 
conducted in accordance with the principles and procedures outlined in National 
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were 
approved by the Animal Care and Use Committee at Loma Linda University.  At the time 
of sacrifice, all visceral organs were autopsied for evidence of gross pathologies and 
tissues were dissected for study.  Rats with any visible lesions, tumors, and evident 
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pathology were removed from this study and their tissues excluded from the analysis. 
Three additional animals per group at older ages in our study were purchased to 
compensate for loss of animals from the study due to pathology and to maintain an n of 8 
per treatment group. 
 
Study Design 
Rats were housed in the vivarium at Loma Linda University for 1 week prior to 
study initiation to acclimate to vivarium conditions. After acclimation to vivarium 
conditions, rats were sacrificed by decapitation, and spleens and trunk blood were 
immediately harvested.  Spleens were cut cross-sectionally into 5 equally-sized pieces.  
The middle piece of the spleen was weighed, immediately frozen on dry ice, and stored at 
-80 °C until samples were prepared for neurochemical measurement of NE by high-
performance liquid chromatography with electrochemical detection (HPLC). The 
adjacent spleen pieces were used for fluorescence histochemical staining to localize NA 
nerves. Trunk blood (8-10 ml per sample) was collected in 12x75 mm tubes containing 
10 mmol/L disodium ethylenediaminetetraacetic acid (EDTA) kept on ice. All blood 
samples were collected within 1 min of decapitation.  After centrifugation (1200 rpm), 
the plasma was collected into microfuge tubes and stored at -80 oC until the 
determination of catecholamine levels. 
 
Fluorescence Histochemistry for Catecholamines 
The glyoxylic acid method of histofluorescence for catecholamines was used to 
visualize NA sympathetic nerves in spleens from BN rats. Spleen blocks from each rat 
were sectioned at 16 µm on a cryostat at -20 °C. The sections were thaw-mounted onto 
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slides and stained using a modification of the glyoxylic acid condensation method (SPG 
method), as previously described by de la Torre (1980). Briefly, 3 sections were mounted 
on each slide, dipped into a solution containing 1% glyoxylic acid, 0.2 M potassium 
phosphate, and 0.2 M sucrose (pH 7.4), and then slides were air dried under a direct 
stream of cool air for 15 minutes. Spleen sections were covered with several drops of 
mineral oil, placed on a copper plate in an oven at 95 °C for 2.5 minutes, then 
coverslipped. Catecholamine-containing nerve terminals were visualized using an 
Olympus BH-2 fluorescence microscope equipped with epi-illumination accessories.  
 
High-Performance Liquid Chromatography (HPLC) with 
Coulometric Detection 
Spleen samples were transferred into labeled centrifuge tubes containing 10X 
volume per tissue wet weight of cold 0.1 M perchloric acid containing 0.25 µM 3, 4-
dihydroxybenzylamine (DHBA) as an internal standard, sonicated using a Branson 
Sonifier 250, and centrifuged at 10,000 rpm for 5 min. Supernatants were transferred to 
microfilterfuge tubes, centrifuged at 14,000 rpm for 20 min and stored at -80 °C until 
assayed for NE content.  Plasma samples (200 µl per sample) were pipetted into a 12x75 
mm glass tube, followed by the addition of 1.0 ml of phosphate buffer (pH 7.0), 1.0 ml of 
1.5 M Tris buffer (pH 8.6), 50 µl of the internal standard, DHBA, and 50 mg of acid 
washed alumina. Plasma samples were vortexed and placed on a shaker for 5 min at 175 
rpm and then the alumina was allowed to settle. Next, the samples were aspirated, 
washed 3X with double distilled H2O, and centrifuged for 2 min at 14,000 rpm.  The 
alumina was placed into a new microfilterfuge tube and vortexed in 200 µl of 0.1 M 
HClO4.  After the  samples were centrifuged again for 2 min at 9000 rpm, 50 µl of 
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supernatant from each sample were transferred to HPLC vials and loaded into an ESA 
Model 542 autosampler to quantify NE concentrations ([NE]) by HPLC using a 
CouleChem HPLC System (ESA, Chelmsford, MA).  The mobile phase was delivered at 
a flow rate of 1.0 ml/min by an ESA Model 582 solvent delivery module through a 
reverse phase C18 5 µm, 8x100 mm Radial-Pak analytical column.  The potential through 
the guard cell and the two detector cells in the ESA CouleChem III coulometric system 
were set at 400 mV, 350 mV, and -350 mV, respectively.  Peak heights and area under 
the curves were analyzed using EZChrom Elite Software (Scientific Software Inc. 
Pleasanton, CA).  Unknown sample catecholamine concentrations were determined by 
comparing peak area (peak height) with those from known standards.  
 
Data Analysis 
Morphometric analysis of splenic NA nerves in the white pulp was carried out 
without knowledge of the treatment groups (i.e., blinded) using the Image Pro® Plus 
software (version 5.0; Media Cybernetics, Bethesda, MD), as previously described 
(Lorton et al., 2005; Bellinger et al., 1987, 2002). The white pulp was selected for 
analysis, because the majority of sympathetic nerve fibers innervate this splenic 
compartment. One randomly selected splenic white pulp in the hilar region (the point of 
NA nerve entry into the spleen) of 4 spleen sections per rat from 6 animals per age group 
was used for analysis. The criteria for selection of white pulps for analysis were that (1) 
there was only one cross-section through the central arteriole in the white pulp; (2) the 
size of the central arteriole was comparable across all samples (80-100 µm across the 
largest diameter of the vessel) and (3) the arteriole was cut in true cross section. Splenic 
white pulps were digitally photographed at 200X and the number of pixels containing NA 
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nerve profiles in each image, based on size and color, were determined. At this 
magnification, all pixels of each image were within the white pulp. The number of 
positive pixels (i.e., those containing nerve fibers) was used to determine the percentage 
of the total area positive for sympathetic nerves in each image.  The average percentage 
area positive for sympathetic nerves from the 4 white pulps that were sampled from each 
animal was calculated, and then the means from each animal per age group were 
averaged to determine the within group mean ± standard error of the mean (SEM).  
Catecholamine concentrations, and spleen and body weights were expressed as a 
mean ± SEM. NE concentrations in the spleen, and plasma NE and EPI concentrations, 
were determined from known standards and concentrations corrected based on the 
recovery rate of the internal standard, DHBA.  Plasma catecholamine concentrations 
were expressed in ng/ml. Splenic NE concentration was expressed in ng per g tissue wet 
weight.  A one-way analysis of variance (ANOVA) was performed on all data to 
determine between group differences using GraphPad Prism 4.0®. Factors reaching 
significance levels of at least p < 0.05 by ANOVA were subjected to Bonferroni post-hoc 
analysis to determine which groups contributed to the significant ANOVA.  Scatter plots 
and least-squares linear regression analysis were performed using GraphPad Prism 4.0® 
to determine correlations between splenic NE content and noradrenergic nerve density 
and age, and splenic NE concentration and age. Lines of best fit with a 95% confidence 
interval were generated.  Significance levels were determined by calculating the 
correlation coefficients (r2 values) and degrees of freedom (n-2); p < 0.05 was considered 
significant. 
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Abstract 
Immune functioning declines with normal aging and with stress, increasing the risk 
for cancer, autoimmunity, and infectious diseases. Age-related changes in sympathetic 
neurotransmission in immune organs occur concomitantly with, and may be causally-
related to, immunosenescence; however, no model has been developed to determine causal 
relationships. Splenic sympathetic activity increases throughout middle-age, followed by a 
decline in activity, sympathetic nerve loss, increased β-adrenergic receptor (β-AR) 
signaling and reduced proliferation of lymphocytes from old Fischer 344 (F344) rats.  Here, 
we investigated the role of increased sympathetic tone during middle-age on 
neurotransmission in the aged rat spleen as a first step towards developing a model for 
determining causal relationships between immune decline and altered sympathetic 
functions with age. Fifteen-month-old (15M) male F344 rats received 90-day rilmenidine 
treatment (0, 0.5 or 1.5 mg/kg/day, i.p.; Veh-18M, Rilmlo, or Rilmhi, respectively) a 
centrally-acting imidazoline-1 receptor agonist that lowers sympathetic activity. Untreated 
3M and 18M rats (Crtl-3M and Crtl-18M, respectively) controlled for handling/injection 
stress. Splenic norepinephrine (NE) concentration with or without synthesis blockade, 
noradrenergic (NA) innervation, β-AR expression and β-AR-stimulated c-AMP production 
were evaluated using high-performance liquid chromatography with coulometric detection, 
fluorescence histochemistry, β-AR radioligand binding, and enzyme immunoassay (EIA), 
respectively.  Rilmenidine treatment reduced splenic NE concentration and turnover, 
plasma NE (but not epinephrine) concentration, and partially reversed age-related nerve 
loss compared with young or old control groups.  Rilmlo increased β-AR density without 
affecting affinity compared with Veh-18M rats. Rilmlo and Rilmhi treatment further 
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augmented the age-related rise in β-AR-stimulated cAMP production. Collectively, these 
findings demonstrate that rilmenidine protected sympathetic nerves and enhanced β-AR-
mediated signaling in immune organs from aging rats that display a heightened sympathetic 
profile. Furthermore, they suggest that rilmenidine could affect host defense against age-
related diseases.      
 
Keywords: rilmenidine, imidazoline-1 receptor agonist, sympathetic nervous system, β-
adrenergic receptors, cAMP production, aging, splenic norepinephrine 
turnover 
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Introduction 
The sympathetic nervous system (SNS) is a homeostatic regulator of 
cardiovascular, metabolic and immune functions under basal conditions, in the face of 
acute or chronic changes in physiological state, and in response to stress. In immune 
organs, the SNS regulates immune function via tonic release of its major transmitter, 
norepinephrine (NE) [Bellinger et al., 2008a,b]. NE binds with adrenergic receptors (AR; 
predominantly β2) expressed on immunocytes to increase cAMP production [Halper et 
al., 1984].  The SNS modulates a wide variety of immune measures, and affects the 
development and progression of immune-mediated diseases [reviewed in Bellinger et al., 
2008b]. 
With aging, basal sympathetic nerve activity (SNA) progressively rises [Docherty, 
2002], and SNS responses after activation are exaggerated [McCarty et al., 1997]. The 
functional significance of hyperactive SNA in immune organs remains unclear and 
understudied. Presumably, it occurs at the expense of fine control, at the risk of over-
stimulating target tissues, and places additional metabolic strain (allostatic load) on all 
target organs [Goldstein and McEwen, 2002]. Higher SNA can alter immune cell 
trafficking [Redwine et al., 2003] and host defense [Bellinger et al., 2008b], and may be a 
risk factor for developing immune-mediated diseases that increase in frequency with 
advancing age [Bellinger et al., 2008b; Cohen et al, 2001].   Furthermore, the extent to 
which aging changes in SNS functioning mediate, or contribute to, the aging changes in 
immune function, i.e. a causal relationship between these two phenomena, remains 
unknown. This lack of information is due, in part, to a lack of clear understanding of 
target-specific changes in SNS functioning across age, and the lack of model systems that 
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can reverse the age-induced SNS changes in immune target organs, which is necessary to 
test this hypothesis in vivo. 
In aging male F344 rats, sympathetic innervation progressively declines in 
secondary lymphoid organs [Bellinger et al., 1992, 2008a,b]. Nerve loss resembles a 
peripheral neuropathy in that nerves recede distally to proximally from their entry sites 
into the spleen, the hilar region.  Nerve loss precedes a significant loss in splenic NE 
levels, suggesting enhanced NE metabolism as an early compensatory event. This is 
consistent with a slight, but significant rise in splenic NE concentrations in 10M rats and 
increased NE turnover between 10 and 15 months.  In 24M rats, splenic NE turnover is 
reduced compared with 8, 10, 12, and 15M rats [Bellinger et al., 2008a]. Age-related 
splenic denervation is associated with increased lymphocyte responsiveness to β-AR 
stimulation that is evident in 15M rats [Bellinger et al., 2008a] and altered immune 
function [Bellinger et al., 2008a,b]. Collectively, our findings indicate that splenocytes 
from aging F344 male rats respond to changing NE concentration in the local milieu, 
with compensatory regulation of β-AR expression and cAMP production to affect 
immune function. 
As a first step in developing an aging model for investigating causal relationships 
between sympathetic and immune dysregulation, we investigated whether heightened 
splenic SNA during middle age is responsible for splenic NA nerve loss and altered β-AR 
signaling in splenocytes. In the brain, high catecholamine concentrations are neurotoxic 
due to increased reactive oxygen species (ROS) from catecholamine degradation [Chinta 
and Anderson, 2008; Burke et al., 2004].  We propose a similar mechanism affects NA 
nerve integrity, with consequences for β-AR-mediated signaling in the F344 rat spleen as 
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SNA rises during middle age. In this study, we investigated the effects of chronically 
reducing SNA centrally during middle age by treatment with rilmenidine (Rilm) on a 
variety of measures to assess sympathetic integrity and function. Rilm is a centrally 
acting antihypertensive drug that selectively inhibits sympathoexcitatory cells in the 
rostroventrolateral medulla (RVLM) [Reis, 1996; Monassier et al., 2004], a brainstem 
autonomic region that regulates SNA in the spleen [Beluli & Weaver, 1991]. This is the 
first study to investigate the effects of Rilm, or other drugs in its class, in normotensive 
rats, with endpoint in immune target organs, and nerve integrity in any organ.  
Here, we report that chronic Rilm discontinuously administered during middle age 
reduced net and splenic SNA, protected splenic NA nerves from age-related damage, and 
further augmented β-AR-mediated signaling of splenic lymphocytes. Protection of 
splenic sympathetic nerves supports our hypothesis. Greater β-AR expression and 
signaling supports reduced NE available to bind with β-AR via reduced SNA and 
indicates functional β-AR and signaling regulation, an important criterion for developing 
a model for studying causality between age-related changes in SNS and immune 
functioning.  We conclude that chronic treatment with Rilm during middle age is a 
strategy for reversing age-related changes in sympathetic neurotransmission in the spleen. 
 
Methods 
Drug Preparation 
Rilm dihydrogenase, a centrally acting third generation antihypertensive drug, was 
a gift from Servier (Suresnes, France). Rilm is stable in solution at room temperature for 
over 24 hours [Monassier et al., 2004], therefore the drug was prepared once daily prior 
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to the first of two daily injections.  Rilm was dissolved in sterile, endotoxin-free, 
physiologic saline at 0.5 mg/ml or 1.5 mg/ml.  Rilm is stable in solution at room 
temperature for over 24 hours [Monassier et al., 2004]. α-Methyl-DL-p-tyrosine methyl 
ester HCl (MPT) (Sigma-Aldrich, St. Louis, MO), an inhibitor of tyrosine hydroxylase, 
the rate-limiting enzyme for the synthesis of NE, was used to determine splenic NE 
turnover. The MPT was dissolved in sterile, endotoxin-free, physiologic saline 
containing 0.1% ascorbic acid at a concentration of 0.2 mg/ml.   
 
Animals 
Seventy-six 15-month-old (15M) male, F344 rats were purchased from the National 
Institute on Aging (NIA) colony (Harlan Sprague-Dawley; Indianapolis, IN).  All animals 
in the study were housed two per cage in the vivarium at Loma Linda University, given 
food and water ad libitum, and placed on a 12-h-on 12-h-off light schedule. In the animal 
room, the ambient temperature was maintained at 22 °C, and the humidity ranged 
between 30-40%. Rats were acclimated to housing conditions for one week, and then 
were handled daily for one week before the start of the experiment.  All animal 
manipulations and procedures were approved by the institutional animal care and use 
committee at Loma Linda University prior to the start of the experiments, and followed 
NIH guidelines on the use and care of animals.  
 
Study Design 
The rats were randomly assigned to one of three treatment groups: low-dose Rilm 
(Rilmlo), high-dose Rilm (Rilmhi) or vehicle (Veh-18M) (n of 12 per treatment group).  
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Rats were treated with sterile, endotoxin-free saline (Veh-18M) or Rilm (500 or 1.5 
mg/ml/kg/day, intraperitoneal (i.p.); Rilmlo or Rilmhi, respectively) by twice-daily 
injections (half the total dose per injection) at 7:30 a.m. and 3:30 p.m. for 90 days. The 
route of Rilm administration and Rilmlo dose used in this study were based on a previous 
report by Monassier et al. [2004] demonstrating that chronic treatment (30 days) with this 
moderate dose of Rilm (250 mg/ml/kg) administered i.p. every twelve hours (i.e., 
discontinuous) induces the optimum anti-hypertensive action in spontaneously 
hypertensive rats, when measured at the peak plasma concentration of the drug (30 
ng/ml).  Discontinuous treatment with 500 mg/kg/day is rapidly eliminated when 
delivered systemically, so it does not induce receptor desensitization, and it did not affect 
α2-AR expression in kidney membrane preparations.  The Rilmhi dose was used to 
determine whether there were dose-response effects and/or whether a dose doubling 
could further potentiate drug effects on measured parameters. An additional 14 untreated 
3M and 18M male F344 rats were obtained from the NIA colony 1 week before the end 
of the 90-day experiment, and used as controls to assess the potential effects of the stress 
of handling and injections.  Where no differences were found between vehicle-treated 
and untreated 18M controls based on Student t-tests (p<0.05), the data were collapsed 
and designated as Ctrl-18M. Body weights were measured prior to starting drug 
treatment, and then weekly until the end of the experiment.  Daily grooming, feeding and 
drinking behaviors were observed to monitor the general health of each rat. Based on 
these qualitative observations, Rilm was well tolerated. 
For the turnover study, 18M rats treated with vehicle or Rilm for 90 days, and 
untreated 3M and 18M control rats were randomly assigned to receive either the vehicle 
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diluent for MPT or MPT.  The MPT was used to estimate basal rates of NE turnover 
in the spleen based on the rate of decline in splenic NE concentration after NE synthesis 
blockade, as previously described [Bellinger et al., 2008a].  At time zero, rats received an 
injection of MPT (200 mg/kg, i.p.) or an equivalent volume of sterile, endotoxin-free 
saline, and sacrificed 6 hr later by decapitation without prior anesthesia.  
Peripheral blood and spleens were immediately harvested from each rat. Peripheral 
blood was collected in 12x75 mm tubes containing 10 mmol/L disodium 
ethylenediaminetetraacetic acid (EDTA) kept on ice. Blood samples were centrifuged at 
1,200 rpm for 10 min. The plasma was collected into microfuge tubes and stored at -80 
°C until used for measuring catecholamine concentrations using high-performance liquid 
chromatography with coulometric detection (HPLC-CD). Spleens were isolated and 
dissected from each animal then cut in half.  Two small pieces were cut cross-sectionally 
from the central region of one half of the spleen (~3-4 mm thick), frozen on dry ice, and 
then stored at -80 °C for subsequent measurement of splenic NE concentration and 
fluorescence histochemistry to localize NA nerves.  The other half of the spleen was used 
to isolate spleen cells for use in cAMP and β-AR binding assays.   
Following the collection of plasma and spleen tissue, a gross examination of the 
brain and all visceral organs was completed for evidence of pathology commonly seen 
with age, including testicular interstitial cell hyperplasia, severe chronic nephropathy 
(enlarged and discolored kidneys), bile duct hyperplasia (rough surface of liver), and 
splenomegaly (enlarged spleen resulting from lymphoma or leukemia originating in the 
spleen). Rats with any visible lesions, tumors, or overt pathology were excluded from this 
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study. Three to four rats per chronic treatment group were removed from the study due to 
overt pathology.   
 
HPLC-CD for Assessing Catecholamine Levels 
Spleen samples were sonicated using a Branson Sonifier 250 in 10 times the 
volume/wet weight of cold perchloric acid (0.1 M) containing 3,4-dihydroxybenzylamine 
(DHBA) (10 ng/ml) (Sigma-Aldrich), as an internal standard. Spleen homogenates then 
were centrifuged at 10,000 rpm for 5 min. The resultant supernatants were transferred to 
microfilterfuge tubes and centrifuged at 14,000 rpm for 20 min resulting in a minimum of 
50 µl of supernatant. Thawed plasma samples (200 µl) were pipetted into 12x75-mm 
glass test tubes containing 1.0 ml of phosphate buffer (pH 7.0), 1.0 ml of 1.5 M (pH 8.6) 
Tris buffer and 50 µl DHBA (10 ng/ml). After the tubes were vortexed, 50 mg of acid 
washed alumina was added, and the tubes were placed on a C10 platform shaker (New 
Brunswick Scientific, Edison, NJ) for 5 min at 175 rpm. The alumina was then allowed to 
settle, and the supernatant was aspirated.  The alumina was washed by adding double-
distilled H2O, allowing the alumina to settle and then aspirating the supernatant for a total 
of 3 times.  At the of the 3rd, wash, the alumina was resuspended in double-distilled H2O 
and the resulting slurry was transferred  in a sample tube of a microfilterfuge tube and 
centrifuged for 2 min at 9,000 rpm. Following centrifugation, the sample tube containing 
the alumna was transferred onto a new receiver tube.  Two hundred microliters of 0.1 M 
HClO4 were added to the alumina.  The catecholamines were eluted by centrifuging the 
microfilterfuge tube  for 2 min at 9,000 rpm and the eluate was collected.   NE and DA 
concentrations were determined using HPLC-CD using a CouloChem III HPLC System 
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(ESA, Chelmsford, MA) and an ESA Model 542 autosampler.  The mobile phase was 
delivered at a flow rate of 1.0 ml/min through a Resolve C18 reverse phase 5-µm, 8x100-
mm Radial-Pak analytical column (Canton, Massachusetts) using an ESA Model 582 
solvent delivery module.  The potentials of the guard cell and two detecting cells of the 
ESA CouleChem III coulometric detector cell system were set at 400 mV, 350 mV, and -
350 mV, respectively.  The signal from the detector was recorded and the peak heights 
and area under the curves were analyzed using EZChrom Elite Software (Scientific 
Software Inc. Pleasanton, CA). 
 
Splenic NE Turnover 
To determine splenic NE turnover, NE decay was estimated using a model in which 
the rate of NE reduction following synthesis blockade is defined by a single mathematical 
factor to which steady-state kinetics can be applied, as previous described [Bellinger et 
al., 2008a].  According to this model the concentration of NE is dependent on the rate of 
synthesis with the following relationship: Log[NE] = Log[NE]o – 0.434kt, where [NE]o is 
the initial concentration of NE and k is the fraction of NE concentration formed or lost 
per unit time. The k of NE was calculated by least-square linear regression of the 
Log[NE] vs. time.  To determine the rate constant, turnover time and turnover rate for NE 
in the spleen, the log of NE (Log[NE]) concentration was plotted versus the time 
following synthesis blockade.  Linear regression analysis of the Log[NE] vs. time 
relationship was performed using individual data points obtained at 0 and 6 hr after 
tyrosine hydroxylase inhibition.  The slope (m) and standard error of the regression 
coefficient (Ser) were computed by the least squares method.  The rate constant for NE 
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disappearance (kNE defined as m/0.434), NE turnover time (1/kNE), and NE turnover 
rate ([NE]o x kNE) were calculated as described. The standard error of the turnover rate 
and the turnover time was calculated from the variance of the regression slope and the 
variance of [NE]o according to the delta method, using the following equation:  
Variance k(NE)o = k2var(NEo) + [NEo]2var(k) + 2kNEo*Covariance k,NEo. 
 
Fluorescence Histochemistry for Catecholamines 
A modification of the glyoxylic acid condensation method (SPG method) of 
histofluorescence for catecholamines was used to visualize sympathetic nerves in fresh 
frozen spleen tissue from F344 rats, as previously described [Bellinger et al., 1992]. From 
each animal, spleen blocks from the hilus (the site of blood vessel and nerve entry into 
the spleen) and regions distal to the hilus were mounted onto chucks with OCT 
compound, and 16 µm cross-sections were cut using a cryostat set at -20 oC. Sections 
were thaw-mounted onto glass slides, and dipped in a 0.2 M potassium phosphate 
solution containing 1% glyoxylic acid and 0.2 M sucrose (pH 7.4).  The slides were air-
dried under a direct stream of cool air for 15 min, several drops of mineral oil placed onto 
each section, and the slides placed on a heat-conducting copper plate in an oven at 95 oC 
for 2.5 min. Excess oil was drained from the slides, and the slides were coverslipped 
using 2 drops of fresh mineral oil. Catecholamine fluorescence was visualized using a 
Zeiss Axiomat fluorescence microscope equipped with epi-illumination accessories, and 
using a 395- to 440-nm excitation filter. Color images were captured with an Olympus 
image high-resolution CCD video capture system.  
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Spleen Cell Preparation 
At sacrifice, one-half of the spleen was placed into a stomacher bag containing 10 
ml Hank’s balanced salt solution (HBSS) (Mediatech Inc., Manassas, VA) containing 
0.035% sodium bicarbonate (Sigma-Aldrich, St. Louis, MO) and 25 mM HEPES 
(Mediatech Inc., Manassas, VA) and dissociated using a stomacher Lab-Blender (Tekmar 
Co., Cincinnati, OH). Cell suspensions were passed through 100 µm cell strainers (BD 
Biosciences Discovery Labware, Bedford, MA) to remove large aggregates, then 
centrifuged, and resuspended in fresh HBSS. Red blood cells were removed from spleen 
cell suspensions by layering over Histopaque 1077 (Sigma-Aldrich), and centrifuging at 
400 x g for 30 min at room temperature. Cells at the interface between Histopaque and 
HBSS were removed and washed three times in HBSS. Cells were counted using a 
Coulter Counter (Coulter Instruments, Hialeah, FL), and then resuspended to 2x106 
cell/ml in HBSS. Spleen cell suspensions were used for β-AR binding and cAMP assays 
after adjusting to the appropriate cell concentrations for each assay. 
 
β-AR Binding Assays 
The experimental design and number parameters evaluated in this study limited our 
ability to carry out binding studies in all treatment groups.  Therefore, radioligand 
binding studies were performed on whole spleen cells from Veh-18M and Rilmlo-treated 
rats (n of 6 per group) using the ligand (-)[125I]cyanopindolol ([125I]CYP), a β-AR 
antagonist with equal affinity for the β1- and β2-AR subclasses.  Rilmlo-treated rats were 
chosen for binding studies based on functional data from Monassier et al [2004], as 
described above. Spleen cells used for β-AR binding assays were resuspended to 5x106 
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cells/ml. [125I]CYP (2200 Ci/mMole) was purchased from GE Healthcare (Piscataway, 
NJ), and diluted in 1% ethanol, 5 mM HCl, and 0.2% bovine serum albumin (BSA).  
Assays were performed in duplicate in 13x100-mm polypropylene tubes containing 1 x 
106 spleen cells with 8 concentrations of [125I]CYP ranging from 15.8-333 pM.  
Nonspecific binding was determined using parallel assays incubated in the presence of 
10-6 M CGP-12177, a hydrophilic β-AR antagonist (Sigma-Aldrich).  Tubes were 
incubated at 37 C for 60 min in a shaking water bath (100 oscillation/min) to ensure that 
equilibrium was reached.  The reaction was terminated by adding 3 ml of ice cold 
hypotonic buffer (3.8 mM KH2PO4, 16.2 mM K2HPO4, 4 mM MnSO4) for 20 min to lyse 
the cells. The reaction mixture was filtered using a cell harvester (Brandel Corp., 
Gaithersburg, MD) and bound radioactivity collected on Whatman fiberglass filters 
(GF/B) (Brandel Corp., Gaithersburg, MD).  Filters were washed with 16 ml (4x4 ml) of 
ice-cold Tris-EGTA buffer to remove the unbound radioligand.  Filters were removed, 
placed in 12x75-mm tubes, and counted in a Wallac 1470 Wizard gamma counter (Long 
Island, Port Jefferson, NY) at 82% efficiency. 
 
β-AR-Stimulated cAMP Production in Spleen Cells 
Spleen cells (1x106) were incubated with 100 µl HBSS containing 100 µM 
isobutylmethylxanthine (IBMX; Sigma-Aldrich) and 0.1% BSA (EMD Chemicals, 
Gibbstown, NJ) (IBMX) in 12x75-mm polystyrene tubes (Thermo Fisher Scientific, 
Pittsburgh, PA) for 20 min at 37 oC in a shaking water bath. Spleen cells were then 
treated with 1 ml 10-5 M isoproterenol (Sigma-Aldrich) for 10 min at 37 oC.  The reaction 
was quenched by adding 2 ml ice-cold IBMX.  The tubes were centrifuged for 8 min at 
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1,800 rpm, and the supernatants discarded.  The pellets were reconstituted with 0.5 ml of 
a 50 mM sodium acetate buffer. The tubes were then exposed to two cycles of boiling 
and freezing to lyse the cells.  The cellular debris was removed by centrifugation (1,800 
rpm for 8 min), the supernatants were collected into microfuge tubes, and then stored at -
80 oC until assayed for cAMP. cAMP levels were determined in triplicate using a 
commercially available enzyme immunoassay (EIA) Kit (GE Healthcare, Piscataway, 
NJ) using the acetylation protocol for highest test sensitivity (lower detection limit of 14 
pg/ml) according to the manufacturer’s instructions. The optical density of the samples 
was determined using a plate reader set at 450 nm.  
 
Data Analysis 
Body and Spleen Weights: Body and spleen weights were expressed in g ± standard 
error of the mean (SEM). Spleen weights were also expressed as a percentage of body 
weight ± SEM.  These data were analyzed by one-way analysis of variance (ANOVA) 
with Bonferroni post-hoc testing for significant ANOVA (p<0.05). 
HPLC-CD Determination of Plasma and Splenic Catecholamine Levels, and NE 
Turnover: Splenic and plasma catecholamine concentrations were determined based on 
standards of known concentrations of NE, DA, and EPI, and expressed as a mean ± SEM 
in ng per g tissue wet weight and ng/ml plasma, respectively. Since age and Rilm 
treatment affect spleen weight, total NE and DA content were also estimated based on 
NE concentrations/mg wet weight and whole spleen weight, and expressed as a mean ± 
SEM in ng/whole spleen. Similarly, turnover rate and time were expressed as means ± 
SEM in ng/g/h and h, respectively. All these data were analyzed using one-way ANOVA 
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with Bonferroni post-hoc testing for significant ANOVA (p<0.05). Splenic NE and DA 
levels (concentration and total content) were correlated with spleen weight using linear 
regression analysis and the statistical software, Prism® 4 (GraphPad, San Diego, CA). 
Morphometric Analysis of Nerve Density:  The density of sympathetic innervation 
of the white pulp from hilar and distal regions was estimated using the spleens of six rats 
from each treatment group. The white pulp was chosen for analysis, because the majority 
of NA nerves in the spleen reside in this compartment [Bellinger et al., 2008b].  Four 
randomly selected white pulps from each of the six rats per treatment group were used for 
analysis. Each white pulp area assessed was from a different spleen section near the hilar 
region or distal to the hilus.  White pulps were photographed at a magnification of 200X.  
The criteria for selecting the white pulps for analysis were that (1) there was only one 
central arteriole in the white pulp; (2) the size of the central arteriole were comparable 
across all samples (80-100 µm across the largest diameter of the vessel) and (3) the 
arteriole was cut in true cross section [Bellinger et al., 2002]. Quantitation of the mean 
area of NA nerves in the splenic white pulp was performed using Image-Pro Plus® 
imaging software (version 5.0; Media Cybernetics, Bethesda, MD).  Using this software, 
the area of NA nerves in the total region of interest (ROI) within the white pulp was 
determined by the number of pixels containing NA nerve profiles in each image, based 
on size and color. The number of positive pixels was divided by the total number of 
pixels in the ROI then multiplied by 100 to calculate the % area of NA nerve profiles in 
each image. The mean % area of NA nerves was determined by averaging the % NA 
nerve area in four white pulps from each animal, and then these means were averaged 
within each treatment group.  Data were expressed as a mean of a mean ± SEM for each 
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treatment group.  Differences in mean % area of NA nerves among the treatment groups 
were analyzed using a one-way ANOVA (p<0.05) followed by Bonferroni post-hoc 
analysis.   
Radioligand Binding: Specific binding was defined as the difference between 
binding of the radioligand at each concentration in the absence and in the presence of (-
)CGP-12177. Nonspecific binding ranged from 10-20% of total binding. Receptor density 
(Bmax) and affinity (KD) were determined using an iterative nonlinear regression curve 
fitting program, Prism® 4, to a model of a single class of homogenous binding sites. Data 
were transformed into a linear form by Scatchard analysis. The lines of best fit were 
generated using the Bmax and KD to determine the X and Y axis intercepts.  The maximal 
number of binding sites per cell was calculated based on simple stoichiometric 
assumptions (1 molecule of ligand bindings to 1 receptor site), expressed as sites/cell.  
Differences in mean KD and Bmax between groups were determined using one-way 
ANOVAs (p<0.05) followed by Bonferroni post-hoc analysis.  
β-AR-Stimulated cAMP Production: β2-AR-stimulated cAMP production was 
expressed as means ± SEM in fmol/2 x 106 cells/10 min.  These data were analyzed using 
a one-way ANOVA (p<0.05) with Bonferroni posthoc testing.  
 
Results 
Rilm Alters Body and Spleen Weights 
F344 rats appeared to tolerate Rilm or vehicle treatment well as all rats were 
observed to eat, drink, and groom.  Prior to beginning the experiment, body weights 
between treatment groups were comparable (Fig. 3.1A). Mean body weights from all 
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Rilm treatment groups receiving twice-daily injections, were slightly reduced, but were 
not significantly different from initial body weights over the 90-day period or compared 
with body weights of vehicle-treated rats. Mean body weights from vehicle- and drug-
treated groups at 12 weeks were significantly (***, p<0.001) lower than Ctrl-18M rats 
(Fig. 3.1A).   
Spleen weights (Fig. 3.1B) were significantly greater (†††, p<0.001) in all 18M 
treatment groups compared with Ctrl-3M rats, and greater in the Rilmhi-treated rats 
compared with Rilmlo and Ctrl-18M rats (***, p<0.001). There were no differences in 
spleen weights between Veh-18M and untreated-18M, so the data were collapsed 
(collectively, Ctrl-18M). Similarly, no differences in spleen weights between Rilmlo-
treated rats and Crtl-18M rats were observed.   Mean spleen weight per body weight (Fig. 
3.1C) was significantly greater in rats treated with Rilmhi compared with all other 
treatment groups (Ctrl-3M: ***, p<0.001; Ctrl-18M: *, p<0.05; Rilmlo: **, p<0.01).  
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Fig. 3.1.  Mean Body Weights over the Time Course of the Experiment. 
A. The effect of age and 90-day treatment with control (Ctrl-18M), vehicle treatment 
(Veh-18M), and low- or high-dose rilmenidine (Rilmlo or Rilmhi, respectively) on mean 
body as means (± SEM) in grams (g) in F344 male rats.  All treatment groups maintained, 
but did not gain weight; Ctrl-18M rats weighed significantly more than all other age-
matched treatment groups (***, p<0.001).  There was no effect of chronic drug treatment 
on mean body weight over the 90-day period.  Ctrl-18M,; Rilmlo, ; Rilmhi, .  Low 
and high-dose rilmenidine, Rilmlo and Rilmhi, respectively; 3- or 18-month-old controls, 
Ctrl-3M or Ctrl-18M, respectively. Ctrl-3M, n=14; Ctrl-18M, n=22; Rilmlo or Rilmhi, 
n=12.  
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Fig. 3.1.  Mean Spleen Weights over the Time Course of the Experiment 
(Continued). 
B.  The effect of age and 90-day treatment on mean spleen weight expressed as means (± 
SEM) in grams (g).  There was a significant effect of age on spleen weight such that all 
18M groups were greater than Ctrl-3M rats (†††, p<0.001), and treatment with Rilmhi, 
further increased (***, p<0.001) mean spleen weight compared with Ctrl-18 and Rilmlo. 
B
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Fig. 3.1. Normalized Spleen Weights over the Time Course of the Experiment 
(Continued). 
C.  Spleen weight per body weights expressed in g per g after a 90-day treatment with 
rilmenidine (Rilm). Treatment with Rilmhi increased spleen weight per body weight 
compared with all other treatment groups (Ctrl-3M: ***, p<0.001; Ctrl-18M: *, 
p<0.05; Rilmlo: **, p<0.01).   
C
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
0.0050
Ctrl-3M Crtl-18M Rilmlo Rilmhi
Sp
le
en
 W
ei
gh
t (
g)
/B
od
y 
W
ei
gh
t (
g)
***
**
*
87 
Rilm Reduces Plasma NE Concentrations, but not 
EPI Concentrations 
 
Mean plasma NE and EPI concentrations (Figs. 3.2A and 3.2B, respectively) were 
similar at 3 and 18 months of age (Ctrl-3M vs. Ctrl-18M). Chronic Rilmlo or Rilmhi 
treatment significantly reduced plasma NE concentrations (Fig. 3.2A) compared with 
Crtl-3M (*, p<0.05) and Crtl-18M (**, p<0.01) control values.  Plasma NE levels in 
Rilmlo- and Rilmhi-treated rats were 35% and 29% lower than the controls, respectively. 
Rilm had no effect on mean plasma EPI concentrations (Fig. 3.2B).  
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Fig. 3.2. Effect of Rilmenidine on Circulating NE. 
A. The effect of rilmenidine treatment on mean plasma norepinephrine (NE) 
concentrations ± SEM expressed in ng/ml. Both doses of rilmenidine over the 90-day 
period significantly reduced  plasma NE concentrations compared with Ctrl-3M and Ctrl-
18M (*, p<0.05 and **, p<0.01, respectively).  Low and high-dose rilmenidine, Rilmlo 
and Rilmhi, respectively; young, 3-month-old controls, Ctrl-3M; old, 18-month-old 
controls, Ctrl-18M). Ctrl-3M, n=14; Ctrl-18M, n=22; Rilmlo or Rilmhi, n=12). 
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Fig. 3.2. Effect of Rilmenidine on Circulating EPI. 
B.  The 90-day treatment with rilmenidine did not affect mean plasma epinephrine (EPI) 
concentrations ± SEM expressed in ng/ml. Low and high-dose rilmenidine, Rilmlo and 
Rilmhi, respectively; young, 3-month-old controls, Ctrl-3M; old, 18-month-old controls, 
Ctrl-18M). Ctrl-3M, n=14; Ctrl-18M, n=22; Rilmlo or Rilmhi, n=12). 
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Rilm Partially Reverses the Age-Related Decline in  
Splenic NA Innervation 
 
In Ctrl-3M rats, NA nerves form a dense plexus surrounding the central arteriole in 
the splenic white pulp in the hilar region (Fig. 3.3A). Linear, varicose fibers extend from 
this vascular plexus into the surrounding periarteriolar lymphatic sheath (PALS), a 
predominantly T cell compartment.  In contrast, while the NA nerves display a similar 
distribution in the white pulp, the density of fluorescent profiles was markedly reduced in 
this compartment in the Ctrl-18M rats (Fig. 3.3B).  Rilmlo or Rilmhi treatment (Figs. 3.3C 
and 3.3D) increased the fluorescence intensity and density of NA nerve fibers associated 
with the central arteriole and in the surrounding PALS compared with the Ctrl-18M rats, 
an effect that appears to be augmented with Rilmlo treatment. 
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Fig. 3.3. Effect of Rilmenidine on Splenic NA Innervation at the Hilus. 
Fluorescence histochemistry for catecholamines demonstrates abundant fluorescent linear 
and punctate NA nerve profiles surrounding the central arteriole (ca) in the white pulp 
(wp) (arrowheads) in the hilar region of the spleen in 3-month-old F344 rats (Ctrl-3M) 
(A.).  At 18 months of age (Ctrl-18M) (B.), the density of fluorescent nerves along the 
central arteriole decline, an effect partially reversed by low- and high-dose rilmenidine 
treatment (Rilmlo (C.) and Rilmhi (D.), respectively. A-D. Glyoxylic acid fluorescence 
histochemistry. Calibration bar = 100 µm. 
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Morphometric analysis confirmed the age-related decline in splenic NA nerve 
area in the hilar region and partial restoration of nerve loss with Rilm treatment (Fig. 
3.3E).  Mean splenic NA nerve density in Ctrl-18M rats declined to 62.3% of Crtl-3M 
values (***, p<0.001). Treatment of rats with Rilmlo or Rilmhi significantly increased the 
density of NA fibers around the central artery and in the white pulp of the spleen by 
60.0% and 44.5%, respectively (**, p<0.001 and *, p<0.05, respectively). Despite the 
dramatic drug-induced increase in mean NA nerve area with Rilmlo- or Rilmhi treatment, 
values remained significantly lower than values in Ctrl-3M rats (p<0.05 and p<0.01, 
respectively). 
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Fig. 3.3. Effect of Rilmenidine on Splenic NA Innervation at the Hilus by 
Morphometric Analysis (Continued). 
Morphometric analysis of fluorescent profiles (E.) expressed as percent mean area is 
consistent with qualitative findings, showing an age-related loss of fluorescent nerves 
(***, p<0.001) that is attenuated by low- or high-dose rilmenidine treatment (Rilmlo: **, 
p<0.001; Rilmhi,*, p<0.05). Low and high-dose rilmenidine, Rilmlo and Rilmhi, 
respectively; young, 3-month-old controls, Ctrl-3M; old, 18-month-old controls, Ctrl-
18M).   
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In the distal region, the effects of age and Rilm treatment on nerve density in the 
white pulp were similar to findings in the hilar region, although the size of the white 
pulps and diameter of central arterioles appear smaller than in the hilus where the splenic 
artery and associated sympathetic nerves enter the spleen (Figs. 3.4A-D).  Similarly, as in 
the hilar region, the distribution of NA nerves in the white pulp in this region was not 
affected by Rilm treatment. Qualitatively, the abundance of NA nerves was reduced 
along the central arteriole and the surrounding white pulp in Ctrl-18M rats (Fig. 3.B) 
compared with Ctrl-3M rats (Fig. 3.4A). Both Rilmlo and Rilmhi appeared to dose-
dependently increased in the presence of NA nerve fibers associated with the arteriole 
and in the periarteriolar lymphatic sheath compared with Ctrl-18M rats.   Morphometric 
analysis (Fig. 3.4E) were consistent with qualitative observations, demonstrating a 66% 
drop in nerve density at 18 months of age compared with young controls (***, p<0.001), 
and Rilmlo or Rilmhi treatment reversed the aging effect by 91% or 54% (vs. Ctrl-18M: 
**, p<0.01 or T, p<0.1 (trend), respectively). Drug treatment did not totally restore nerve 
density to young adult levels; nerve densities were 35% or 47% lower with Rilmlo or 
Rilmhi than in young adult controls (††, p<0.01 or †††, p<0.001, respectively) (Fig. 3.4E).  
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Fig. 3.4. Effect of Rilmenidine on Splenic NA Innervation Distal to the Hilus. 
Distal to the hilus, fluorescence histochemistry for catecholamines demonstrates 
fluorescent linear and punctate NA nerve profiles surrounding the central arteriole (ca) in 
the white pulp (wp) (arrowheads) of the spleen in 3-month-old F344 rats (Ctrl-3M) (A.).  
In this region of the spleen, the white pulps are smaller, central arterioles have a smaller 
diameter and there are fewer NA nerve surrounding the arterioles compared with the hilar 
region. However, the compartmentation of nerves is comparable to the hilar region. At 18 
months of age (Ctrl-18M) (B.), the density of fluorescent nerves along the central 
arteriole decline, an effect partially reversed by low- and high-dose rilmenidine treatment 
(Rilmlo (C.) and Rilmhi (D.), respectively. Low and high-dose rilmenidine, Rilmlo and 
Rilmhi, respectively; 3- or 18-month-old controls, Ctrl-3M or Ctrl-18M, respectively).  A-
D. Glyoxylic acid fluorescence histochemistry. Calibration bar = 100 µm. 
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Fig. 3.4. Effect of Rilmenidine on Splenic NA Innervation Distal to the Hilus by 
Morphometric Analysis. 
Morphometric analysis of fluorescent profiles (E.) expressed as percent mean area is 
consistent with qualitative findings, showing an age-related loss of fluorescent nerves 
(Ctrl-18M vs. Ctrl-3M: ***, p<0.001) that is attenuated by low- or high-dose rilmenidine 
treatment (Rilmlo or Rilmhi vs. Ctrl-18M: **, p<0.01 or T, p<0.1, respectively; Rilmlo or 
Rilmhi vs. Ctrl-3M: † , p<0.01 or †† , p<0.001).   
 
E 
97 
Rilm Affects Splenic NE and DA Content and Concentration 
The mean total splenic NE concentration (Fig. 3.5A) was lower in Ctrl-18M and Rilmhi 
than in Ctrl-3M rats (***, p<0.001).  NE concentration in spleens from Rilmhi- treated 
rats also fell significantly compared with levels found in Ctrl-18M- and Rilmlo-treated 
rats (*, p<0.05 and **, p<0.01, respectively). 
A significant age-related decline in mean total splenic NE content (Fig. 3.5B) was 
observed, such that Ctrl-18M rats displayed lower values than Ctrl-3M (*, p<0.05). The 
mean splenic NE content in Rilmlo-treated rats was similar to values obtained for Crtl-
18M, but tended to be lower than in Ctrl-3M rats (T, p<0.1) (Fig. 3.5B).   
No difference in mean splenic NE content was observed between the Rilmlo and 
Ctrl-18M rats.  Mean total NE content in the spleen was reduced in Rilmhi-treated rats 
compared with Ctrl-3M (***, p<0.001), but did not differ significantly from the Ctrl-18M 
or Rilmlo groups.  Regression analyses revealed a decrease in NE levels as spleen weight 
increases (Figs. 3.5C and 3.5D).  Both splenic NE concentration and total content were 
significantly correlated with spleen weight, with the former having a greater effect 
(p<0.001 and p<0.01, respectively). 
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Fig. 3.5.  Rilmenidine and Splenic NE Concentration. 
A.  Mean total splenic NE concentrations (expressed as ng/gm wet weight ± SEM) in 3M 
and 18M controls, and rats treated with low- or high-dose rilmenidine treatment (Ctrl-
3M, Ctrl-18M, Rilmlo, and Rilmhi, respectively). Splenic NE concentration was reduced 
with advancing age (Ctrl-3M vs. Ctrl-18M: ***, p<0.001), an effect augmented by high-
dose rilmenidine treatment (Rilmhi) (Ctrl-3M or Ctrl-18 vs. Rilmhi: *, p<0.05 or ***, 
p<0.001, respectively).  Splenic NE concentration also was lower in Rilmhi than the 
Rilmlo group (**, p<0.01). Ctrl-3M, n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11. 
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Fig. 3.5.  Rilmenidine and Total Splenic NE Content. 
B.  Mean total splenic NE content (expressed as ng/spleen ± SEM) in 3M and 18M 
controls, and rats treated with low- or high-dose rilmenidine treatment (Ctrl-3M, Ctrl-
18M, Rilmlo, and Rilmhi, respectively). Splenic total NE content in the spleen was 
diminished in old (Ctrl- 18M) and with a trend for lower levels in Rilmlo compared with 
Ctrl-3M (*, p<0.05 or T, p<0.1, respectively). Rilmhi further reduced total splenic NE 
content compared with young (Ctrl-3M) rats (***, p<0.001). Ctrl-3M, n=13; Ctrl-18M, 
n=23; Rilmlo or Rilmhi, n=11. 
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Fig. 3.5.  Correlation between Spleen Weight and Splenic NE Concentration 
(Continued). 
C.   Splenic NE concentration was negatively correlated with spleen weight (R2=0.68). 
Ctrl-3M, n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11.
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Fig. 3.5.  Correlation between Spleen Weight and Total Splenic NE Content. 
D. Splenic NE content was negatively correlated with spleen weight (R2= 0.35). Ctrl-3M, 
n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11. 
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There was no effect of either age or low dose drug treatment on splenic DA 
concentration (Fig. 3.6A). However, Rilmhi significantly raised DA levels in the spleen to 
approximately 30%, 34% or 54% of Ctrl-3M, Ctrl-18M, or Rilmlo, respectively (*, 
p<0.05; *, p<0.05, or **, p<0.01, respectively) (Fig. 3.6A).   Similarly, Rilmhi-treated rats 
had a higher total splenic DA content (Fig. 3.6B) than Ctrl-3M (*, p<0.05), Ctrl-18M (*, 
p<0.05) and Rilmlo (**, p<0.01) treatment groups. There were no differences between the 
other treatment groups.  In contrast to NE in the spleen, there was no correlation between 
either DA concentration or total content in the spleen and spleen weight (Figs. 3.6 C or 
3.6D, respectively). 
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Fig. 3.6.  Rilmenidine and Splenic DA Concentration. 
A.  Mean total splenic DA concentrations (expressed as ng/gm wet weight ± SEM) in 3M 
and 18M controls, and rats treated with low- or high-dose rilmenidine treatment (Ctrl-
3M, Ctrl-18M, Rilmlo, and Rilmhi, respectively). There was no effect of age or Rilmlo on 
splenic DA concentration; however, Rilmhi significantly increased splenic DA 
concentration compared with the other treatment groups (Ctrl-3M or Ctrl-18M: *, 
p<0.05; Rilmlo: **, p<0.01). Ctrl-3M, n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11.
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Fig. 3.6.  Rilmenidine and Total Splenic DA Content. 
B.  Mean total splenic DA content (expressed as ng/spleen ± SEM) in 3M and 18M 
controls, and rats treated with low- or high-dose rilmenidine treatment (Ctrl-3M, Ctrl-
18M, Rilmlo, and Rilmhi, respectively). No effect of age or Rilmlo on splenic DA content 
was noted; however, Rilmhi significantly increased splenic DA content compared with the 
other treatment groups (Ctrl-3M or Ctrl-18M: *, p<0.05; Rilmlo: **, p<0.01). Ctrl-3M, 
n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11. 
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Fig. 3.6.  No Correlation between  Splenic DA Concentration. 
C. There was no correlation between splenic DA concentration and spleen weight 
(R2=0.0004). Ctrl-3M, n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11. 
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Fig. 3.6.  No Correlation between Rilmenidine and Splenic Total DA Content. 
D.  Splenic DA concentration content did not correlate with spleen weight (R2= 0.046). 
Ctrl-3M, n=13; Ctrl-18M, n=23; Rilmlo or Rilmhi, n=11. 
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Rilm Treatment Reduced Splenic NE Turnover 
Intraperitoneal injection of MPT reduced mean concentrations of NE in spleens 
from Ctrl-18M and Rilmlo or Rilmhi treatment groups during the 6-h period after NE 
synthesis blockade (Fig. 3.7 and Table 3.1).  The rate of decline in splenic NE 
concentration was greatest in Ctrl-18M rats and lowest in the Rilmhi treatment group 
(Fig. 3.7). 
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Fig. 3.7. Effect of Rilmenidine on NE Turnover. 
The effect of rilmenidine or control on splenic NE concentrations 0 and 6 hours post-
injection with MPT to inhibit NE synthesis is shown. 90-day treatment with low- or 
high-dose rilmenidine (Rilmlo,  or Rilmhi, , respectively) slowed the rate of decline in 
splenic NE concentration over the 6-hour period compared with age-matched controls 
(Ctrl-18M, ).  Each group represents an n of 12 rats. 
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Calculated NE turnover rate, based on the slopes of the lines (Table 3.1) and 
regression analysis revealed a 32.6% and 81.7% decline in splenic NE concentration 6 h 
after NE synthesis blockade with Rilmlo- or Rilmhi-18M treatment compared with the 
Ctrl-18M group, respectively.  Turnover rate at 18M in this study was approximately 3.6-
fold higher than in 15M rats based on a previous report from our laboratory [Bellinger et 
al., 2008a], and Rilmlo or Rilmhi turnover rates were 2.4-fold higher or 0.7-fold lower 
than reported in 15M rats, respectively (Table 3.1). Rilm dose-dependently increased 
turnover time (the time required to synthesize the steady-state pool of splenic NE) 
compared with Ctrl-18M by the 90th day of treatment (Table 3.1).   There was no 
significant difference in NE content between age-matched and vehicle-treated controls 6 
h post-treatment and rats treated with vehicle or MPT at time 0 (data not shown). 
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Table 3.1. Turnover rates and turnover times of NE in the spleen of F344 male rats 
treated with low- or high-dose rilmenidine (Rilmlo or Rilmhi, respectively). Initial NE 
concentrations and splenic turnover rate declined in a dose-dependent manner after 
treatment with αMPT rats compared with age-matched controls (Ctrl-18M) rats. 
Rilmenidine treatment increased turnover time in a dose-dependent manner.  Initial levels 
of splenic NE and the rate constants are expressed as means ± SEM. αMPT, α-
methylparatyrosine; NE, norepinephrine; n, number of rats per age group. 
 
 
  TABLE 1. Effect of Chronic Rilmenidine on Splenic NE Turnover Rate
Treatment 
Group
Initial Levels 
(ng/g±SEM) n
a
Rate Constant 
of NE Lossb 
k(h)
n c
Turnover 
Rated (ng/g/h)
Turnover 
Timee (h)
Fold Change in 
Turnover Rate 
from Veh-15Mf
Ctrl-18M 584.9 ± 50.9 15 0.42 7 246.1 2.4 3.6
Rilmlo 483.3 ± 53.7 16 0.34 8 165.9 2.9 2.4
Rilmhi 364 ± 51.6 13 0.1 7 45.1 10.0 0.7
aNumber of αMPT- or vehicle-treated rats at time 0
bCalculated from the slope of decline of log NE content
cNumber of αMPT rats sacrificed at time 6
dNE synthesized and degraded per gram spleen tissue per hour
eTime required to synthesize the steady-state tissue pool of NE
fCalculations based on turnover rates from vehicle-treated 15M rats reported in Bellinger et al 2008c
TABLE 3.  
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Rilm Treatment Alters β-AR Binding and Affinity in 
Spleen Cells 
 
Figs. 3.8A and 3.8B show saturation isotherms obtained from saturation binding 
experiments of splenocytes obtained from Veh-18M- and Rilmlo-treated rats, 
respectively.  Binding of the radioligand was rapid, saturable, and of high affinity in both 
treatment groups. Specific binding was greater than 90% of the total binding at near 
saturating radioligand concentrations.   The Scatchard plots shown in the insets of Figs. 
3.8A and 3.8B, indicated similar KD values between the two treatment groups (similar 
slope of the line), but the Bmax was greater in rats treated with Rilmlo.     
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Fig. 3.8. Effect of Rilmenidine on β-AR Binding in Splenocytes 
A.  Specific binding and Scatchard plots of (-)-[125I]cyanopindolol ([125I]CYP) in whole 
spleen cells from age-matched vehicle-treated rats (Veh-18M). Spleen cells were 
incubated under equilibrium binding conditions at 37 ºC with ICYP (0.9-220 pM) for 60 
min, then the reaction was stopped and the radioactivity was quantified by gamma 
scintillation spectrometry. Specific binding and plots represent means of duplicate 
determinations of specific (■) binding cpm, counts/min. This group represents an n of 6 
rats.
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Fig. 3.8. Effect of Rilmenidine on β-AR Binding in Splenocytes (Continued). 
B.  Specific binding and Scatchard plots of (-)-[125I]cyanopindolol ([125I]CYP) in whole 
spleen cells from low-dose rilmenidine (Rilmlo)-treated rats. Spleen cells were incubated 
under equilibrium binding conditions at 37 ºC with ICYP (0.9-220 pM) for 60 min, then 
the reaction was stopped and the radioactivity was quantified by gamma scintillation 
spectrometry. Specific binding and plots represent means of duplicate determinations of 
specific (■) binding cpm, counts/min. This group represents an n of 6 rats. 
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In spleen cells from rats with Rilmlo treatment, the mean Bmax was significantly 
higher (22%, *, p<0.05) compared with Veh-18M rats (Fig. 3.9A), but there was no 
significant difference in the mean KD between these treatment groups (Fig. 3.9B). Spleen 
cells from rats with Veh-18M and Rilmlo treatment expressed approximately 759 and 
1080 sites/cell, respectively (95% confidence intervals were 672-846 for Veh-18M vs. 
861-1298 for Rilmlo).
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Fig. 3.9.  Effect of Rilmlo and Vehicle treatment on Mean β-Receptor Expression 
(Bmax).                                                      
A. The mean density of β-AR, expressed as sites/cell on spleen cells, from vehicle- (Veh-
18M) and low-dose (Rilmlo)-treated rats demonstrates that chronic treatment with Rilmlo 
significantly increased  β-AR expression on splenocytes (*, p<0.05). Mean values were 
calculated from the Bmax determined from specific binding curves generated for each rat 
in this treatment group.   
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Fig. 3.9.  Effect of Rilmlo and Vehicle Treatment on Mean β-Receptor Binding 
Affinity (KD).                                                       
B.   Affinity binding, as expressed by KD values on spleen cells from vehicle- (Veh-18M) 
and low-dose rilmenidine (Rilmlo)-treated rats (n of 6 per group), demonstrates that 
chronic treatment with Rilmlo did no affect KD. Mean values were calculated from the KD 
determined form specific binding curves generated for each rat from each treatment 
group. 
B 
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Rilm Treatment and β-AR-Stimulated cAMP Production in 
Spleen Cells 
 
Isoproterenol-stimulated cAMP production in spleen cells rose significantly (35%; 
*, p<0.05) in Ctrl-18M compared with Ctrl-3M rats (Fig. 3.10). Chronic Rilmlo or Rilmhi 
treatment further augmented isoproterenol-induced production of cAMP (***, p<0.001 
and **, p<0.01, respectively) compared with Ctrl-3M rats.  In addition, there was a 
respective 36% (†, p<0.05) and 23% increase in cAMP production in the Rilmlo- or 
Rilmhi-treated compared with Ctrl-18M rats.  
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Fig. 3.10.  Effect of Rilmenidine on Splenocyte cAMP Production 
Isoproterenol-stimulated cAMP production in spleen cells in vitro was increased in all 
18M groups compared with young controls (Ctrl-3M) (Ctrl-18M: *, p<0.05; Rilmlo: ***, 
p<0.001; Rilmhi: **, p<0.01). Data are expressed in fmol/106 cells/10 min. Low and high-
dose rilmenidine, Rilmlo and Rilmhi, respectively; 3-month-old controls, Ctrl-3M; 18-
month-old controls, Ctrl-18M).  Ctrl-3M, n=11; Ctrl-18M, n=19; Rilmlo, n=12; Rilmhi, 
n=11.
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Discussion 
There are several salient and novel findings in this study. First,  in normotensive 
rats [McCarty, 1985], reduced splenic NE turnover and plasma NA concentrations 
indicate that chronic Rilm treatment dose-dependently reduced splenic and whole body 
SNA, respectively. Next, chronic Rilm treatment dose-dependently protected NA nerves 
from age-related damage in the white pulp in both hilar and distal regions, indicating that 
age-related loss of sympathetic nerves can be prevented. Collectively, these two findings 
support our hypothesis that elevated sympathetic tone in the aging spleen causes 
sympathetic nerve loss.  Finally, Rilm augmented β-AR signaling in splenic lymphocytes. 
This finding neither supports nor refutes our hypothesis, but can be explained by the 
drugs action on splenic SNA. Reduced SNA reduces NE availability and consequently 
ligand-receptor interactions, which causes a compensatory increase in β-AR expression, 
consistent with our findings.   
The RVLM regulates SNA in a number of organs [McAllen et al., 1995], including 
the spleen [Beluli and Weaver, 1991]. The Rilm-induced reduction in splenic and net 
SNA is consistent with its stimulatory action on sympathoexcitatory neurons in the 
RVLM via interaction with IR1 (and α2-AR) (Fig. 3.11A) [Bruban et al., 2001]. 
Activation of these RVLM neurons dampens the firing rate of postganglionic NA nerves 
via inhibition of preganglionic neurons in the intermediolateral cell column (IML) in the 
spinal cord (Fig 3.11A). Not all of our drug effects may be mediated centrally. IR1 are 
expressed in other sympathetic target tissues [Dardonville and Rozas, 2004; Dontenwill 
et al., 1999], but have not been reported in the spleen. Also, imidazoline binding sites are 
presynaptically expressed on NA nerves in other visceral organs and can block NE  
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  Fig. 3.11. Rilmenidine Modifies the Activity of the RVLM to Affect  
Sympathetic Outflow to the Spleen 
General schematic diagram identifying potential central neural sites involved in the 
regulation of sympathetic outflow to lymphoid organs. The rostral ventrolateral medulla 
(RVLM) is a site of a complex convergence of descending and ascending neural inputs.   
The excitatory drive from the RVLM is intrinsically generated, but can be modulated 
by excitatory and inhibitory inputs from other regions of the central nervous system 
(e.g., pons, hypothalamus and amygdala) that process a wide array of sensory stimuli 
(including baroceptive, nociceptive, and immunological) and participate in stress, 
emotion and behavioral responses. The neurons of the RVLM drive sympathetic 
outflow by synapsing onto preganglionic neurons in the intermediolateral cell column 
(IML) to modulate the activity of postganglionic neurons that supply lymphoid organs.  
Inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha 
(TNF-) act on the circumventricular organ (CVO) and visceral afferent fibers to 
influence the activity of the paraventricular nucleus (PVN) and nucleus tractus 
solitarius (NTS), which in turn, modulates the activity of the RVLM.  Rilmenidine 
(Rilm) acts on IR1 and 2-AR primarily in RVLM to inhibit the sympathoexcitatory 
neurons that impinge on the 2-neuron sympathetic chain that supplies the spleen.                     
(Modified from Dampney, 1994)  
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release [Göthert et al., 1999]. However, α2-ARs are expressed presynaptically in 
sympathetic nerves [Docherty, 2002] and splenic macrophages [Spengler et al., 1990].  
Effects of Rilm via presynaptic α2-AR would be expected to augment its central effect via 
presynaptic inhibition of NE release [Szabo, 2002]. It is unlikely that drug interactions 
with α2-AR on immunocytes contribute to β2-AR-mediated cAMP production in splenic 
lymphocytes, as baseline cAMP levels were not affected, α2-AR or IR1 have not been 
reported on splenocytes, and both receptor types signal through different intracellular 
pathways [Ernsberger, 1999].  
The drug-induced reduction in plasma NE levels, which reflect NE spillover into 
the blood after its release from NA nerves, and is consistent with reduced net SNA in 
other studies [Monassier et al., 2004; Burke et al., 2009].  The magnitude of reduced 
plasma NE levels in this study is comparable to both human and animal studies using 
Rilm as an antihypertensive agent [Esler et al., 2004; Monassier et al., 2004]. The low 
doses of Rilm in this study did not change plasma EPI levels, consistent with a study in 
hypertensive patients [Esler et al., 2004].  These findings indicate that the SNS and the 
sympathoadrenal-medullary (SAM) axis are differentially regulated by autonomic centers 
in the brainstem, and the SNS can be functionally disconnected from the SAM axis. 
  The age-related loss in splenic NE concentration and content and NA nerve loss in 
aging is consistent with our previous findings [Bellinger et al., 2008a].  NA nerve loss 
contributes to reduced NE in the spleen, but other aging-related mechanisms likely play a 
role, like reduced NE reuptake [Docherty, 2002] (Fig. 3.11B). Tissue NE levels are 
normally stable even under extreme conditions, such as stress [Del Rey et al., 1982].  
Tight regulation of tissue NE levels explains unaltered static splenic NE concentration 
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and content with Rilmlo treatment and in control groups, but at a lower set point in old 
rats. Precise regulation of NE reuptake, and enzymes that synthesize and catabolize NE, 
assures stable tissue NE concentrations (Fig. 3.11B). Altered splenic NE and DA 
concentrations with Rilmhi suggest dysregulation of NE homeostasis. Greater ROS from 
catabolized DA after release could explain the lower nerve sparing ability of Rilmhi, 
consistent with findings centrally in DA neurons [Chinta and Anderson, 2008].  While 
altered splenic NE levels provide information about homeostatic dysregulation, unaltered 
levels are inconclusive, and may mask altered SNS functioning. With synthesis blockade, 
Rilm dose-dependently reduced the rate of NE degradation and increased turnover time, 
consistent with reduced NE utilization and supporting reduction of SNA by Rilm.  
Rilmhi, but not Rilmlo, reduced splenic NE concentration and content compared with 
age-matched controls. These data indicated NE synthesis did not keep pace with NE 
utilization in the Rilmhi treatment group, despite reduced turnover at both drug doses.  In 
aging, higher SNA increases TH activity [Parrish et al., 2008; Morgenroth et al., 1974], 
an effect reduced by Rilm (Fig. 3.11B). Our finding of greater splenic DA levels with 
Rilmhi also supports reduced TH activity via end product inhibition (Fig. 3.11B) 
[Flatmark et al., 2000]. High vesicular DA concentrations drive small rates of DA into 
the cytosol [Reed et al., 2010; Wallace, 2007] to inhibit TH activity. Additionally, the 
drug-induced SNA decrease may affect TH phosphorylation, critical for its activity and 
the primary mechanism for maintaining tissue NE levels after secretion [Dunkley et al., 
2004; Kumer and Vrana, 1996].  Still, high vesicular DA should drive DA conversion to 
NE by dopamine-β-hydroxylase (DBH) downstream of TH (Fig. 3.11B). Thus, reduced 
splenic NE levels with Rilmhi suggests reduced DBH expression or activity (Fig. 3.11B).  
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Preservation of NA nerves in hilar and distal regions with Rilm supports our 
hypothesis that SNA during middle-age contributes to nerve loss, an effect that is greater 
with Rilmlo. Our findings are consistent with reports in aging rats that splenic NA nerves 
remain plastic [ThyagaRajan et al., 2000]. This supports the feasibility for developing a 
model to investigate causality between aging SNS and immune functional changes.  
Greater protection may be afforded by earlier treatment, since altered splenic architecture 
and immune cell subsets occur before 15 months of age [Bellinger et al., 1992]. Also, 
combined Rilm treatment with trophic factors (i.e., NGF) may potentiate the Rilm effect. 
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Fig. 3.12.  Schematic diagram of a NA junction in the spleen.  
Proposed effects of age (shown in blue) and rilmenidine (shown in red) on biosynthesis 
of NE, and NA neurotransmission. 1. Tyrosine (Tyr) is transported into the NA 
varicosity by a sodium-dependent carrier (AAT). 2. Tyr is converted to DOPA via the 
rate-limiting enzyme, tyrosine hydroxylase (TH). 3. Decarboxylation by dopamine 
decarboxylase (DDC) forms DA. 4. DA is transported into the vesicle by the vesicular 
monoamine transporter (VMAT). This same carrier transports NE into these granules. 
5. DA is converted to NE in the vesicle by dopamine-β-hydroxylase (DBH). 6. 
Physiological release of transmitter occurs via tonic firing of the nerve (). 7. Action 
potentials open voltage-sensitive calcium channels and increase intracellular calcium 
(Ca2+). A decline in Ca2+ ATPase activity in smooth endoplasmic reticulum can 
increase stimulation-evoke NE release in older NA nerves (blue arrow).  8. Fusion of 
vesicles with the surface membrane results in expulsion of NE, DA, other 
cotransmitters, as well as DBH.  9. After release, NE diffuses into the cleft.  10. NE 
binds with postsynaptic receptors, predominantly β2-AR in lymphocytes, which 
increases intracellular cAMP. 11. NE binds with presynaptic autoreceptors (α2-AR), 
providing feedback regulation of NE release.  12. Cotransmitters (NT) released with 
NE interact with presynaptic (heteroreceptors) and postsynaptic receptors; signaling via 
cotransmitters can affect β-AR mediated signaling. 13. Binding with heteroreceptors 
also regulates NE release. 14. NE degradation in the cleft occurs by monoamine 
oxidase (MAO) and catechol-O-methyltransferase (COMT), which increases reactive 
oxygen species (ROS).  15. NE is transported back into the terminal by the NE 
transporter (NET). 16. NE diffuses away from the cleft and into the bloodstream. 
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Neuroprotection occurred without reversal of splenic NE levels. However, splenic NE 
levels may be restored once Rilmlo is withheld, because it appears that synthetic 
regulatory mechanisms are intact in the aging spleen.   
We propose that increased neurotoxic ROS from CA breakdown destroys splenic 
NA nerves (Fig. 3.11B). This mechanism of nerve loss occurs in other CA neurons with 
increased activity, including NA nerves in cerebral vessels [Cowen and Thrasivoulou, 
1990], and locus coeruleus and nigrostriatal neurons [Jinsmaa et al., 2009; Chen et al., 
2003].  Changes in the microenvironment of the aging spleen may also contribute to 
nerve loss via intracellular calcium dysregulation [Stirling et al., 2010; Tsai et al., 1998], 
altered splenocyte subset percentages/absolute numbers [Jiang et al., 1992; Wong et al., 
2010; Banerjee et al., 2000; Fló and Massouh, 1997], or stromal/immunocyte mediators 
[Pachówka et al., 2011; Wong et al., 2010].   
Greater β-AR upregulation and signaling in aging splenocytes ex vivo (Fig. 3.11B) 
are inconsistent with the age-related increase in SNA. However, degeneration of NA 
nerves increases the distance for NE diffusion, and therefore reduces ligand availability, 
which may explain this discrepancy (Fig. 3.11B). This interpretation is consistent with 
other types of neurotoxic damage to NA nerves [Tumer et al., 1990; Chatelain et al., 
1983].  Also, rising free plasma corticosterone (CORT) levels with age (~70%, 9-19M) 
[Sabatino et al., 1991] can upregulate β-AR transcriptionally [Kumer and Vrana, 1996; 
Sabban et al., 2006].  Rilmlo further augmented β-AR density and signaling ex vivo, 
consistent with lower NE availability from reduced SNA and NE turnover (Fig. 3.11B).  
Stress-induced effects on body weights in injected rats suggest hypothalamo-
pituitary adrenal axis (HPA) and/or SNS activation [Kyrou and Tsigos, 2009]. There is 
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no supporting evidence for SNS involvement as there were no stress effects on plasma 
NE or EPI. However, SNA does not always increase plasma NE levels [Esler et al., 
1984], and stress-induced SNA may be transient, returning to baseline before blood 
collection.  Rilm treatment should not remarkably affect stress-induced effects, as 
sympathetically-mediated reflexes and psychological stressors are still elicited after Rilm 
treatment [Burke et al., 2010; Esler et al., 2004]. Altered hemostasis may explain the 
Rilmhi-induced increase in spleen weights.  Since, the splenic red pulp is a reservoir for 
blood, vasodilation by Rilm would favor blood accumulation [Kimura et al., 2001; 
Stewart and McKenzie, 2002]. The negative correlations between spleen weight and NE 
concentration or content support this hypothesis.    
Collectively, our data indicate that, Rilm, or other IR1 agonists that act in the 
RVLM can reduce SNA and protect NA nerves in the aging spleen. Our data support a 
role for heightened SNA in NA nerve loss in the aging spleen, and that Rilm can affect 
NE synthesis. β-AR density and signaling data support normal regulation of postsynaptic 
events in aging.  They also suggest that drugs in this class can affect immune function 
indirectly by altering splenic SNA.  While refinement of the timing of treatment relative 
to age and drug wash-out studies are needed, our data indicate that reducing central SNA 
may be a useful strategy for reversing age-related nerve loss.  This is a necessary 
requirement for developing a model to study causal relationships between age-related 
changes in the SNS and immune system.  
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Abstract 
 INTRODUCTION: Sympathetic innervation in the white pulp of the spleen, 
norepinephrine (NE) concentration, signaling via β-adrenergic receptor (β-AR) and 
mitogen-stimulated proliferation of T lymphocytes decline in the spleen of aging Brown 
Norway (BN) rats. Effects of these age-related changes on neurotransmission that may 
modulate immunity have not been explored in this rat strain. OBJECTIVE: Therefore, we 
begin to develop a model that explores a causal relationship between altered sympathetic 
activity and immunity, by investigating the role of sympathetic tone on sympathetic 
neurotransmission in the spleen of middle-aged BN rats. METHODS: Fifteen month-old 
(15M) male BN rats received intraperitoneal (i.p.) injections twice per day, for total doses 
of 0, 0.5 or 1.5 µg/kg/day rilmenidine for 90 days (Veh-18M, Rilmlo, and Rilmhi, 
respectively). Rilmenidine affects imidazoline-1 receptors, located in sympathetic centers 
of the brains stem, to lower sympathetic tone. Untreated 3M and 18M (Crtl-3M and Crtl-
18M) male BN rats were used to control for effects of aging and stress of 
handling/injection.   Plasma and splenic catecholamine levels were quantified using high-
performance liquid chromatography (HPLC). And inhibition of NE measured with -
methyl-paratyrosine (αMPT), via i.p. injection 6 h before sacrifice, measured splenic NE 
turnover rate. Noradrenergic (NA) nerves, β-AR expression and β-AR-stimulated c-AMP 
production were determined by fluorescence histochemistry, β-AR radioligand binding, 
and enzyme immunoassay (EIA), respectively.  RESULTS: Rilmenidine treatment 
reduced circulating catecholamines (NE but not EPI), and splenic NE turnover in a dose-
dependent manner.   Restorative effects of rilmenidine treatment were observed on NA 
nerves distal to the hilus dose-dependently.  And the optimum dose elevated β-AR 
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density, without changing affinity, and partially reversed the age-related decline in β-AR-
stimulated cAMP production. CONCLUSIONS: Overall these results revealed that 
rilmenidine lessened the age-related decrease in sympathetic signaling via β-ARs, 
without significantly affecting NE levels in the spleen of normotensive BN rats.  Results 
here suggest that in age resilient rats, rilmenidine could modulate neurotransmission 
during exposure to pathogens or age-related diseases.  
Keywords: imidazoline-1 receptor agonist, neurotransmission, β-AR- stimulated cAMP 
production, aging, NE turnover, Brown Norway rat. 
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Introduction 
The sympathetic nervous system (SNS), with its wide distribution to most organ 
systems of the body, regulates physiological processes during basal and aroused states.  
In immune organs, the SNS modulates immune cells, primarily via its major transmitter, 
norepinephrine (NE) after release of micromolar concentrations from varicosities of 
adrenergic nerve fibers [Madden et al., 1995]. NE then signals lymphocytes mostly via β-
adrenergic receptors (β-ARs) [Elenkov et al., 2000; Nance and Sanders, 2007; Bellinger 
et al., 2008a] to activate the cAMP/protein kinase A (PKA) signaling cascade to regulate 
lymphocyte activation, expansion, and differentiation, cytokine production, and cell 
trafficking [Kammer, 1988; Cole et al., 1998; Sanders and Straub, 2002].  Both the SNS 
and the immune system undergo an age-related change in function with adverse 
consequences for health [MacGilchrist et al. 1989; Petrie et al., 2000; Bellinger et al., 
2008a].  
In the Fischer 344 (F344) rat, we demonstrated that an age-related increase in 
splenic SNA was contributory to sympathetic nerve loss in the spleen [manuscript in 
review].  Reduced splenic NE concentration, increased β-AR expression and β-AR-
stimulated cAMP production in splenocytes, suggest that adaptive mechanisms may 
compensate for nerve loss in order to provide continued regulation of the immune system 
with advancing age [Bellinger et al., 2008b].  Previously, we have reported increased 
SNA activity to the spleen in aging BN rats between 15 and 18M (unpublished data), 
consistent with reports of an age-related increase in SNS outflow [Perez et al. 2009; 
Docherty, 2002], and presumably contributes to dysregulation of signaling events in 
aging target organs, including the spleen [Bellinger et al 2008a,b].  In 18M BN rats, 
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sympathetic innervation declined noticeably in the hilar region, where nerves and blood 
vessel enter the spleen,, and then maintained at this lower level of nerve density through 
32 months of age. Splenic NE concentration was also reduced at 18M, but was 
maintained at this lower level through 32M [Perez et al., 2009].  β-AR expression spleen 
cells is increased in old BN rats; however, stimulation of β-AR in old spleen cells with 
isoproterenol reveal a significantly reduced rise in cAMP production compared with 3M 
controls. Taken together, these findings suggest dysregulation of sympathetic regulation 
of immune function in the spleen that is characterized by an uncoupling of the β-AR with 
its second messenger, cAMP.  These findings were consistent with in vitro studies 
[Goonwardene and Murasco 1994; Silverman et al., 1995] demonstrating an age-related 
decline in concanavalin A (Con A) stimulated proliferative responses and lower IL-2 
production in spleen cells.   
In the present study, we focus our attention to the effects of increased sympathetic 
nerve activity (SNA) during middle age on nerve integrity in the aging BN rat spleen, a 
secondary lymphoid organ important for host defense against systemic pathogens. We 
hypothesized that a transient increase in SNA during middle age may be responsible for 
of the loss of NA nerves in the spleen.  Damage to sympathetic nerves due to an increase 
in reactive oxygen species (ROS) produced by greater NE degradation,  would be 
consistent with mechanisms found to damage peripheral and central NA axons in aging 
and neurodegenerative diseases [Chen et al., 2003; Burke et al., 2004]. Our approach to 
test this hypothesis, was to treat middle-aged BN rats with rilmenidine, an imidazoline-1 
receptor agonist (IR1) that inhibits sympathoexcitatory cells in the rostral ventrolateral 
medulla [RVLM] [Reis, 1996], to reduce SNA in the spleen.  In addition to regulating 
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sympathetic outflow to the cardiovascular system, the RVLM tonically controls the 
discharge of postganglionic sympathetic neurons that supply the spleen [Beluli and 
Weaver 1991a, b; Perez et al., in press].  Previously, rilmenidine given discontinuously 
twice daily, reduced SNA outflow in spontaneously hypertensive rats (SHR) at peak 
concentration, without changing IR1 or α2-AR expression in the RVLM [Monassier et al., 
2004]. Therefore we used this method for pharmacologically reducing net sympathetic 
outflow to test the effects of increased SNA on neurotransmission in the spleen of 
middle-aged BN rats on splenic NA innervation and β-AR signaling in splenocytes. 
Therefore, sympathetic neurotransmission was assessed in spleens from BN rats 
treated with rilmenidine between 15 and 18 months of age.  Net and splenic SNA were 
assessed by circulating and splenic catecholamines, and also NE turnover studies in the 
spleen. We report here, that reducing SNA in the BN rat spleen during middle age 
partially increased nerve fiber density in splenic white pulps distal to the hilus but not at 
the hilus, without significantly affecting splenic NE or dopamine (DA) concentration.  
Collective our data demonstrate that reduced SNA during middle age had limited 
neuroprotective properties on sympathetic nerves in the aging BN rat spleen, and 
increased splenic NE levels and splenocyte b-AR density, but did not reverse the age-
related defect in β-AR mediated signal via cAMP.  Contrasting findings reported here 
compared with our previous findings in F344 rats support strain-specific differences in 
mechanisms responsible for age-related changes in sympathetic regulation of the immune 
system.  
 
 
139 
Methods 
Drug Preparation 
Rilmenidine dihydrogenase, a centrally acting, third generation, antihypertensive 
drug, was provided by Servier (Suresnes, France). Since rilmenidine is stable in solution 
at room temperature for over 24 hr [Monassier et al. 2004], the drug was prepared once 
daily in the morning by reconstitution in sterile, endotoxin-free, physiologic saline at 0.5 
or 1.5 mg/ml.  To study splenic NE turnover, α-methyl-DL-p-tyrosine methyl ester HCl 
(MPT; Sigma Chemical Co., St. Louis, MO), an inhibitor of the rate-limiting enzyme 
for NE synthesis, tyrosine hydroxylase, was prepared in sterile, endotoxin-free, 
physiologic saline containing 0.1% ascorbic acid at a concentration of 0.2 mg/ml.   
 
Animals 
Eighty-three male BN rats were purchased from the National Institute on Aging 
(NIA) colony (Harlan Sprague-Dawley; Indianapolis, IN).  Three- or 18-month-old (3M 
or 18M, respectively) rats (10 per age) were purchased for arrival to the vivarium 1 week 
before the end of the study to provide age-matched controls (18M) for stress and handling 
effects, and baseline young adult values (3M). The remainder of the rats were 15 months 
of age, and were used for a 3-month, chronic drug study. All animals in this study were 
housed two per cage in the vivarium at Loma Linda University, given food and water ad 
libitum, and placed on a 12-h-on 12-h-off lighting schedule. The ambient temperature of 
the vivarium was maintained at 22 °C and humidity ranged between 30-40%. Animals 
were left undisturbed to acclimate to housing conditions for one week followed by 
another week of daily handling to prepare them for the daily injection regimen.   All 
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animal procedures used in this study were approved by the institutional committee for 
animal use and care committee at Loma Linda University; and follow NIH guidelines. 
 
Study Design 
 Rats at 15 months of age were randomly assigned to one of the following treatment 
groups (n of 24 per treatment group): (1) vehicle treatment (Veh-18M), low-dose 
rilmenidine (500 μg/ml/kg/day; Rilmlo), or high-dose rilmenidine (1.5 mg/ml/kg/day; 
Rilmhi). Rats received a twice-daily injection of an equivalent volume of sterile 
endotoxin-free saline as the drug treatment or rilmenidine (half the total daily dose) at 
7:30 a.m. and 3:30 p.m. for 90 days. The rilmenidine treatment regimen was based on a 
previous report demonstrating sustained anti-hypertensive action in spontaneous 
hypertensive rats with twice daily intraperitoneal (i.p.) injections of 250 µg/ml/kg 
rilmenidine every twelve hours [Monassier et al. 2004]. Untreated, 3M and 18M, male, 
control BN rats arrived one week before the end of the 90-day experiment. Body weights 
from vehicle or drug-treated groups were measured before starting treatment, then once 
every week until the conclusion of the experiment, and, for all rats, before sacrifice. Body 
weights were expressed in g ± standard error of the mean (SEM). The health of the rats 
undergoing treatments was monitored by observing overall appearance, general activity, 
grooming, feeding and drinking behaviors daily, and body weight weekly.  
α-Methyl-p-tyrosine (MPT) Treatment.  At the end of the 90-day drug treatment, 
rats randomly chosen from vehicle- or rilmenidine-treated (Rilmlo, or Rilmhi) groups (n of 
16 rats per treatment group) were assigned to receive either vehicle or MPT.  Basal 
rates of NE turnover in the spleen were estimated by a method previously described by 
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Trayhurn and Wusteman [1987], in which the rate of decline in splenic NE concentration 
is measured after treatment with MPT [Trayhurn and Wusteman, 1987; Bellinger et al., 
2008b].  Rats were injected with MPT (200 mg/kg, i.p.) or an equivalent volume of 
sterile, endotoxin-free saline at time zero, and sacrificed 6 hr later by decapitation 
without prior anesthesia.  
Peripheral blood from each rat was harvested in 12x75-mm tubes containing 10 
mmol/L disodium ethylenediaminetetraacetic acid (EDTA) kept on ice. Blood samples 
were centrifuged at 1,200 rpm for 10 min, the plasma was collected into microfuge tubes, 
and. the plasma samples stored at -80 °C until measurement of catecholamine 
concentrations using high-performance liquid chromatography with coulometric 
detection (HPLC-CD). Spleens were dissected and transversely cut into two halves. Next,  
two cross-sectionally pieces cut from the central region of one half of the spleen (~3-4 
mm thick) were frozen on dry ice and then stored at -80 °C until measurement of splenic 
NE concentration, and staining with fluorescence histochemistry to localize sympathetic 
nerves.  Spleen cells were isolated from the other half of the spleen and used to evaluated 
β-AR-stimulated cAMP production, and for β-AR binding assays.   
Gross examination of the brain and all visceral organs was carried out after tissue 
collection, to assess possible age-related pathology, including splenomegaly (enlarged 
spleen resulting from lymphoma or leukemia originating in the spleen), bile duct 
hyperplasia (rough surface of liver), chronic nephropathy (enlarged and discolored 
kidneys), and testicular interstitial cell hyperplasia. Any rat with visible tumors, lesions 
or overt pathology was excluded from this study. One or two rats per chronic treatment 
group were removed from the study due to overt pathology.   
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HPLC-CD for Measuring Catecholamine Levels 
Using a Branson Sonifier 250, spleen samples were sonicated after adding a 10X 
volume/wet weight of cold 0.1 M perchloric acid and the internal standard, 3,4-
dihydroxybenzylamine (DHBA) (10 ng/ml; Sigma-Aldrich) .  Next, homogenates were 
centrifuged for 5 min at 10,000 rpm and the supernatants were harvested into 
microfilterfuge tubes and centrifuged for 20 min at 14,000 rpm.   After centrifugation, 
supernatants were collected and stored at -80 ºC until assayed for catecholamines. 
To assess circulating catecholamine content, 200 µl of plasma from each rat was 
transferred into a 12x75-mm glass tube, and 50 µl of the internal standard (DHBA), 1.0 
ml of a 0.1 M phosphate buffer (pH 7.0), 1.0 ml of 1.5 M Tris buffer (pH 8.6), and 50 mg 
of acid-washed alumina (Bioanalytical Systems Inc., West Lafayette, IN) were added. 
After covering the top with parafilm, the tubes were, briefly vortexed, and then placed on 
a C10 platform shaker (New Brunswick Scientific, Edison, NJ) for 5 min at 175 rpm. 
After the alumina settled, the samples were aspirated until dry, the alumina was washed 
with double-distilled H2O three times, and then the resulting alumina slurry was 
transferred to microfilterfuge tubes. Next, the microfuge tubes were centrifuged for 2 min 
at 9,000 rpm, the alumina was transferred to a new microfilterfuge tube, and 200 µl of 0.1 
M HClO4 was added. Then, the samples were vortexed, the tubes were centrifuged again 
for 2 min at 9,000 rpm and the supernatants collected.   Vials containing the supernatants 
were loaded into an ESA Model 542 autosampler, and NE and DA concentrations were 
determined by HPLC using a CouleChem HPLC System (ESA, Chelmsford, MA).  An 
ESA Model 582 solvent delivery module delivered the mobile phase through a Resolve 
C18 5-µm, 8x100-mm Radial-Pak analytical column at a flow rate of 1.0 ml/min.  In the 
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ESA CouleChem III coulometric detector cell system, the potentials of the guard cell and 
two detecting cells were set at 400 mV, 350 mV, and -350 mV, respectively.  The signal 
from the detector was recorded and the peak heights and area under the curves were 
analyzed using EZChrom Elite Software (Scientific Software Inc. Pleasanton, CA). 
Standards of known concentrations of NE, Dopamine (DA) and epinephrine (EPI) were 
used to determine splenic and plasma catecholamine concentrations and these data were 
expressed as a mean ± SEM in ng per g tissue wet weight and ng/ml plasma, respectively.  
Total splenic NE and DA content was estimated using NE and DA concentrations/mg wet 
weight and whole spleen weight respectively, and expressed as a mean ± SEM in 
ng/whole spleen. Circulating NE and EPI were expressed as a mean ± SEM in ng/ml 
plasma. 
 
Splenic NE Turnover 
 Splenic NE turnover was determined by calculating the rate of NE concentration 
decay after blocking NE synthesis using a model that applies steady-state kinetics, as 
previous described [Bellinger et al., 2008b]. In this model, NE concentration depends on 
the rate of synthesis as defined by the equation, Log[NE] = Log[NE]o – 0.434kt, where 
[NE]o is the initial concentration of NE and k, the rate constant, is the fraction of NE 
concentration formed or lost per unit time.    
To determine the rate constant, turnover time and turnover rate for NE in the spleen, 
the log of NE (log[NE]) concentration was plotted versus the time after synthesis 
blockade.  Linear regression analysis of the log[NE] vs. time relationship was carried out 
using individual data points obtained at 0 and 6 hr after tyrosine hydroxylase inhibition.  
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The slope (m) and standard error of the regression coefficient (Ser) were computed by the 
least squares method.  The rate constant for NE disappearance (kNE defined as m/0.434), 
NE turnover time (1/kNE), and NE turnover rate ([NE]o x kNE) were calculated as 
described. The standard error of the turnover rate and the turnover time were calculated 
from the variance of the regression slope and the variance of [NE]o according to the delta 
method [Bishop et al. 1975], using the following equation:  
Variance k(NE)o = k2var(NEo) + [NEo]2var(k) + 2kNEo*Covariance k,NEo.  Splenic NE 
turnover rate and time were expressed as a means ± SEM in ng/g/h and h, respectively. 
 
Fluorescence Histochemistry for Splenic Sympathetic Nerves 
NA sympathetic nerves in spleens from BN rats were visualized by a modification 
of the glyoxylic acid condensation method (SPG method) of histofluorescence for 
catecholamines, as previously described [de la Torre et al, 1980; Bellinger et al, 1992].  
Spleen sample blocks taken from the hilar region (zone of blood vessels and nerves entry 
into the spleen) and distal to the hilus, were mounted onto chucks with OCT compound, 
and 16 µm sections were cross-sectionally cut in a cryostat set at -20 oC. After thaw-
mounting three sections onto a glass slide, the slide was dipped in a 1% glyoxylic acid 
solution containing 0.2 M potassium phosphate and 0.2 M sucrose (pH 7.4), and then air 
dried using a direct stream of cool air for 15 min. Then, spleen sections were covered 
with several drops of mineral oil, and the slides were placed on a heat-conducting plate in 
an oven at 95 oC for 2.5 min. After draining the excess mineral oil from the slides, the 
slides were cover slipped with fresh mineral oil. Slides were examined using a Zeis 
Axiomat fluorescence microscope equipped with epi-illumination accessories and color 
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images were captured and digitized with an Olympus image high-resolution CCD video 
capture system.  
Morphometric Analysis of Sympathetic Nerve Density:  Estimating the mean area of 
NA nerves in the white pulp was carried out blinded to the treatment groups. The white 
pulp of the spleen was selected for analysis, because it is the compartment of the spleen 
with the largest proportion of sympathetic innervation [Bellinger et al., 2008b].  One 
splenic white pulp from each, at the hilar region (the point of NA nerve entry into the 
spleen), or distal to the hilar region, was randomly selected from 4 spleen sections per rat 
from 6 rats per treatment group for analysis. The criteria for selection of white pulps for 
analysis were that (1) there only one central arteriole was visible in the white pulp; (2) the 
size of the central arteriole was between 80-100 µm across the largest diameter of the 
vessel and comparable across all samples, and (3) the arteriole was cut in true cross 
section cut through the central arteriole, as previously described [Bellinger et al., 2002; 
Lorton et al., 2005].  White pulps were photographed and stored as digital images onto a 
computer using the 200X objective on a Zeiss fluorescent microscope containing a 395 to 
440 nm excitation filter.  The number of pixels containing NA nerve profiles in each 
image was determined, based on size and color using Image-Pro® imaging software 
(version 5.0; Media Cybernetic, Bethesda, MD) and the mean area of NA nerves in the 
white pulp was quantitated. The ratio of positive pixels and the total number of pixels in 
the image was multiplied by 100 to calculate the % area of NA nerve profiles in each 
image. The average of the % NA nerve area in the four white pulps from each animal was 
used to determine the mean % NA area for each animal. These mean values were 
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averaged for rats within each treatment group, thus, data were expressed as a mean of a 
mean ± SEM as a percent NA nerve area.   
 
Spleen Cell Preparation 
At the time of sacrifice, spleens were removed and weighed using sterile technique.  
Spleen mass was later expressed in g and as a percentage of body weight ± SEM.  Spleen 
cells were dissociated using a stomacher Lab-Blender (Tekmar Co., Cincinnati, OH). 
After placing approximately half of the spleen into a stomacher bag containing 10 ml 
Hank’s balanced salt solution (HBSS) (Mediatech Inc., Manassas, VA) containing 
0.035% sodium bicarbonate (Sigma-Aldrich, St. Louis, MO) and 25 mM HEPES 
(Mediatech Inc., Manassas, VA).  Larger aggregates in each spleen cell suspensions were 
removed by passage through a fine 100 µm cell strainers (BD Biosciences Discovery 
Labware, Bedford, MA).  Next, the cell suspensions were centrifuged, resuspended in 
HBSS, and then layered over Histopaque 1077 (Sigma Chemical Co.) and centrifuged at 
400 x g for 30 min at room temperature to remove red blood cells.  Spleen cells removed 
from the interface between Histopaque and HBSS were washed three times in HBSS, 
counted using a Coulter Counter (Coulter Instruments, Hialeah, Fl), and resuspended to 
2x106 cell/ml in RPMI 1640 (Mediatech Inc.) media supplemented with 5% heat-
inactivated fetal bovine serum (Omega Scientific, Tarzana, CA), 1mM sodium pyruvate 
(Hyclone Laboratories Inc., Logan UT), 2mM L-glutamate (Mediatech Inc.), 10 mM non-
essential amino acids (#SM302381; Hyclone Laboratories Inc.), 4.7x10-5 M 2-
mercaptoethanol (Sigma-Aldrich), 100 U/mol penicillin, 100 mg/ml streptomycin 
Mediatech Inc.), 0.2% sodium bicarbonate (Sigma-Aldrich), 0.2 mg/ml folic acid (Sigma-
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Aldrich), and 10 mM HEPES (Hyclone Laboratories Inc.). The spleen cell suspensions 
were then used for β-AR binding and cAMP assays after adjusting to the appropriate cell 
concentrations for each assay. 
 
β-AR Binding Assays 
Resuspended whole spleen cells (5x106 cells/ml) from vehicle or low-dose 
rilmenidine treatment groups (n of 6 per group) were assayed for radioligand binding 
studies. The radioligand ligand, (-)[125I]cyanopindolol ([125I]CYP) ( 2200 Ci/mmole) (GE 
Healthcare, Piscaway, NJ), was diluted in 1% ethanol, 5 mM HCl, and 0.2% bovine 
serum albumin (BSA).  ([125I]CYP) is a β-AR antagonist with equal affinity for the β1 and 
β2 subclasses [Sundaresan et al., 1987].  Assayed in duplicate, 1x106 spleen cells were 
placed in 13x100-mm polypropylene tubes containing one of eight concentrations of 
[125I]CYP ranging from 15.8-333 pM.  Another set of tubes containing the same number 
of spleen cells were incubated with 10-6 M CGP-12177 (Sigma-Aldrich), a hydrophilic β-
AR antagonist, were performed to control for nonspecific binding.  All tubes were 
incubated at 37 C for 60 min in a shaking water bath set at 100 oscillations/min, and 
then 3 ml of ice cold hypotonic buffer containing 3.8 mM KH2PO4, 16.2 mM K2HPO4, 
and 4 mM MnSO4, for 20 min was added to lyse cells. The content of each tube was 
filtered through Whatman fiberglass filters (GF/B) (Brandel Corp., Gaithersburg, MD) 
under reduced pressure using an automatic cell harvester (Brandel Corp., Gaithersburg, 
MD) to collect bound radioactivity. The filters were washed with 16 ml (4x4 ml) of ice-
cold Tris-EGTA buffer to remove the remaining unbound radioligand.  Filters were 
removed from the cell harvester, placed in 12x75-mm plastic tubes, and counted in a 
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Wallac 1470 Wizard gamma counter (Long Island, Port Jefferson, NY) at 82% 
efficiency. 
The difference between binding of the radioligand at each concentration in the 
absence and in the presence of (-) CGP-12177 was used to define specific binding. From 
10-20% of total binding was due to nonspecific binding. It was assumed was made in 
calculating binding that [125I] CYP decomposed into non-β-AR active products in direct 
relation to radioactive decay, as previously [Doyle et al., 1984].  The maximal number of 
binding sites/cell was calculated based on stoichiometric assumptions that 1 molecule of 
ligand binds to 1 receptor An interactive nonlinear regression curve fitting program from 
Prism® (GraphPad, San Diego, CA) to a single class of homogeneous binding sites was 
used to determine receptor density (Bmax) and affinity (Kd).   Specific binding was 
expressed in cpm vs. the concentration of [I125]-CYP in pM.  Data also were transformed 
into a linear form by Scatchard analysis and shown in Scatchard plots with bound in 
sites/cells vs. bound/free. The lines of best fit were determined using the Bmax and Kd to 
determine the X and Y intercepts.   
 
β-AR-Stimulated cAMP Production in Spleen Cells 
Spleen cell suspensions (1x106) were transferred into 12x75-mm polystyrene round 
bottom tubes (Thermo Fisher Scientific, Pittsburg, PA), and 100 μl HBSS containing 100 
µM isobutylmethylxanthine (IBMX) (Sigma-Aldrich) and 0.1% bovine serum albumin 
(BSA) (EMD Chemicals, Gibbstown, NJ), was added. In a shaking water bath at 37 oC, 
the tubes were incubated for 20 min, and then spleen cells were treated with 1 ml 10-5 M 
isoproterenol (Sigma-Aldrich) for 10 min.  Then, tubes were removed from the water 
149 
bath, and 2 ml ice-cold HBSS/BSA/IBMX buffer to quench the reaction. Spleen cell 
suspensions were centrifuged for 8 min at 1,800 rpm and the supernatant was discarded.  
After reconstituting the pellets with 0.5 ml of sodium acetate (50 mM) buffer, the tubes 
were exposed to two boiling-freezing cycles to lyse the cells. Cellular debris was 
removed by centrifugation at 1800 rpm for 8 min. The supernatants were collected into 
microfuge tubes, and then immediately stored at -80 oC.  Cyclic AMP levels , were 
determined in triplicate with a commercially available EIA Kit (GE Healthcare, 
Piscataway, NJ) following manufacturer’s instructions for acetylation EIA protocol, 
which provides the highest sensitivity with this kit (lower detection limit of 14 pg/ml). 
cAMP concentration in samples was determined by measuring the optical density in each 
well using a plate reader set at 450 nm. β-AR-stimulated cAMP production was 
expressed as a mean ± SEM in fmoles/2 x 106 cells/10 min. 
 
Data Analysis 
For data where mean ± standard error of the mean (SEM) were calculated, data 
were analyzed using one-way analysis of variance (ANOVA) and Bonferroni post-hoc 
testing was used for significant ANOVA (p<0.05) to determine significant differences 
between treatment groups . Where no statistical differences between vehicle-treated and 
untreated 18M control groups were found, the data were collapsed and designated Ctrl-
18M.  Where no differences were found between Ctrl-18M and Veh-18M via Student t-
test, the data were collapsed and designated a Ctrl-18M.  
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Results 
 
Chronic Rilmenidine Treatment Did Not Alter Mean Body or 
Spleen Weights 
 
BN rats appeared to tolerate the twice daily, 90-day vehicle or drug treatments, 
qualitatively displaying comparable activity, feeding, drinking, and grooming behaviors.  
There was no difference in mean body weights between the 18M treatment groups over 
the 90-day period (Fig. 4.1A).  Similarly, within each treatment group, mean body mass 
did not change over the 3-month course of the experiment.  Body mass from all 18M 
groups were significantly greater (***, p<0.001) than in Ctrl-3M rats (Fig. 4.1A).  Spleen 
weights from Ctrl-18M, Veh-18M, Rilmlo (**, p<0.001), and Rilmhi (*, p<0.05) rats 
increased significantly compared with young control rats (Ctrl-3M) (Fig. 4.1B).  There 
was also a trend (T, p<0.1) for lower spleen weights with Rilmhi treatment compared with 
Ctrl-18M rats. Finally, the spleen-to-body weight ratio was increased in Ctrl-18M 
compared with Ctrl-3M rats (††, p<0.001); and decreased in Veh-18M-treated rats (**, 
p<0.01), Rilmlo (*, p<0.05), or Rilmhi (*, p<0.05), compared with Ctrl-18M values (Fig. 
4.1C). 
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Fig. 4.1. Effect of Rilmenidine Treatment on Body Weights  
A.  The effect of 90-day treatment with low- or high-dose rilmenidine (Rilmlo or Rilmhi, 
respectively) or vehicle (Veh-18M) on mean body weight of male BN rats expressed as 
means (± SEM) in grams. Drug treatment began at 15 months of age and continued for 12 
weeks (18 months of age). Mean body weight progressively rose over the 12-week period 
of study, with no significant effect of vehicle or chronic drug treatment.  Veh, ; Rilmlo, 
; Rilmhi, . There was an expected age-related increase (*, p < 0.001) in body weight 
in all 18M rat groups compared with Ctrl-3M rats. Young, 3-month-old controls, Ctrl-
3M; Old, 18-month-old controls, Ctrl-18M; Vehicle, low and high-dose rilmenidine, 
Veh-18M, Rilmlo and Rilmhi, respectively. Ctrl-3M, n=10; Ctrl-18M, n=10; Veh, Rilmlo 
or Rilmhi, n=20. 
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Fig. 4.1. Effect of Rilmenidine Treatment Mean Spleen Weights.  
B.  The effect of 90-day treatment with low- or high-dose rilmenidine (Rilmlo or Rilmhi, 
respectively) or vehicle (Veh-18M) on mean spleen weight of male BN rats expressed as 
means (± SEM) in grams. An expected increasing effect by age on spleen weight was 
observed (**, p< 0.001, Ctrl-18M, Veh-18M, or Rilmlo; *, p< 0.05 Rilmhi).  Only a 
decreasing trend (T, p < 0.1) in spleen weight was found in Rilmhi rats compared to Ctrl-
18M rats. Veh, ; Rilmlo, ; Rilmhi, . Young, 3-month-old controls, Ctrl-3M; Old, 18-
month-old controls, Ctrl-18M; Vehicle, low and high-dose rilmenidine, Veh-18M, Rilmlo 
and Rilmhi, respectively. Ctrl-3M, n=10; Ctrl-18M, n=10; Veh, Rilmlo or Rilmhi, n=20. 
B 
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Fig 4.1.  (Continued). Mean Spleen Weights/ Mean Body and vs. Time after 
Treatment  
C.   Mean spleen weight per body weight ratio was greater (††, p<0.05) in Ctrl-18M rats 
than in Ctrl-3M rats; and greater in Ctrl-18M rats than in Veh-18M-rats (**, p< 0.01), 
Rilmlo- (*, p< 0.05), or Rilmhi-treated rats (*, p< 0.05). Spleen weight per body weight in 
these rats is expressed in g per g.  
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Rilmenidine Reduced Plasma NE, Without Affecting Plasma  
EPI Concentrations 
 
There was no significant effect of age on mean plasma catecholamine 
concentrations (NE or EPI) (Figs. 4.2A and 4.2B, respectively). Chronic treatment with 
Rilmlo or Rilmhi significantly reduced (*, p<0.05) plasma NE concentrations compared 
with Ctrl-3M and age-matched, Ctrl-18M rats, without an apparent dose response (Fig. 
4.2A). In contrast, rilmenidine treatment had no effect on mean plasma EPI 
concentrations. 
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Fig. 4.2. Effect of Rilmenidine on Circulating NE Concentration  
A.  Mean plasma norepinephrine (NE) concentrations in BN rats treated with low- or 
high-dose rilmenidine (Rilmlo or Rilmhi), and in 3M and 18M controls. Age-matched 
(18M) untreated and vehicle-treated rats were not different, so data were collapsed 
and expressed as Ctrl-18M. Rilmenidine treatment, regardless of dose, reduced (*, 
p<0.05) circulating NE. Young, 3-month-old controls, Ctrl-3M; old, 18-month-old 
controls, Ctrl-18M; Low and high-dose rilmenidine, Rilmlo and Rilmhi, respectively. 
Ctrl-3M, n=10; Ctrl-18M, n=22; Rilmlo or Rilmhi, n=14. 
A
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Figure. 4.2. Effect of Rilmenidine on Circulating EPI Concentration.                       
B.  Mean plasma epinephrine (EPI) concentrations in BN rats treated with low- or high-
dose rilmenidine (Rilmlo or Rilmhi), and in 3M and 18M controls. Age-matched (18M) 
untreated and vehicle-treated rats were not different, so data were collapsed and 
expressed as Ctrl-18M. Rilmenidine treatment for 90 days, regardless of dose, did not 
have an effect on EPI.  Young, 3-month-old controls, Ctrl-3M; old, 18-month-old 
controls, Ctrl-18M; Low and high-dose rilmenidine, Rilmlo and Rilmhi, respectively. Ctrl-
3M, n=10; Ctrl-18M, n=22; Rilmlo or Rilmhi, n=14. 
B 
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Rilmenidine and the Age-Related Decline in  
Splenic NA Innervation 
 
At the hilus, fluorescence histochemistry revealed a dense plexus of NA nerves 
surrounding the central arteriole in the white pulp of the spleen from Ctrl-3M rats (Fig. 
4.3A). Noradrenergic fibers coursed into the adjacent periarteriolar lymphatic sheath 
(PALS) where T cells reside. A similar distribution of NA nerves was present around the 
central arteriole in the splenic white pulp and PALS from Ctrl-18M rats; however, the 
density of fluorescent NA fibers was markedly reduced compared with Ctrl-3M rats (Fig. 
4.3B).  There were no apparent differences in the density of NA nerves between Veh-
18M (data not shown) and Ctrl-18M rats.  Similarly, treatment with Rilmlo or Rilmhi 
(Figs. 4.3C and 4.3D, respectively) did not appear to affect either the distribution or the 
density of NA nerves in the white pulp compared with Ctrl-18M rats.   
Morphometric analysis (Fig. 4.3E) confirmed an age-related decline (***, p < 
0.001) in splenic NA nerve density in the splenic white pulp of approximately 41.7% in 
all 18M treatment groups compared with Ctrl-3M rats, but no change in splenic NA 
density in the white pulp of Rilmlo or Rilmhi compared with Ctrl-18M rats. 
 
 
 
 
 
 
 
 
158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. Effect of Rilmenidine on NA Innervation at the Hilus 
Fluorescence histochemistry for catecholamines reveals abundant fluorescent linear and 
punctate (arrowheads) noradrenergic (NA) nerve profiles surrounding the central arteriole 
(ca) in the white pulp (wp) in the hilar region of the spleen in 3-month-old F344 rats 
(Ctrl-3M) (A.).  The density of fluorescent nerves alongside the central arteriole is 
diminished at 18 months of age (Ctrl-18M) (B.); and maintained in spleens of rats treated 
with low- or high-dose rilmenidine, Rilmlo (C.) and Rilmhi (D.), respectively.  The 
intensity and density of NA nerves in the white pulp, at the hilus, of spleens from vehicle-
treated (Veh) were similar to Ctrl-18M (data not shown).  A-D. Glyoxylic acid 
fluorescence histochemistry. Calibration bar = 100 µm.
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Fig. 4.3. Effect of Rilmenidine on NA Innervation at the Hilus (Continued).  
E.  Morphometric analysis of fluorescent NA nerve profiles (E.) expressed as percent 
mean area is consistent with qualitative findings, showing an age-related loss of 
fluorescent nerves in the white pulp (***, p<0.001) in all 18M groups (Ctrl-18M, Rilmlo, 
or Rilmhi) compare with Ctrl-3M. Each group is representative of an n of 8 rats. There 
was no difference in NA nerve area in Ctrl-18M and Veh rats, so the data was collapsed.  
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 Distal from the hilus, the area of the white pulp and the diameter of the central 
arteriole were smaller than at the hilus (Figs. 4.4A-D). Consistent with findings in the 
hilar region, there was an apparent age-related loss of NA nerve fibers along the central 
arteriole (Figs 4A-B); fewer NA nerves were present in the white pulp from Ctrl-18M 
(Fig. 4.4B) compared with Ctrl-3M rats (Fig. 4.4A)effects of age, but not drug treatment 
on NA nerve density.  The distribution and density of NA nerve in the white pulps from 
Rilmlo (Figs. 4.4C) were similar to that observed in Ctrl-18M rats (Fig. 4B); however, 
NA innervation of the central arteriole and surround PALS in the white pulp from Rilmhi 
rats (Figs. 4.4D) was similar to Ctrl-3M (Figs. 4.4A). Morphometric analysis (Fig. 4.4E) 
confirmed qualitative observations in the white pulp distal to the hilus. There was a 
significant (*, p<0.05) reduction in nerve density of 25% and 21% in Ctrl-18M and 
Rilmlo respectively, compared with Ctrl-3M rats.   
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Fig. 4.4. Effect of Rilmenidine on Splenic NA Innervation Distal to the Hilus 
Fluorescence histochemistry for catecholamines, in the region distal to the hilus, exposes 
NA nerves surrounding the central arteriole (ca) in the white pulp (wp), as fluorescent 
punctuate and linear profiles extending to surrounding areas (arrowheads) (Ctrl-3M) (A.).  
In the white pulp distal to the hilus central arterioles are of smaller diameter surrounded 
by fewer NA nerves than in the hilar region; and compared to Ctrl-3M rats, reduced NA 
nerve profile density along the central arteriole and white pulp is observed at 18 months 
of age (Ctrl-18M) (B.) or in rats treated with a low dose of rilmenidine (Rilmlo) (C.).  
Nerve density in high-dose rilmenidine-treated rats (Rilmhi) (D.) appears similar to Ctrl-
3M rats. Low and high-dose rilmenidine, Rilmlo and Rilmhi, respectively; young, 3-
month-old controls, Ctrl-3M; old, 18-month-old controls, Ctrl-18M).  A-D. Glyoxylic 
acid fluorescence histochemistry. Calibration bar = 100 µm. 
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Fig. 4.4. Effect of Rilmenidine on Splenic NA Innervation Distal to the Hilus by 
Morphometric Analysis (Continued). 
E. Morphometric analysis confirmed the age-related decline of fluorescent NA nerves 
that was maintained with Rilmlo (*, p<0.05).  Low and high-dose rilmenidine, Rilmlo and 
Rilmhi, respectively; young, 3-month-old controls, Ctrl-3M; old, 18-month-old controls, 
Ctrl-18M).   
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Rilmenidine Affects Splenic NE and DA Concentrations and Content 
in a Dose-Dependent Manner 
 
There was an age-related decline in mean splenic NE concentration and total NE 
content in the spleen (Ctrl-18M vs. Ctrl-3M; ***, p<0.001 and *, p<0.05) (Fig. 4.5A and 
Fig 4.5B, respectively). A slight dose-dependent increase in NE concentration and 
content resulted from Rilm treatment compared with Ctrl-18M rats. Splenic NE 
concentration in Rilmlo rats was significantly lower than in Ctrl-3M (Fig. 4.5A), but no 
other treatment groups were different for splenic NE concentration or content.  
Regression analyses (Figs. 4.5C and 4.5D), revealed significant negative correlations 
between splenic NE concentration or total content and spleen weight (p<0.001and 
p<0.01, respectively).    
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Fig. 4.5.  Rilmenidine and Splenic NE Concentration. 
A.  Mean splenic NE concentration (mg/g wet weight ± SEM) in rats treated for 90 days 
with vehicle, low- or high-dose rilmenidine (Veh-18M, Rilmlo or Rilmhi, respectively). 
Mean splenic NE concentration was reduced in Ctrl-18M rats (***, p<0.001) and Veh-
18M- or Rilmlo-treated (**, p<0.01) compared with Ctrl-3M rats. A non-significant trend 
toward increased splenic NE concentration with Rilmhi compared with Ctrl-18M was 
noted. Ctrl-3M or Ctrl-18M, respectively; and low- or high-dose rilmenidine, Rilmlo or 
Rilmhi, respectively. Ctrl-3M, n= 10; Ctrl-18M, n=10 ; Rilmlo or Rilmhi, n=14. 
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Fig. 4.5.  Rilmenidine and Splenic NE Content. 
B.   Mean splenic total content (ng/spleen ± SEM) in rats treated for 90 days with vehicle, 
low- or high-dose rilmenidine (Veh-18M, Rilmlo or Rilmhi, respectively). Mean splenic 
NE content was reduced in Ctrl-18M rats (*, p<0.05) compared to Ctrl-3M rats. No other 
significant differences in splenic total NE content among treatment groups were found. 
Ctrl-3M or Ctrl-18M, respectively; and low- or high-dose rilmenidine, Rilmlo or Rilmhi, 
respectively. Ctrl-3M, n= 10; Ctrl-18M, n=10 ; Rilmlo or Rilmhi, n=14. 
B 
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Fig. 4.5.  Correlation between Spleen Weight and Splenic NE Concentration. 
C.   A negative correlation was observed between splenic NE concentration with spleen 
weight (R2=0.2394). Untreated 3M and 18M BN controls rats, Ctrl-3M or Ctrl-18M, 
respectively; and low- or high-dose rilmenidine, Rilmlo or Rilmhi, respectively. Ctrl-3M, 
n= 10; Ctrl-18M, n=10 ; Rilmlo or Rilmhi, n=14. 
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Fig. 4.5.  Correlation between Rilmenidine and Splenic NE Content. 
D.  A negative correlation was observed between splenic NE content with spleen weight 
(R2=0.1454). Untreated 3M and 18M BN controls rats, Ctrl-3M or Ctrl-18M, 
respectively; and low- or high-dose rilmenidine, Rilmlo or Rilmhi, respectively. Ctrl-3M, 
n= 10; Ctrl-18M, n=10 ; Rilmlo or Rilmhi, n=14. 
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DA concentration (Fig. 4.6A) or content (Fig. 4.6B) were not significantly affected 
by age, but was more variable in Ctrl-3M and tended to be lower in Ctrl-18M compared 
Ctrl-3M.  However, treatment with Rilmlo significantly decreased DA concentration 
(p<0.01) or total content of DA (p<0.05) in the spleen by approximately 45% compared 
with Ctrl-3M rats. No correlation between either DA concentration or total content in the 
spleen and spleen weight was found (Figs. 4.6C and 4.6D respectively). 
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Fig. 4.6.  Rilmenidine and Splenic DA Concentration. 
A.  Mean total splenic DA concentrations (expressed as ng/gm wet weight ± SEM) in 
3M and 18M controls (Ctrl-3M, Ctrl-18M), and rats treated with low- or high-dose 
rilmenidine treatment, Rilmlo, and Rilmhi, respectively). There was no effect of age on 
splenic DA concentration; however, Rilmlo decreased splenic DA concentration (*, 
p<0.05) compared with Ctrl-3M. There was a non-significant trend for reduced DA 
concentration in the spleen, with Rilmlo compared with Ctrl-18M. Rilmhi did not 
affect splenic DA concentration.  Ctrl-3M, n=10; Ctrl-18M, n=10; Rilmlo or Rilmhi, 
n=14.
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Fig. 4.6.  Rilmenidine and Total Splenic DA Content. 
B.  Mean total splenic DA content (expressed as ng/spleen ± SEM) (B.) in 3M and 
18M controls (Ctrl-3M, Ctrl-18M), and rats treated with low- or high-dose 
rilmenidine treatment, Rilmlo, and Rilmhi, respectively). There was no effect of age on 
splenic DA content; however, Rilmlo decreased splenic DA content (*, p<0.05) 
compared with Ctrl-3M. There was a non-significant trend for reduced total DA 
content in the spleen with Rilmlo compared with Ctrl-18M. Rilmhi did not affect 
splenic DA content. 
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Fig. 4.6.  Correlation between Spleen Weight and Splenic DA Concentration. 
C. No correlation was found between Spleen weight and Splenic DA concentration 
(R2=0.0118). Ctrl-3M, n=10; Ctrl-18M, n=10; Rilmlo or Rilmhi, n=14. 
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Fig. 4.6.  Correlation between Spleen Weight and Total Splenic DA Content. 
D. No correlations was found between Spleen weight and Splenic DA content 
(R2=0.0068). Ctrl-3M, n=10; Ctrl-18M, n=10; Rilmlo or Rilmhi, n=14. 
D
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Rilmenidine Reduces Splenic NE Turnover 
NE synthesis blockade by treatment with αMPT reduced splenic NE concentration 
6 h later regardless of treatment groups (Fig. 4.7 and Table 4.1).  However, a slower rate 
of decline was observed with rilmenidine treatment compared with Veh-18M controls, 
and this effect was dose-dependent (59% by Rilmlo and 31% Rilmhi) (Fig. 4.7).  NE 
turnover rates were calculated based on the slopes of the lines.  Regression analysis 
revealed a 14.5% and 8.3% decline in splenic NE turnover rate with Rilmlo and Rilmhi 
treatment compared with Veh-18M rats, respectively (Table 4.1).  The turnover rate in 
spleens from Veh-18M rats was 1.9 fold higher than previously reported in 15M rats; and 
Rilmlo or Rilmhi turnover rates were 0.1-fold higher and 1.7-fold lower that in 15M rats. 
Rilmenidine dose-dependently increased the time required to synthesize the constant pool 
of NE in the spleen (turnover time) compared with Ctrl-18M rats (Table 4.1).    
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Fig. 4.7.  Effect of Rilmenidine on MPT-Induced Decline in Splenic NE 
Concentration 
The effect of rilmenidine on mean splenic norepinephrine (NE) concentrations at 0 and 6 
hours post-injection with MPT, an inhibitor of NE synthesis. Ninety-day treatment with 
low-dose (Rilmlo, ) or high-dose rilmenidine (Rilmhi, ○) slowed the rate of decline in 
splenic NE concentration over the 6-hour period compared with age-matched vehicle 
controls (Veh-18M, ).  Data are expressed in ng/g/hr vs. time and each group 
represents an n of 8 rats. 
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Table 4.1. Turnover rates and turnover times of NE in the spleen of BN male rats treated 
with vehicle, low- or high-dose rilmenidine (Veh-18M, Rilmlo or Rilmhi, respectively). 
Initial NE concentrations and splenic turnover rate declined in a dose-dependent manner 
after treatment with αMPT rats compared with vehicle-treated rats (Veh-18M) rats. 
Turnover time was increased by rilmenidine treatment in a dose-dependent manner.  
Initial levels of splenic NE and the rate constants are expressed as means ± SEM. αMPT,  
α-methylparatyrosine; NE, norepinephrine; n, number of rats per age group. 
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Rilmenidine Treatment Increased Splenocyte β-AR Receptor Binding 
Without Affecting Affinity 
 
Binding of the radioligand was rapid, saturable, and of high affinity in spleen cells 
from Veh-18M and Rilmlo-treated rats (Fig. 4.8A-B, respectively). Scatchard plots (insets 
in both Fig 4.8A and 4.8B, respectively) show the slopes of the line for Veh-18M- 
(4.8A) and Rilmlo- (4.8B) treated rats, where each point represented the ratio of bound 
ligand per sites per cell over bound ligand.   The X and Y intercepts of the line were 
determined by Bmax and KD respectively.   
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Fig. 4.8. Effect of Rilmenidine on β-AR Binding in Splenocytes 
A. Specific binding and Scatchard plots of (-)-[125I]cyanopindolol([125I]CYP) in whole 
spleen cells from age-matched vehicle-treated rats. Spleen cells were incubated under 
equilibrium binding conditions at 37 ºC with ICYP (0.9-220 pM) for 60 min, then the 
reaction was stopped and radioactivity was quantified by gamma scintillation 
spectrometry. Specific binding and plots represent means of duplicate determinations of 
for specific binding (■), counts/min (cpm). This group represents an n of 5 rats. 
A 
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Fig. 4.8. Effect of Rilmenidine on β-AR Binding in Splenocytes (Continued). 
B.  Specific binding and Scatchard plots of (-)-[125I]cyanopindolol([125I]CYP) in whole 
spleen cells from low-dose rilmenidine (rilm)-treated rats. Spleen cells were incubated 
under equilibrium binding conditions at 37 ºC with ICYP (0.9-220 pM) for 60 min, then 
the reaction was stopped and radioactivity was quantified by gamma scintillation 
spectrometry. Specific binding and plots represent means of duplicate determinations of 
for specific binding (■), counts/min (cpm). This group represents an n of 5 rats. 
B 
0 100 200 300 400
0
200
400
600
800 Bmax = 757.0
    Kd = 43.3
Rilmlo
Concentration [I125]-CYP (pM)
Sp
ec
ifi
c 
B
in
di
ng
(s
ite
s/c
el
l)
0 200 400 600 800
0
10
20
Scatchard
Bound (sites/cell)
B
ou
nd
/F
re
e
D
179 
The mean Bmax increased 36% (*, p<0.001) in spleen cells from Rilmlo-treated rats 
(750±65 sites/cell) over that seen with Veh-18M 560±58 sites/cell) treatment (Fig 4.9A). 
The mean KD was not significantly different between Rilmlo- and with Veh-treated rats 
(Fig 4.9B). 
 
 
180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9. Effect of Rilmlo and Vehicle Treatment on Mean β-Receptor 
Expression (Bmax) in BN Rats 
A.  Mean density of β-AR expressed as sites/cell on spleen cells from vehicle-treated 
(Veh-18M) and low-dose rilmenidine (Rilmlo)-treated rats (n of 6 per group).  
Treatment with Rilmlo increased β-AR expression on splenocytes (*, p<0.05).  Mean 
values were calculated from the Bmax and KD determined form specific binding 
curves generated for each rat from each treatment group. 
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Fig. 4.9. Effect of Rilmlo or Veh-18M on Mean β-Receptor Binding Affinity (KD). 
B.  Meand binding Affinity expressed as sites/cell KD on spleen cells from vehicle-
treated (Veh-18M) and low-dose rilmenidine (Rilmlo)-treated rats (n of 6 per group).  
Treatment with Rilmlo did not affect KD.  Mean values were calculated from the Bmax 
and KD determined form specific binding curves generated for each rat from each 
treatment group. 
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Rilmenidine Treatment and β-AR-Stimulated cAMP Production in 
Spleen Cells 
The isoproterenol stimulation of β-AR increased the production of cAMP in spleen 
cells differentially depending on treatment group (Fig. 4.10). In spleen cells from Ctrl-
18M rats cAMP production was 42% lower (**, p<0.01) in Ctrl-18M compared with 
Ctrl-3M rats. In rats treated with Rilm, cAMP production was comparable to Ctrl-18M 
levels, and Rilmlo did not differ statistically from Ctrl-3M levels. However, Rilmhi 
significantly reduced cAMP production levels (51%; **, p<0.001), compared with Ctrl-
3M rats.     
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Fig. 4.10. Effect of Rilmenidine on β-AR-Stimulated cAMP Production in 
Splenocytes 
Isoproterenol-stimulated cAMP production in spleen cells is expressed in fmol/106 
cells/10 min ± SEM. Vehicle (Veh) and non-treated age-matched controls were not 
different, and therefore were collapsed (collectively Ctrl-18M).  cAMP production in 
spleen cells was significantly lower in Ctrl-18M rats or Rilmhi-treated rats (*, p<0.05 and 
**, p<0.001 respectively) compared with Ctrl-3M rats. Low and high-dose rilmenidine, 
Rilmlo and Rilmhi, respectively; 3-month-old controls, Ctrl-3M; 18-month-old controls, 
Ctrl-18M.  Ctrl-3M, n=10; Ctrl-18M, n=20; Rilmlo=14, Rilmhi, n=16. 
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Discussion 
 
In this study, we investigated the effect of reducing SNA by treatment with 
rilmenidine on sympathetic neurotransmission in the spleen of aging BN rats. Reduced 
circulating NE concentrations and NE turnover in the spleen in Rilm-treated rats indicate 
lower net SNA and SNA in the spleen.  Interestingly, we found that the Rilm-induced 
increase in β-AR binding did not affect β-AR-stimulated cAMP production in 
splenocytes, and minimally affected NA nerve density in the spleen at the highest dose.    
Consistent with previous pharmacological studies in hypertensive [Monassier et al., 
2004; El-Mas et al., 2009] and F344 rats [Perez et al., in press], rilmenidine globally 
reduced sympathetic outflow as indicated by the reduced circulating NE concentrations in 
rilmenidine-treated rats compared with age-matched controls. This effect was not dose-
dependent, consistent with the findings of Raasch et al [2003].  In contrast, there we no 
effect of rilmenidine treatment on circulating EPI, also consistent with a previous report 
from our laboratory in F344 rats [Perez et al., in press]. These findings are consistent with 
the actions of rilmenidine on sympathoexcitatory neurons in the RVLM, via IR1 and α2-
AR [Urban et al., 1995; Bruban et al., 2001], which causes a net inhibition of spinal 
preganglionic neurons that ultimately diminishes the firing rate of postganglionic NA 
nerves at the target site [Dampney 1994].  
Importantly, rilmenidine reduced splenic NE turnover, indicating lower SNA in the 
spleens from BN rats treated with rilmenidine compared with age-matched controls. This 
finding is consistent with the spleen as a target organ of regulation by the RVLM based 
on anatomical and electrophysiological data [Beluli and Weaver, 1991a, b]. However, 
rilmenidine was not as effective in reducing circulating NE or splenic NE turnover as 
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seen previously in our laboratory in age-matched F344 rats with the same treatment 
regimen and doses [Perez et al., in press].  The reason for the this strain-related difference 
is not clear, but may be related to strain differences in the splenic microenvironment, 
immune response profile to antigens, α2-AR and/or IR1 expression or coupling efficacy 
with second messenger systems, and/or distribution in target tissues.  
We cannot discount that some the effect of rilmenidine may be mediated 
peripherally, for example via α2-AR expressed on NA nerve terminals of all 
postganglionic nerves, including in the spleen, which act to dampen their firing when 
these receptors are stimulated [Docherty, 2002]. Similarly, IR1 are expressed in other 
tissues that are densely innervated by SNS [Dontenwill et al., 1999], and therefore may 
indirectly regulate the net sympathetic tone.  Expression of IR1 in the spleen has not been 
confirmed thus far; however, rilmenidine may interact with α2-ARs expressed on cells of 
the immune system, such as splenic macrophages [Spengler et al., 1990].  Activation of 
α2-AR in splenic macrophages can increase TNF-α and IL-1 [Spengler et al., 1990], 
cytokines which can reduced reduce splenic NE concentration [Khom and Sanders 2000] 
and SNA nerve activity [Madden and Felten 1995]. Future studies will investigate further 
the possible actions of rilmenidine on splenic SNA at sites other than the RVLM.  
The small effects of rilmenidine on NA innervation in the aging spleen, which were 
seen only with Rilmhi, does not support our hypothesis that elevated SNA in the BN rat 
spleen contributes significantly to sympathetic nerve damage in this lymphoid organ.  
This finding is in contrast with previous findings in aging F344 rats from our laboratory 
[Bellinger et al., 2008b] demonstrating that reducing SNA activity by treatment with 
rilmenidine partially, but significantly, reversed NA nerve loss in the spleen [Perez et al., 
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in press]. There are several key differences in age-related changing of sympathetic 
neurotransmission between these two strains. F344 rats exhibit a chronic increase in NE 
turnover rate in the spleen that begins at 10M (early middle age) and persists throughout 
late middle age (17M) [Bellinger et al., 2008b], whereas BN rats exhibit a transient 
increase in splenic NE turnover at 15M of age.  Also, the decline in NA nerve density in 
the aging F344 rat spleen is more severe and begins early [Bellinger et al., 2008b] than in 
BN rats [Perez et al., 2009]. Finally, differences in immune responses to antigen 
challenge [Bellinger et al., 2002] and behavioral responses to stress [Gómez et al 1998], 
suggest differences in stress pathways that regulate these behaviors.  
The transient nature of increased SNA in spleens from aging BN rats [Perez et al., 
2009] would be expected to have a lower negative impact on NA nerve integrity from 
oxidative stress [Tamariello et al., 2000; Lipton 1997] compared with a chronically 
increased sympathetic tone in F344 rats.  In aging BN rats, there is an increase in NE 
turnover rate at 15M, followed by more than a 2-fold decline at 18M that stays reduced 
into old age (32M) [Perez et al., 2009]. This transitory spike in NE turnover correlates 
with decline in both NA innervation (at 15M) and splenic NE concentrations (at 18M), 
which are not further diminished in old age.  The transient nature of sympathetic nerve 
activity in the BN rat spleen during middle age may permit better repair from insults due 
to increased oxidative stress on the nerves; or at 15M BN rats may have a greater inherent 
resilience to heightened sympathetic activity [Madden et al., 1997].  However, we cannot 
rule out that heighten SNA activity may occur earlier in middle age, at time points not 
examined in our previous studies. If this is the case, then starting treatment of rilmenidine 
at an earlier age may be efficacious for preventing sympathetic nerve loss in the aging 
187 
spleens of BN rats. More extensive investigation of SNA at earlier middle aged time 
points is needed to address this question. 
 Important factors that may protect sympathetic nerve integrity include better 
buffering capacity for eliminating free radicals, which are toxic to neurons [Madden et 
al., 1995] and adequate levels of neurotrophins that protect nerves from oxidative stress 
[Laurenzi et al., 1994]. With increasing age, there is a decrease in the antioxidant 
capacity in target tissues; and reduced ability of target cells or neurons to absorb free 
radical that may lead to neuronal atrophy [Tammariello et al., 2000].  The role of 
antioxidant enzymes and neurotrophic support on sympathetic nerves preservation of that 
supply the aging spleen, and whether there are strain differences, remains unknown and 
warrants investigation. A balance between positively and negatively acting neurotrophins 
in target tissues determine the extent of innervation [Ernfors et al., 1994].  Sympathetic 
nerve activity is important in regulating NGF synthesis in target tissues [Falckh et al., 
1992]; and expression of neurotrophic factors may be linked to the degree of the age-
related decline in NA innervation of the spleen in the BN rat strain.  Unchanged 
concentrations in NGF or NT-3 in the spleen of old vs. young BN rats observed in our 
laboratory (unpublished observations) may suggest neuroprotection for sympathetic 
fibers by trophic factors are maintained in aging; however, whether aging affect 
neurotrophin receptor expression or function remains unknown.   
Sympathetic nerve integrity may also be influenced by age-related changes in the 
composition of immune cell populations that reside in the aging spleen, which contribute 
to local microenvironment.  For instance, in F344 rats, loss of sympathetic nerves in the 
spleen is accompanied by a loss of T lymphocytes and ED3+ macrophages [Bellinger et 
188 
al., 1992].  Aging increases the numbers of anergic CD8+ T cells [Komuro et al., 1990] 
and memory T and B cell populations [Ernst et al., 1990], alters the CD4+/CD8+ ratio 
[Matour et al., 1989], and affects the functioning of lymphocytes and macrophage 
[Dunston and Griffith , 2010]. These aging changes may contribute to altered nerve 
integrity. Consistent with this hypothesis, T and B lymphocytes, eosinophils, follicular 
dendritic cells, reticular cells and mast cells synthesize NGF [Yoshida et al., 1992].  
The minimal effect by rilmenidine on NA nerve density in BN rats is in contrast 
with our previous findings of a neuroprotective role in aging F344 rats. This difference 
may be due to greater resistance to rilmenidine effects in BN rats compared with F344 
rats. This hypothesis is consistent with our finding that rilmenidine did not lower 
circulating NE or splenic SNA as effectively in BN rats as it did in F344 rats, and 
rilmenidine was better tolerated in BN rats as indicated by their weight gain over the 90 
day period that was not seen in F344 rats.  Studies investigating the effects of rilmenidine 
on sympathetic neurotransmission in the aging spleen need to be carried out with optimal 
doses of rilmenidine, and earlier in middle age. The difference in weight gain between 
BN and F344 rats may be related to strain difference in behavioral responses to the stress 
of injections and handling as BN rats are lower responders to acute and chronic stress 
compared with F344 rats [Gómez et al., 1998].  
Splenic NE levels are consistent with our anatomical findings, because 
neurotransmitter (i.e. NE) concentration and total content in the spleen correlated with 
lower density of NA nerve fibers. These results suggest that neuronal NE homeostasis 
was maintained under the low and high rilmenidine drug condition of our study, and are 
consistent with no change in splenic DA concentrations and content. This finding differs 
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from our findings in F344 rats, where Rilmhi increased splenic DA concentration and 
content; greater end product inhibition of DA on TH activity in F344 rats may in part 
explain the greater reduction in splenic NE concentration and SNA activity with high 
dose treatment compared with our findings in BN rats.   
Despite lower splenic NE concentration in Rilmhi-treated BN rats, there was no 
significant difference between the levels in this group compared with Ctrl-3M rats, 
suggesting some reversal toward young adult levels.  This nonsignificant increase in NE 
splenic levels with Rilmhi were consistent with the slight increase in NA nerve density in 
distal regions of the spleen toward levels in young adult rats (Ctrl-3M).   
The age-related blunting of β-AR-mediated signaling via intracellular cAMP was 
not affected by rilmenidine treatment, suggesting that lowering SNA to the spleen does 
not affect aging changes in β-AR signal transduction in aging lymphocytes.  However, 
the upregulation of β-ARs, evident by a 36% increase in β-AR expression indicates that 
these receptors are still responsive to changes in local concentrations of NE, with 
increasing receptor density as concentrations declined.  Mechanisms responsible β-AR 
uncoupling with its second messenger, cAMP, are not understood, but may result from an 
uncoupling of β-AR with Gs protein, caused in part from an age-related reduction in 
membrane fluidity, and resulting in reduced AC activity and increased intracellular 
calcium [Scarpace and Abrass 1983].  In cardiac myocytes, increased availability of NE 
results in increased phosphorylation of MAPK and causes an uncoupling to the Gs 
protein [Daaka et al., 1997].  β-AR under certain conditions can switch coupling from Gs 
to either a Gi or Go protein, which then causes β-AR stimulation to signals through a 
different intracellular signaling cascade [Hausdorff et al., 1990]. It remains unknown 
190 
whether under reduced NE concentration in the spleen of the aging BN rats; this 
mechanism may be responsible for the decline in β-AR-stimulated cAMP production. 
Rilmenidine has been suggested to have direct effects on intracellular G-proteins to 
modulate the production of cAMP.  IR1 are coupled to cAMP pathway as its second 
messenger, as well as ability for cross talk between the cAMP and PC-PLC pathways, 
using the same intracellular machinery, and leading to complex effects [Greney et al., 
2000; Separovic et al., 1996; Ho and Wang, 1998]. Collectively, our data here and from 
previous studies in F344 rats, suggests that age-related alterations in SNA and nerve 
integrity in the spleen may contribute to aging changes in NA neurotransmission in a 
strain-specific manner. Our data also suggest that different strategies will be needed in 
BN and F344 rats to restore NA signal transduction in aging lymphocytes in order to 
evaluate the causal relationships between aging changes in the SNS and immune 
function.   
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CHAPTER 5 
CONCLUSIONS & FUTURE DIRECTIONS 
 
Summary and Conclusions 
The studies presented in this doctoral project evaluated the effects of aging on 
sympathetic neurotransmission in secondary lymphoid organs of F344 rats or BN rats; 
two rat strains that differ in SNS activity and immunity that potentially predispose them 
to particular types of age-related diseases. The goal of these studies was to investigate the 
role of the age-related altered sympathetic activity on neurotransmission in the spleen. 
This constituted an initial step toward developing laboratory rat models to study causal 
relationships between age-related changes in the SNS and immune system aging in 
humans. Below, we summarize and discuss the significance of our findings; and propose 
future specific interventions and aims to refine the feasibility of our model. 
In chapter 2, a longitudinal study in BN rats was conducted to identify the effects 
of normal aging on basal sympathetic tone, and SNA, NA innervation as well as NE 
levels in the spleen. The BN rat lives an average of 25% longer than the commonly used 
rat model for aging, the F344 rat. We did not need to conduct a similar study in the F344 
rat because we had previously characterized the age-related changes in sympathetic 
factors in the spleen of F344 rats, across age. Results from this study demonstrated an 
age-related decline in both, sympathetic nerve density and NE concentration in the spleen 
of BN rats, evident at 18 months of age. Unlike the F344 rat, the decline in splenic 
sympathetic innervation in BN rats did not progress further than middle-age (18M).  
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Splenic NE concentration however, continued a moderate progressive decline that leveled 
off by 27 months of age, well before the mean age of survival for BN rats (32M). It was 
clear that despite the decline in sympathetic innervation during middle age, both 
sympathetic postganglionic fibers and NE levels in the spleen of BN rats were relatively 
preserved into senescence (compared with the aging F344 rat).  These observations in the 
BN rat suggest that as age progresses metabolism of NE was relatively maintained and 
may be contingent to levels of postganglionic nerves in the spleen. This assertion is 
supported by preliminary studies in our laboratory in which there was a decrease in NE 
turnover rate concomitant to reduced sympathetic signaling via β-ARs.  These results 
suggest that in the BN rat, there is a change in sympathetic beginning at middle age 
(15M) that is transient in nature. Therefore these observations in the spleen suggest that 
in BN rats compensatory mechanisms of neurotransmission may be masked or non-
existing; and reveal a clear distinction with the aging F344 rats, which exhibit a sustained 
increased in SNA and enhanced sympathetic signaling well into old age (147). 
Additionally, these findings in the spleen of BN rats correlated with decreased basal 
sympathetic tone, as shown by circulating catecholamine (NE and EPI) (148) that 
contrasted  elevated levels of these circulating CAs in aging F344 rats (147).  Aged BN 
rats have a striking Th2 bias, and may provide a good model for discovering the 
mechanisms that predispose the elderly to increased risk for Th2-mediated autoimmune 
diseases and asthma.  
Overall our longitudinal studies across age in F344 and BN rats implied that 
sympathetic innervation in old rats, though diminished, may still provide regulatory 
signals to aged target cells in the spleen that may be more sensitive to changes in NE 
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concentrations.  In the F344 rat maintenance of adequate sympathetic signaling in old age 
may be achieved by enhancing and sustaining sympathetic activity with detrimental 
effects to sympathetic nerve integrity; whereas in the BN rat, a transient increase in SNA 
may have less detrimental effects on innervation with blunting effects on sympathetic 
signaling.  The mode of age-related changes in neurotransmission in the spleen of BN 
rats may confer this rat strain with better sympathetic immune interaction that may 
contribute to its longevity.   
In chapters 3-4, chronic studies were used to test the hypothesis that heightened 
splenic SNA during middle age is responsible for splenic NA nerve loss and altered β-AR 
signaling in splenocytes, in a strain-dependent manner.  We tested this hypothesis by 
reducing sympathetic tone with rilmenidine, a centrally active antihypertensive agent that 
has high affinity to IR1 and α2-AR receptors in cardiovascular centers of the brain stem. 
We administered rilmenidine via discontinuous i.p. injections, as it previously reduced 
sympathetic tone in spontaneous hypertensive rats (SHR) (149). 
The results from these studies demonstrated that a 90-day treatment with 
rilmenidine, regardless of dose, confirmed its antihypertensive properties by reducing 
circulating NE concentration without changing EPI levels, in both rat strains, despite 
acute sympathetic activation by decapitation.  However, this drug treatment caused body 
weight gain suppression in F344 rats only, and suggests a hypothalamo-pituitary adrenal 
axis (HPA) and/or SNS activation (150) in this rat strain. Our observations were 
consistent with other reports that regarded the F344 rat as hyper-responsive to 
experimental periodic stress (151, 152).  In some rat strains, alterations in spleen weight 
during the course of a chronic study are not uncommon. Increased weight can be 
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attributed to enhanced splenic function in compensation to, either diminished blood flow 
or vascular tension (153); or blood accumulation due to a drug-induced vasodilatation in 
the splenic red pulp (154), as it may be the case in the F344 rats in our studies.  
In the spleen, rilmenidine reduced net SNA in both F344 and BN middle-aged rats, 
as demonstrated by the dose-dependent reduction of splenic NE turnover rate.  
Rilmenidine (Rilmlo and Rilmhi) treatment reversed the age-related loss of sympathetic 
nerves at both, the hilar (site of blood vessels and nerve entry) and distal regions of the 
spleen in F344 rats only.  In correlation with restored sympathetic nerves, total NE 
content in the spleen increased in F344 rats that were treated with the optimum dose of 
rilmenidine (Rilmlo).  NE concentration or total content in the spleen of BN rats were not 
significantly altered, suggesting that mechanisms promoting steady NE production and 
utilization were sustained in this rat strain during the drug treatment. Also in BN rats 
Rilmhi induced a nonsignificant increase in NE splenic levels, consistent with a small 
gain in more NA nerve fibers in distal regions of the spleen toward levels in young adult 
rats. However, there was a sharp reduction in splenic NE concentration and content in 
Rilmhi-F344 rats compared with age-matched control rats, despite NA nerve restoration. 
This data indicates that NE synthesis did not keep pace with NE utilization in the Rilmhi 
treatment group, despite reduced turnover with both drug doses.  As our data indicated, 
greater splenic DA levels with Rilmhi may cause small rates of DA to be driven into the 
cytosol from the neurotransmitter vesicle (146) to further inhibit TH activity.  At high 
doses, the drug-induced SNA decrease may affect TH phosphorylation, which is critical 
for its activity and the primary mechanism for maintaining tissue NE levels after 
secretion (155).  And downstream of TH, reduced dopamine-β-hydroxylase (DBH) 
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expression or activity may have depressed the conversion of NE from high vesicular DA 
thereby yielding lower splenic NE levels. Incidentally, the protective effects of Rilmhi on 
sympathetic innervation were less significant than with Rilmlo. And alteration of NE 
metabolism, with elevated DA content, toxic to neurons, may be responsible for this 
hindrance.  These results highlight the effect of age-related changes in SNA for altered 
NA innervation and adequate transmitter levels release from viable nerves in the spleen.  
And further give an insight on the strain related susceptibility for immune-mediated 
diseases by higher SNA that may alter activation and immune function in lymphoid 
organs (156).  
Because the optimum dose Rilmlo was demonstrated to reduce net SNA by previous 
pharmacological studies (149), it was used to investigate the effects of drug treatment on 
β-ARs activation and signaling via β-ARs in spleen cells. In F344 rats, increased -AR 
expression and -AR-stimulated production of cAMP were consistent with lower NE 
availability from reduced SNA and NE turnover; and support under reduced SNA 
conditions there is normal regulation of postsynaptic events in aging.  In BN rats, β-AR 
expression was increased but no significant effect on the age related decline in signaling 
was observed.  The presence of more β-ARs without change in receptor binding affinity 
in both F344 and BN rats may reflect decreased phosphorylation of β-ARs, a feature in 
splenocytes of aged rats (74, 157).  Or β-AR uncoupling with Gs protein may induce a 
decrease in cyclase adenylate activity, with a new set of signaling events via alternative 
activation of Gi (158). Of importance to our studies here, rilmenidine may directly 
modulate intracellular G-proteins to modulate the production of cAMP as suggested by ex 
vivo and in vitro studies. This mechanism consist in a cross talk between the cAMP and 
201 
PC-PLC pathways using the same intracellular machinery by which IR1 agonists can be 
linked with the cAMP pathway (159, 160, and 161).  These proposed mechanisms remain 
to be explored, as well as the effect of appropriate rilmenidine doses for BN rat, in order 
to investigate neurotransmission in aging. 
Collectively, our data indicate that reducing central SNA may be a useful strategy 
for reversing age-related nerve loss. And restoration of NA nerves in the spleen of the 
F344 rat and supports the feasibility for developing this strain as a model to investigate 
causality between aging SNS and immune functional changes. Because rilmenidine did 
not have significant effects in NA nerve restoration or neurotransmission despite lower 
SNA in the spleen, we believe that fine tuning of this rat strain as a model is in need.     
From our results we conclude that the F344 rat may be the strain that may benefit from 
reduction of SNA with stronger effects in NA nerve restoration. From previous studies in 
the F344 rat we know that although NA nerves in the spleen diminished greatly with 
aging, they retain plasticity (162); and therapeutic treatments may target this property in 
this rat strain. Adequate NA innervation can provide the environment for more efficient 
immune functions such as cell proliferation, cell trafficking, clonal expansion, and 
cytokine production that can contribute to optimal immune responses (163).  The F344 
rat and murine models have demonstrated that although diminished with age, NA 
innervation in the spleen is not completely lost.  This fact reveals that the SNS may 
continue to play a role in modulating immunity into well into very old age.  Other studies 
have shown that although sympathetic innervation in the spleen of aging rodents is 
diminished with age, sympathetic signaling of the immune system remains viable (165, 
166, and 167).   
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Chronic reduction of sympathetic activity in the spleen while enhancing 
sympathetic signaling in splenocytes is a novel finding in adult rats.  Although this was 
true for both rat strains, this experimental approach was not effective for the aging BN 
rat, because the age-related decline in sympathetic innervation and β-AR activation and 
signaling were not reversed by rilmenidine treatment.  Appropriate neurotransmission in 
the spleen may trigger important functional outcomes for immune cell activation in rat 
models.  The increase in cAMP with β-AR agonists (non-selective for β-ARs or selective 
for β2-AR) in adult rodents inhibits either mitogen- or anti-CD3 antibody-induced T cell 
proliferation (168, 169, 170, 171, and 172).  And β-AR-mediated inhibition of T cell 
proliferation may be explained, at least in part, by induced inhibition of IL-2R expression 
and/or IL-2 production by activated T cells (172, 173, and 174). Agonist-stimulated 
increase in cAMP may also enhance β-AR-mediated cytokine production in spleen cell 
culture; and a similar effect can be achieved experimentally by antigen challenge (175, 
176).    In addition to β-AR activation and β-AR-stimulated cAMP production in immune 
cells, experiments in adult rodents have demonstrated that chemical sympathectomy prior 
to antigen challenge with a T-cell dependent antigen, can either reduce (177, 178) or 
enhance (179, 180) antibody production in response to the endotoxin Keyhole limpet 
hemocyanin (KLH), depending on Th dominance (Th1 vs Th2).   
 Therefore immunomodulatory effects via adequate NA innervation and NE levels 
are crucial for satisfactory cell signaling events in targeted immune cells (73); and this 
becomes more important in aging, as the SNS remains able to modulate immune 
functions in the spleen (178, 181). Also, the direction of sympathetically mediated 
changes in immune responses may vary across species and strains, dose of antigen, site of 
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the immune response, and type of immune response (Th1 vs. Th2) (73).  Collectively, the 
experimental results discussed in chapter 3 and 4, as well as observations from other 
studies, underscores the role of the sympathetic system in the spleen across rat strains. 
Therapeutically reducing the age-related increase in SNA may confer specific benefits, 
depending on the strain of the rat model used.   
 
Future Directions 
From previous studies and observations presented in chapters 2 through 4, we 
have determined that changes in SNA, sympathetic innervation, and neurotransmitter 
levels in the spleen occur during middle age across rat strains.  And here, we reduced the 
age-related increase in SNA experimentally, and assess the effects of this intervention on 
NA innervation and sympathetic signaling in the spleen. Future research will investigate 
immune functional effects from the chronic treatment with rilmenidine, in order to 
determine probable causal relationships of age-related changes in SNA and immunity.  
Future proposed studies are outlined below. 
First, it will be important to determine the mechanism(s) by which chronic 
treatment with rilmenidine is conducive to the preservation of sympathetic nerves.  Nerve 
destruction in the spleen of aging rats is attributed to the increased sympathetic activity in 
the spleen which leads to the formation of oxidative metabolites from heightened released 
of NE that may cause pruning of nerve terminals (60, 2008).  Studies with other 
populations of catecholaminergic neurons support this hypothesis (182), and a similar 
event in the spleen will need to be confirmed.  Effects of reducing SNA on the formation 
of oxidative metabolites by ROS concentrations, via ELISA or Western blotting, will 
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confirm this proposed mechanism by which NA nerves are destroyed in the spleen. 
Supplementary to ROS level determination, the role of MAO can also be explored. 
Increased SNA involves enhanced degradation of catecholamines by a heightened MAO 
activity (183, 184). Studies in both, human and rat brain (184), and adipose tissue (175), 
have shown inhibition of monoamine oxidase A and B (MAO-A and MAO-B) by 
imidazoline ligands via pathways independent of either α-AR or β-AR pathways.  In vitro 
experiments can help to determine whether incubation with rilmenidine ameliorates 
neuron survival. Additional experiments in the presence of cultured immune cells and 
platelets, which are said to express IRs (185), will measure the contribution of immune 
cells in the inhibition of MAOs.  
Second, previously in our laboratory we were able to link sympathetic nerve 
plasticity to changes in the microenvironment in the splenic white pulp of aging F344 
rats, by changes in the density of T cells and ED31 macrophage populations (54, 186, 
and 187). Macrophage recruitment and infiltration into damaged tissue influence nerve 
regeneration and maintenance via regulation of NGF synthesis and NGF receptor 
expression (188). Thus in aging reduction of splenic macrophages and T cells in the 
white pulp promote loss in neurotrophic factor support for sympathetic nerves in the aged 
F344 spleen (188, 189).  Therefore correlations between sympathetic nerve preservation 
and density of immune cells populations following rilmenidine treatment can be 
addressed by immunohistochemistry labeling of tyrosine hydroxylase for NA nerves with 
simultaneous specific labeling for T cells and macrophages. Flow cytometric analysis can 
be used to confirm immunohistological experiments, and further identify possible shifts 
in immune cell populations in the spleen of rilmenidine-treated rats versus control rats in 
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both rat strains. Possible strain specific adjustments of immune cell populations in the 
spleen following chronic treatment with rilmenidine can be determined with this 
approach. 
Other studies have suggested that not only reduced population of resident cells in 
the spleen, but possibly a gradual decline in cytokines production may be a mechanism of 
NA sympathetic nerve fiber loss in the aged spleen (190). Cytokines have been also 
referred as neurotrophic for sympathetic neurons, either by directly or indirectly 
stimulating the release of neurotrophic factors.  In rat’s dissociated sympathetic neurons, 
IL-2 has been shown to stimulate neurite outgrowth via IL-2 receptors on the neurons 
(191).  And other cytokines of macrophage origin, such as IL-1 and TNF-, have been 
reported to play a critical role in regulating the synthesis of NGF and other neurotrophins 
in lymphoid tissues (192, 193, and 194).  Measurement of cytokine levels in the spleen, 
by cytokine production assays, can be used as a first step for correlation to sympathetic 
nerve density restoration.   
Third, neurotrophic factors, such as neurotrophin-3 (NT-3) and nerve growth 
factor (NGF), are important in supporting and maintaining sympathetic nerves (195, 196). 
Expression of mRNA for neurotrophic factors (NGF, NT-3, and BDNF) and their 
receptors (p75NGFR, trkA, trkB, and trkC) are ubiquitous in multiple cell types in the 
young adult mammalian spleen (197, 198, 199, and 200). Particularly in the rat spleen, 
p75NTR expression has been localized to dendritic cells in the PALS (201), and Trks 
expression on the surface of immune cells throughout various compartments of the 
spleen, as mentioned above has been detected (200, 201).  However no studies have 
examined the effect of aging on the concentration and/or production of these neurotrophic 
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factors and their receptors in the spleen. Similarly, the effects of rilmenidine treatment on 
neurotrophic factors and their receptors, specially of NGF and NT3, in the spleen of 
aging F344 or BN rats represents an opportunity for investigation.  For unknown reasons, 
so far at the protein level, only NT-3 has been detected in the spleen of young rats (one-
month old) (202, 203 ).  Despite its known physiological role for nerve preservation, the 
mature nerve growth factor has being referred as the minor species in peripheral tissues, 
compared to high molecular weight NGF species (205).  Recent studies in old F344 rats 
(24M) have revealed that expression of proNGF forms (proNGF-A or proNGF-B) may 
serve as indicators for aged neurons that are susceptible to neuronal atrophy in the spleen 
(204, 205, ). Moreover, it has been suggested that some pro-neurotrophins and high 
molecular weight neurotrophin species can directly interact with p75 and trkA receptors 
in target organs (207, 208, , and 209). 
Experimentally, it is crucial that the adequate extraction methods and prompt 
processing are used when attempting to measure total concentrations of NGF in lymphoid 
tissues from young adult and aged rats. Immediate assaying of harvested tissue is crucial 
for accurate neurotrophins concentration determination, as they readily undergo 
proteolytic degradation over time (206).  Accurate identification as well as the 
distribution of loosely bound NGF and NT-3 in the spleen can be challenging but 
attainable by highly sensitive detection methods (i.e. ELISA or selective optical sensor 
chips for real-time monitoring of antibody–antigen interactions) (198, 210).  In addition, 
complementary molecular experiments can help to determine whether the increase in 
proNGF-A or -B in the spleen is the result of the large-scale increase in NGF mRNA 
and/or due to altered post-translational processing and/or retrograde transport. The BN 
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rat, with significantly less splenic sympathetic nerve loss, provides an excellent 
alternative model to compare the effects of chronic treatment with rilmenidine on 
neurotrophin expression in the F344 rat spleen. Studies measuring neurotrophin levels 
will confirm possible reversal of age-related changes in expression of neurotrophins 
and/or their receptors in the spleen of rilmenidine-treated rats.  As a comparative study, 
combined rilmenidine treatment with trophic factors (i.e., NGF, NT3 or BDNF) may 
confirm the potentiation effect of neurotrophins on the rilmenidine effect. 
Fourth, most in vitro experiments indicate that adrenergic agonists can modulate 
all aspects of immune responses that include initiative, proliferative and effector phases 
(4).  Because chronic rilmenidine treatment enhanced sympathetic signaling by altering 
receptor expression in responsive spleen cells in both rat strains, the functional effects of 
this treatment on mitogen and antigen activated clonal expansion can be investigated with 
cell proliferative response assays. Possible strain differences in the type of immunity 
(Th1 vs. Th2) prevalent in these middle-aged rats that have been treated with rilmenidine 
can be explored with cytokine assays and correlated with flow cytometric profiling of 
macrophages, T cells and B cells. Also in vivo antibody production, following treatment 
with rilmenidine, can be tested with an optimum dose of the endotoxin KLH; and 
potential connections of this antigen activation with Th predisposition under reduced 
basal levels of sympathetic activity can be determined.  Findings from these experiments 
may give important insight on vaccine-induce immunity under sympathetic activity in 
these rats. 
Fifth, we have concluded that, chronic treatment with rilmenidine may induce 
sympathetic nerve preservation and the enhancement of neurotransmission in the spleen 
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of middle-aged F344 and BN rats, respectively. However we do not know whether 
reduction of SNA initiated well before changes are manifested in middle- age will be 
more beneficial to these animals.  Rilmenidine treatment begun as early as 10M, in F344 
rats, and at 12M in BN rats, may provide maintenance of young profiles rather than 
reversal of age-related changes in NA innervation and mechanisms involved in 
neurotransmission. Our studies in the BN rat revealed that this rat strain was more 
resistance to rilmenidine treatment at the indicated doses. We think that higher doses are 
appropriate for the BN rat in order to investigate accurately the effect of increase in SNA 
on neurotransmission in the spleen. Also an immediate confirmation of the effects 
observed in our experiments, can be carried out by allowing a drug wash out period at the 
end of the chronic treatment with rilmenidine. This experiment will determine whether 
the effects of this drug persist after it has clear the body of the animals completely. Thus 
anatomical and functional effects of rilmenidine treatment may reflect true adaptation to 
lower SNA in the aging spleen by these rat models.   
Overall our experimental results comprise initial findings that may help further 
characterize therapeutic interventions tailored to individuals with different SNS profile. 
The immune system is the best “weapon” that the body has to fight off pathogens that can 
affect the body's chances of optimal survival. Although the immune system is inherent to 
normal physiological processed in the body, the type of immunity that it acquires are 
obtained differently among individuals.  Perhaps changes in sympathetic measures with 
advancing age in rat models used in our studies may reflect an adaptation to the reshaping 
of immune function with age. Thus therapeutic interventions to counter the effects of 
aging on sympathetic signaling may enhance or interfere with adjustment in 
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neurotransmission mechanisms. Future studies will help to enhance the understanding of 
the mechanisms of age-related changes in sympathetic-immune interactions.  The 
significance of the results reported here represent an initial step to begin understanding 
the link between  adequate sympathetic modulation and immune function  conducive to 
resilience towards infectious diseases, tumor immunity, and autoimmune-mediated 
diseases during aging. 
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Fig 5.1  Model for Neurotransmission in the Aging Spleen 
An age related increase of sympathetic outflow driven by the rostral ventral lateral 
medulla (RVLM) induces an increase in sympathetic nerve activity (SNA) the spleen. 
This increase in local SNA is characterized by elevated levels of free radical metabolites 
produced by enhanced activity of metabolic enzymes (MAO-B, COMT) in the face of 
elevated concentration of norepinephrine (NE), via heightened enzymatic activity by 
tyrosine hydroxylase (TH).  Excess of free radical metabolites causes deleterious damage 
to sympathetic nerves in the face of diminished neurothrophic support. Contributing 
factors to this effect may include altered immune population, reduced target cell density, 
reduced anti-oxidant activity, and chronic inflammation. In splenocytes expression of β-
adrenergic receptors increase but subsequent coupling to alternative G protein subunits, 
such as Gi or Go, may induce alteration the production of cAMP by adenylate cyclase 
differentially in a strain-related manner. This age-related alteration in neurotransmission 
in the spleen may influence immune responsiveness with advancing age. 
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